 EXHIBIT 2.1     


 Exhibit 2.1

  

  

 

  

EXECUTION COPY

  

  

    

  

  

  

  

  

AGREEMENT AND PLAN OF MERGER

  

  

  

by and among

  

  

  

CVS CAREMARK CORPORATION,

  

  

  

ULYSSES MERGER SUB, L.L.C.

  

  

  

and

  

  

  

UNIVERSAL AMERICAN CORP.

  

  

  

_________________________

  

  

  

  

Dated as of December 30, 2010

  

  

  

  

    

 

 

 

  

 

  

 

  

 

 

 

   
 

 

  

TABLE OF CONTENTS

  

  

Page

  

  

 

    

ARTICLE I THE MERGER

  |  

2

   
---|--- 
  

Section 1.1

  |  

The Merger

  |  

2

   
  

Section 1.2

  |  

Closing

  |  

2

   
  

Section 1.3

  |  

Effective Time

  |  

3

   
  

Section 1.4

  |  

Effects of the Merger

  |  

3

   
  

Section 1.5

  |  

Certificate of Incorporation

  |  

3

   
  

Section 1.6

  |  

Bylaws

  |  

3

   
  

Section 1.7

  |  

Directors

  |  

3

   
  

Section 1.8

  |  

Officers

  |  

3

   
   |   
  

ARTICLE II EFFECT OF THE MERGER ON CAPITAL STOCK

  |  

3

   
  

Section 2.1

  |  

Conversion of Capital Stock

  |  

3

   
  

Section 2.2

  |  

Surrender of Certificates and Book-Entry Shares

  |  

5

   
  

Section 2.3

  |  

Part D Options; Part D Employee Restricted Shares; and Part D Employee
Performance Shares

  |  

8

   
   |   
  

ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE COMPANY

  |  

10

   
  

Section 3.1

  |  

Organization and Power

  |  

10

   
  

Section 3.2

  |  

Organizational Documents

  |  

11

   
  

Section 3.3

  |  

Governmental Authorizations

  |  

11

   
  

Section 3.4

  |  

Corporate Authorization

  |  

12

   
  

Section 3.5

  |  

Non-Contravention

  |  

12

   
  

Section 3.6

  |  

Capitalization

  |  

13

   
  

Section 3.7

  |  

Subsidiaries

  |  

14

   
  

Section 3.8

  |  

Voting

  |  

14

   
  

Section 3.9

  |  

SEC Reports

  |  

14

   
  

Section 3.10

  |  

Financial Statements; Internal Controls

  |  

15

   
  

Section 3.11

  |  

Undisclosed Liabilities

  |  

16

   
  

Section 3.12

  |  

Absence of Certain Changes

  |  

16

   
  

Section 3.13

  |  

Litigation

  |  

16

   
  

Section 3.14

  |  

Material Contracts

  |  

17

   
  

Section 3.15

  |  

Benefit Plans

  |  

18

   
  

Section 3.16

  |  

Labor Relations

  |  

20

   
  

Section 3.17

  |  

Taxes

  |  

21

   
  

Section 3.18

  |  

Environmental Matters

  |  

22

   
  

Section 3.19

  |  

Intellectual Property

  |  

22

   
  

Section 3.20

  |  

Real Property; Personal Property

  |  

24

   
  

Section 3.21

  |  

Permits; Compliance with Law

  |  

25

   
  

Section 3.22

  |  

Regulatory Matters

  |  

25

   
  

Section 3.23

  |  

Takeover Statutes

  |  

27

   
  

Section 3.24

  |  

Transactions with Affiliates

  |  

27

   
  

Section 3.25

  |  

Insurance

  |  

27

   
  

  

  

 

 

 

  

   

  

 

 

 

  

  

  

Page

  

     

Section 3.26

  |  

Insurance Reports

  |  

27

   
---|---|--- 
  

Section 3.27

  |  

Insurance Laws

  |  

28

   
  

Section 3.28

  |  

Insurance Business

  |  

29

   
  

Section 3.29

  |  

Reinsurance

  |  

29

   
  

Section 3.30

  |  

Agents

  |  

29

   
  

Section 3.31

  |  

Opinion of Financial Advisor

  |  

30

   
  

Section 3.32

  |  

Brokers

  |  

30

   
  

Section 3.33

  |  

Sufficiency of Assets

  |  

30

   
   |   
  

ARTICLE IV REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB

  |  

30

   
  

Section 4.1

  |  

Organization and Power

  |  

30

   
  

Section 4.2

  |  

Governmental Authorizations

  |  

30

   
  

Section 4.3

  |  

Authorization

  |  

31

   
  

Section 4.4

  |  

Non-Contravention

  |  

31

   
  

Section 4.5

  |  

Capitalization; Interim Operations of Merger Sub; Ownership of Common Stock;
Section 912 of the NYBCL

  |  

32

   
  

Section 4.6

  |  

Sufficient Funds

  |  

33

   
  

Section 4.7

  |  

Litigation

  |  

33

   
  

Section 4.8

  |  

Absence of Arrangements with Management

  |  

33

   
  

Section 4.9

  |  

Brokers

  |  

33

   
  

Section 4.10

  |  

Independent Investigation

  |  

33

   
   |   
  

ARTICLE V COVENANTS

  |  

34

   
  

Section 5.1

  |  

Conduct of Business of the Company

  |  

34

   
  

Section 5.2

  |  

Conduct of Business of Parent

  |  

37

   
  

Section 5.3

  |  

Access to Information; Confidentiality

  |  

38

   
  

Section 5.4

  |  

Solicitation

  |  

39

   
  

Section 5.5

  |  

Preparation of the Newco Form S-4 and Company Proxy Statement

  |  

41

   
  

Section 5.6

  |  

Company Shareholders Meeting

  |  

43

   
  

Section 5.7

  |  

Employees; Benefit Plans

  |  

43

   
  

Section 5.8

  |  

Reasonable Best Efforts

  |  

45

   
  

Section 5.9

  |  

Consents; Filings; Further Action

  |  

46

   
  

Section 5.10

  |  

Public Announcements

  |  

48

   
  

Section 5.11

  |  

Applicable Exchange De-listing

  |  

48

   
  

Section 5.12

  |  

Newco Common Stock Listing

  |  

48

   
  

Section 5.13

  |  

Fees and Expenses

  |  

48

   
  

Section 5.14

  |  

Takeover Statutes

  |  

49

   
  

Section 5.15

  |  

Obligations of Merger Sub

  |  

49

   
  

Section 5.16

  |  

Rule 16b-3

  |  

49

   
  

Section 5.17

  |  

Resignation of Directors

  |  

49

   
  

Section 5.18

  |  

Split-Off and Related Matters

  |  

49

   
  

Section 5.19

  |  

Notification of Certain Matters

  |  

51

   
  

Section 5.20

  |  

Adjustment Certificates

  |  

52

   
  

Section 5.21

  |  

Termination of Medco Agreement

  |  

53

   
  

Section 5.22

  |  

2012 CMS Bid Process

  |  

53

   
  

  

  

 

 

 

  

 

ii  

  

 

 

 

  

  

 

  

Page

  

 

     

Section 5.23

  |  

Relationships with Certain Parties

  |  

54

   
---|---|--- 
  

Section 5.24

  |  

Certain Litigation

  |  

55

   
  

Section 5.25

  |  

Designated Bonds

  |  

55

   
  

Section 5.26

  |  

Parent Standstill

  |  

56

   
   |   
  

ARTICLE VI CONDITIONS

  |  

56

   
  

Section 6.1

  |  

Conditions to Each Party's Obligation to Effect the Split-Off and the Merger

  |  

56

   
  

Section 6.2

  |  

Conditions to Obligations of Parent and Merger Sub

  |  

57

   
  

Section 6.3

  |  

Conditions to Obligation of the Company

  |  

58

   
  

Section 6.4

  |  

Frustration of Closing Conditions

  |  

58

   
   |   
  

ARTICLE VII TERMINATION, AMENDMENT AND WAIVER

  |  

58

   
  

Section 7.1

  |  

Termination by Mutual Consent

  |  

58

   
  

Section 7.2

  |  

Termination by Either Parent or the Company

  |  

59

   
  

Section 7.3

  |  

Termination by Parent

  |  

59

   
  

Section 7.4

  |  

Termination by the Company

  |  

60

   
  

Section 7.5

  |  

Effect of Termination

  |  

60

   
  

Section 7.6

  |  

Fees and Expenses Following Termination

  |  

61

   
   |   
  

ARTICLE VIII MISCELLANEOUS

  |  

62

   
  

Section 8.1

  |  

Certain Definitions

  |  

62

   
  

Section 8.2

  |  

Interpretation

  |  

71

   
  

Section 8.3

  |  

No Survival

  |  

72

   
  

Section 8.4

  |  

Governing Law

  |  

72

   
  

Section 8.5

  |  

Submission to Jurisdiction; Service

  |  

72

   
  

Section 8.6

  |  

WAIVER OF JURY TRIAL

  |  

73

   
  

Section 8.7

  |  

Notices

  |  

73

   
  

Section 8.8

  |  

Amendment

  |  

74

   
  

Section 8.9

  |  

Extension; Waiver

  |  

74

   
  

Section 8.10

  |  

Entire Agreement

  |  

75

   
  

Section 8.11

  |  

No Third-Party Beneficiaries

  |  

75

   
  

Section 8.12

  |  

Severability

  |  

75

   
  

Section 8.13

  |  

Rules of Construction

  |  

75

   
  

Section 8.14

  |  

Assignment

  |  

76

   
  

Section 8.15

  |  

Remedies

  |  

76

   
  

Section 8.16

  |  

Specific Performance

  |  

76

   
  

Section 8.17

  |  

Counterparts; Effectiveness

  |  

76

   
  

Section 8.18

  |  

Merger Sub

  |  

76

   
 

  


 

  

  

Disclosure Letters

  

  

Company Disclosure Letter

  

Parent Disclosure Letter

  

  

  

 

 

 

  

 

iii  

  

 

 

 

  

  

 

  

Page

 

  

Exhibits

  

  

    

Exhibit A

  |  

Reinsurance Agreement Term Sheet

   
---|--- 
  

Exhibit B

  |  

PBM Agreement Term Sheet

   
  

Exhibit C

  |  

Transition Services Agreement Term Sheet

   
 

 

  

  

  

  

 

 

 

  

 

iv  

  

 

 

 

  

  

  

INDEX OF DEFINED TERMS

  

  


 

  


 

  

    

Term

  |  

Section

   
---|--- 
  

Acceptable Confidentiality Agreements

  |  

5.4(b)

   
  

Actuarial Firm

  |  

5.22(a)

   
  

Agent

  |  

3.30

   
  

Agreement

  |  

Preamble

   
  

American Progressive

  |  

5.18(c)

   
  

AmPro Part D Business

  |  

5.18(c)

   
  

Authorized Control Level Amount

  |  

5.20(a)

   
  

Balance Sheet Date

  |  

3.11(a)

   
  

Bid Submission

  |  

5.22(a)

   
  

Book-Entry Shares

  |  

2.1(d)(ii)

   
  

Certificate of Merger

  |  

1.3

   
  

Certificates

  |  

2.1(d)(ii)

   
  

Closing

  |  

1.2

   
  

Closing Consideration

  |  

2.1(c)(i)

   
  

Closing Date

  |  

1.2

   
  

Closing Date Indebtedness Amount

  |  

5.20(a)

   
  

Closing Date Indebtedness Certificate

  |  

5.20(a)

   
  

CMS

  |  

3.3(g)

   
  

CMS Notice Requirements

  |  

3.3(g)

   
  

Code

  |  

2.2(f)

   
  

Common Stock

  |  

Recitals

   
  

Company

  |  

Preamble

   
  

Company Adverse Recommendation Change

  |  

5.4(c)

   
  

Company Benefit Plans

  |  

3.15(a)

   
  

Company Board

  |  

Recitals

   
  

Company Board Recommendation

  |  

Recitals

   
  

Company Disclosure Letter

  |  

III

   
  

Company Financial Advisor

  |  

3.31

   
  

Company Intellectual Property

  |  

3.19(a)

   
  

Company Option

  |  

3.6(a)

   
  

Company Organizational Documents

  |  

3.2

   
  

Company Permits

  |  

3.21(a)

   
  

Company Proxy Statement

  |  

3.3(b)

   
  

Company SEC Reports

  |  

3.9

   
  

Company Severance Plan

  |  

5.7(d)

   
  

Company Shareholders Meeting

  |  

3.3(b)

   
  

Company Termination Fee

  |  

7.6(c)

   
  

Computer Software

  |  

3.19(e)

   
  

Confidentiality Agreement

  |  

5.3(b)

   
  

Continuation Period

  |  

5.7(a)

   
  

Converted Performance Share Award

  |  

2.3(c)

   
  

Converted Restricted Share Award

  |  

2.3(b)

   
  

  

  

 

 

 

  

 

v  

  

 

 

 

  

  


 

  

 

    

Term

  |  

Section

   
---|--- 
 

 

     

Covered Persons

  |  

5.24(a)

   
---|--- 
  

Designated Bond Exchange

  |  

5.25(b)

   
  

Designated Part D Bonds

  |  

5.25(b)

   
  

Designation Date

  |  

5.25(b)

   
  

Effective Time

  |  

1.3

   
  

ERISA

  |  

3.15(a)

   
  

Exchange Act

  |  

3.3(c)

   
  

Exchange Agent

  |  

2.2(a)

   
  

Exchange Fund

  |  

2.2(b)

   
  

Excluded Shares

  |  

2.1(b)

   
  

Exercise Price

  |  

2.3(a)

   
  

FIN 48

  |  

8.18(b)

   
  

Fractional Shares Fund

  |  

2.2(j)(ii)

   
  

GAAP

  |  

3.10(a)(ii)

   
  

GAAP Statements

  |  

3.26

   
  

Good Faith Bid

  |  

5.22(a)

   
  

Governmental Authorizations

  |  

3.3

   
  

Healthcare Information Laws

  |  

3.22(d)

   
  

HSR Act

  |  

3.3(f)

   
  

Insurance Contracts

  |  

3.28

   
  

Insurance Laws

  |  

3.26

   
  

Insurance Policies

  |  

3.25

   
  

Interim Part D Financial Statements

  |  

3.10(b)

   
  

IRS

  |  

8.18(a)

   
  

Legal Actions

  |  

3.13

   
  

Liabilities

  |  

3.11

   
  

Material Contract

  |  

3.14(a)

   
  

Maximum Divestiture Amount

  |  

5.9(e)

   
  

Merger

  |  

Recitals

   
  

Merger Sub

  |  

Preamble

   
  

NASDAQ

  |  

3.3(e)

   
  

New Plans

  |  

5.7(g)

   
  

Newco

  |  

Recitals

   
  

Newco Common Stock

  |  

Recitals

   
  

Newco Exchange Ratio

  |  

2.1(c)(i)

   
  

Newco Form S-4

  |  

3.3(b)

   
  

Non-Voting Common Stock

  |  

3.6(a)

   
  

Novation Agreement

  |  

5.18(c)

   
  

Novation Effective Date

  |  

5.18(c)

   
  

NYBCL

  |  

1.1

   
  

NYLLCA

  |  

1.1

   
  

Old Plans

  |  

5.7(g)

   
  

Parent

  |  

Preamble

   
  

Parent Assets

  |  

4.4(b)

   
  

Parent Contracts

  |  

4.4(c)

   
  

  

  

 

 

 

  

 

vi  

  

 

 

 

  

  

 


 

  


 

  

    

Term

  |  

Section

   
---|--- 
 

 

     

Parent Disclosure Letter

  |  

IV

   
---|--- 
  

Part D Employee

  |  

3.15(i)

   
  

Part D Employee Performance Share

  |  

2.3(c)

   
  

Part D Employee Restricted Share

  |  

2.3(b)

   
  

Part D Entities

  |  

III

   
  

Part D Insurance Entities

  |  

3.26

   
  

Part D Option

  |  

2.3(a)

   
  

Part D Reinsurance Agreement

  |  

5.18(c)

   
  

Part D Reinsurer

  |  

5.18(c)

   
  

PBM Agreement

  |  

5.18(b)

   
  

Performance Share

  |  

3.6(a)

   
  

Permits

  |  

3.21(a)

   
  

Post-Signing Returns

  |  

8.18(b)

   
  

Preferred Stock

  |  

3.6(a)

   
  

Pre-Split-Off Common Stock Value

  |  

2.3(a)

   
  

Real Property Leases

  |  

3.20(b)

   
  

Regulatory Material Adverse Effect

  |  

5.9(e)

   
  

Reinsurance Agreement

  |  

5.18(b)

   
  

Required Consents

  |  

3.3(h)

   
  

Requisite Experience

  |  

5.18(e)

   
  

Restricted Share

  |  

3.6(a)

   
  

Retention Pool

  |  

5.7(f)

   
  

SAP

  |  

3.26

   
  

SAP Statements

  |  

3.26

   
  

SEC

  |  

3.3(b)

   
  

Section 5.23 Matters

  |  

5.23(a)

   
  

Section 5.23 Persons

  |  

5.23(a)

   
  

Securities

  |  

3.6(b)

   
  

Securities Act

  |  

3.9

   
  

Separation Agreement

  |  

Recitals

   
  

Series A Preferred Stock

  |  

2.1(d)(i)

   
  

Series B Preferred Stock

  |  

3.6(a)

   
  

Shareholder Litigation

  |  

5.24(a)

   
  

Split-Off

  |  

Recitals

   
  

Split-Off Agreement Arbitrator

  |  

5.18(e)

   
  

Split-Off Agreement Date

  |  

5.18(e)

   
  

Split-Off Consideration

  |  

2.1(c)(i)

   
  

Split-Off Consideration Value

  |  

2.3(a)

   
  

Statutory Capital 12/31 Amount

  |  

5.20(a)

   
  

Statutory Capital Accounting Firm

  |  

5.20(d)

   
  

Statutory Capital Adjustment Certificate

  |  

5.20(a)

   
  

Statutory Capital Objections Statement

  |  

5.20(c)

   
  

Surviving Bylaws

  |  

1.6

   
  

Surviving Charter

  |  

1.5

   
  

Surviving Corporation

  |  

1.1

   
  

  

  

 

 

 

  

 

vii  

  

 

 

 

  

  

 


 

  


 

  

    

Term

  |  

Section

   
---|--- 
 

 

     

Tax Matters Agreement

  |  

5.18(a)

   
---|--- 
  

Termination Date

  |  

7.2(a)

   
  

Transition Services Agreement

  |  

5.18(d)

   
  

WARN Act

  |  

3.16(b)

   
 

  


 

  

  

  

 

 

 

  

 

viii  

  

 

 

 

  

  


 

  

AGREEMENT AND PLAN OF MERGER

  

  

AGREEMENT AND PLAN OF MERGER, dated as of December 30, 2010 (this
"Agreement"), by and among CVS Caremark Corporation, a Delaware corporation
("Parent"), Ulysses Merger Sub, L.L.C., a New York limited liability company
and a direct or indirect wholly owned subsidiary of Parent ("Merger Sub"), and
Universal American Corp., a New York corporation (the "Company").

  

  

RECITALS

  

  

WHEREAS, in addition to its other businesses, the Company, directly and
through certain of its Subsidiaries (as defined below) owns and operates the
Medicare Part D Business (as defined below);

  

  

WHEREAS, the Company and Parent desire to effect Parent's acquisition of the
Company's Medicare Part D Business through a merger of Merger Sub with and
into the Company on the terms and subject to the conditions of this Agreement
(the "Merger");

  

  

WHEREAS, concurrently with the execution of this Agreement, the Company and
Ulysses Spin Corp., a newly-formed Subsidiary of the Company ("Newco"), are
entering into a Separation Agreement (the "Separation Agreement") pursuant to
which, upon the terms and subject to the conditions set forth therein, prior
to the Effective Time, (i) all of the assets of the Company and its
Subsidiaries, other than the assets of the Company and its Subsidiaries
primarily related to the Medicare Part D Business, will be transferred to or
retained by Newco or one or more Subsidiaries of Newco and (ii) Newco or one
or more of Newco's Subsidiaries will assume the Newco Liabilities (as defined
in the Separation Agreement);

  

  

WHEREAS, after the Split-Off (as defined below), it is intended that, subject
to the terms and conditions set forth in the Separation Agreement, the Company
and its Subsidiaries will own only the Medicare Part D Business;

  

  

WHEREAS, in order to effect the foregoing, upon the terms and subject to the
conditions set forth in this Agreement, at the Effective Time, the holders of
shares of common stock, par value $0.01 per share, of the Company (the "Common
Stock"), will, pursuant to the Merger, be entitled to receive, in the
aggregate, all of the shares of common stock, par value $0.01 per share, of
Newco ("Newco Common Stock") (the "Split-Off");

  

  

WHEREAS, upon the terms and subject to the conditions set forth in this
Agreement, at the Effective Time, Merger Sub shall be merged with and into the
Company and each issued and outstanding share of Common Stock, other than
Excluded Shares (as defined below), will be converted into the right to
receive (i) shares of Newco Common Stock and (ii) the Per Share Merger
Consideration, without interest, as more fully set forth herein;

  

  

  

 

 

 

  

   

  

 

 

 

  

  

  

WHEREAS, the board of directors of the Company (the "Company Board") at a
meeting thereof duly called and held (a) approved and declared advisable this
Agreement, the Merger, the Split-Off and the transactions contemplated by this
Agreement and the Split-Off Agreements (as defined below), (b) declared that
it is in the best interests of the shareholders of the Company that the
Company enter into this Agreement and consummate the Merger and the Split-Off
on the terms and subject to the conditions set forth in this Agreement and the
Split-Off Agreements, (c) directed that the adoption of this Agreement be
submitted to a vote at a meeting of the shareholders of the Company and (d)
recommended to the shareholders of the Company that they adopt this Agreement
(the "Company Board Recommendation");

  

  

WHEREAS, as a condition to Parent's and Merger Sub's willingness to enter into
this Agreement, concurrently with the execution of this Agreement certain
stockholders of the Company are entering into Voting Agreements (the "Voting
Agreements") with Parent; and

  

  

WHEREAS, the board of directors of Merger Sub has unanimously approved and
declared advisable, and the board of directors of Parent has approved, this
Agreement, the Merger and the transactions contemplated by this Agreement, on
the terms and subject to the conditions set forth in this Agreement.

  

  

NOW, THEREFORE, in consideration of the mutual representations, warranties,
covenants and agreements set forth herein and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties to this Agreement, intending to be legally bound, agree as
follows:

  

  

ARTICLE I

  

  

THE MERGER

  

  

Section 1.1 The Merger. Upon the terms and subject to the conditions set forth
in this Agreement, and in accordance with the New York Business Corporation
Law (the "NYBCL") and the New York Limited Liability Company Act (the
"NYLLCA"), at the Effective Time, (a) Merger Sub shall be merged with and into
the Company and (b) the separate existence of Merger Sub shall cease and the
Company shall continue its corporate existence under the NYBCL as the
surviving corporation in the Merger (the "Surviving Corporation").

  

  

Section 1.2 Closing. Subject to the satisfaction or waiver of all of the
conditions to closing contained in Article VI, the closing of the Merger (the
"Closing") shall take place (a) at the offices of Paul, Weiss, Rifkind,
Wharton and Garrison LLP, 1285 Avenue of the Americas, New York, New York, at
10:00 a.m. (local time) on the second Business Day after the day on which the
conditions set forth in Article VI (other than any conditions that by their
nature are to be satisfied at the Closing, but subject to the satisfaction or
waiver of those conditions) are satisfied or waived in accordance with this
Agreement or (b) at such other place and time as Parent and the Company may
agree in writing. The date on which the Closing occurs is referred to as the
"Closing Date."

  

  

  

 

 

 

  

 

2  

  

 

 

 

  

  

  

Section 1.3 Effective Time. At the Closing, Parent and the Company shall cause
a certificate of merger (the "Certificate of Merger") to be executed, signed,
acknowledged and filed with the Department of State of the State of New York
in such form as is required by the relevant provisions of the NYBCL and the
NYLLCA. The Merger shall become effective when the Certificate of Merger has
been duly filed with the Department of State of the State of New York or at
such other subsequent date or time as Parent and the Company may agree and
specify in the Certificate of Merger in accordance with the NYBCL and the
NYLLCA (the "Effective Time").

  

  

Section 1.4 Effects of the Merger. The Merger shall have the effects set forth
in the NYBCL, the NYLLCA, this Agreement and the Certificate of Merger.

  

  

Section 1.5 Certificate of Incorporation. The certificate of incorporation of
the Company, as in effect immediately before the Effective Time, shall be the
certificate of incorporation of the Surviving Corporation until thereafter
amended in accordance with applicable Law (the "Surviving Charter").

  

  

Section 1.6 Bylaws. The bylaws of the Company in effect immediately prior to
the Effective Time shall be, from and after the Effective Time, the bylaws of
the Surviving Corporation (the "Surviving Bylaws") until amended in accordance
with applicable Law.

  

  

Section 1.7 Directors. The officers of Merger Sub immediately prior to the
Effective Time shall be, from and after the Effective Time, the directors of
the Surviving Corporation until their successors are duly elected and
qualified or until their earlier death, resignation or removal in accordance
with applicable Law.

  

  

Section 1.8 Officers. The officers of Merger Sub immediately prior to the
Effective Time shall be, from and after the Effective Time, the officers of
the Surviving Corporation until their successors are duly elected or appointed
and qualified or until their earlier death, resignation or removal in
accordance with applicable Law.

  

  

ARTICLE II

  

  

EFFECT OF THE MERGER ON CAPITAL STOCK

  

  

Section 2.1 Conversion of Capital Stock. At the Effective Time, by virtue of
the Merger and without any action on the part of Parent, Merger Sub, the
Company or the holder of any shares of capital stock of the Company or of any
membership interests of Merger Sub:

  

  

(a) Conversion of Merger Sub Membership Interests. Each membership interest of
Merger Sub issued and outstanding immediately before the Effective Time shall
be converted into and become one fully paid and non-assessable share of common
stock, par value $0.01 per share, of the Surviving Corporation.

  

  

  

 

 

 

  

 

3  

  

 

 

 

  

  

  

(b) Cancellation of Treasury Stock and Parent-Owned Stock. Each share of
Common Stock held in the treasury of the Company, owned by the Company or any
of its wholly owned Subsidiaries or by Parent or any of its Subsidiaries
(including Merger Sub) immediately before the Effective Time (collectively,
the "Excluded Shares") shall be canceled automatically and shall cease to
exist, and no consideration shall be paid for those Excluded Shares.

  

  

(c) Conversion of Common Stock.

  

  

(i) Each share of Common Stock issued and outstanding immediately before the
Effective Time (other than Excluded Shares) shall be converted into the right
to receive (A) from the Company, subject to the last sentence of Section 8.8,
one (1) (the "Newco Exchange Ratio") validly issued, fully paid and
nonassessable share of Newco Common Stock (the "Split-Off Consideration") and
(B) from Parent, the Per Share Merger Consideration in cash, without interest
(clauses (A) and (B), and any cash in lieu of fractional shares of Newco
Common Stock to be issued or paid in accordance with Section 2.2(j),
collectively, the "Closing Consideration").

  

  

(ii) All shares of Common Stock that have been converted pursuant to Section
2.1(c)(i) shall be canceled automatically and shall cease to exist, and the
holders of (i) certificates which immediately before the Effective Time
represented such shares or (ii) shares represented by book-entry shall cease
to have any rights with respect to those shares, other than the right to
receive the Closing Consideration in accordance with Section 2.2, without
interest.

  

  

(d) Conversion of Preferred Stock.

  


 

  

(i) Each share of Series A Preferred Stock, par value $1.00 per share (the
"Series A Preferred Stock"), issued and outstanding immediately before the
Effective Time shall be converted into the right to receive an amount equal to
the Closing Consideration for each share of Common Stock issuable upon
conversion of such share of Series A Preferred Stock immediately before the
Effective Time.

  

  

(ii) All shares of Series A Preferred Stock that have been converted pursuant
to Section 2.1(d)(i) shall be canceled automatically and shall cease to exist,
and the holders of certificates which immediately before the Effective Time
represented such shares (together with the certificates which represented
shares of Common Stock, the "Certificates") or shares represented by book-
entry (together with the shares of Common Stock represented by book-entry,
"Book-Entry Shares") shall cease to have any rights with respect to those
shares, other than the right to receive the Closing Consideration in
accordance with Section 2.2, without interest.

  

  

(e) Equitable Adjustment. If at any time during the period between the date of
this Agreement and the Effective Time, any change in the outstanding shares of
capital stock of the Company shall occur as a result of any reclassification,
recapitalization, reorganization, stock split (including a reverse stock

  

  

  

 

 

 

  

 

4  

  

 

 

 

  

  

  

split) or combination, exchange or readjustment of shares, or any stock
dividend or stock distribution is declared with a record date during such
period, the Closing Consideration shall be equitably adjusted to reflect such
change.

  


 

  

Section 2.2 Surrender of Certificates and Book-Entry Shares.

  

  

(a) Exchange Agent. Not less than ten Business Days before the Effective Time,
Parent shall (i) select a bank or trust company, satisfactory to the Company
in its reasonable discretion, to act as the exchange agent in the Merger (the
"Exchange Agent") and (ii) enter into an exchange agent agreement with the
Exchange Agent in form and substance reasonably satisfactory to the Company.
Parent and Newco shall be responsible for all fees and expenses of the
Exchange Agent as set forth in the Separation Agreement.

  

  

(b) Exchange Fund. At or before the Effective Time, for the benefit of the
holders of Common Stock and Series A Preferred Stock (i) the Company shall
provide to the Exchange Agent certificates representing the shares of Newco
Common Stock issuable pursuant to Section 2.1(c) and Section 2.1(d) and (ii)
Parent shall provide to the Exchange Agent cash in an amount sufficient for
the payment of the aggregate Per Share Merger Consideration payable under
Section 2.1(c) and Section 2.1(d). Such shares of Newco Common Stock and funds
provided to the Exchange Agent are collectively referred to as the "Exchange
Fund."

  

  

(c) Exchange Procedures.

  

  

(i) Letter of Transmittal. As promptly as practicable but in no event later
than two Business Days following the Effective Time, Parent shall cause the
Exchange Agent to mail to each holder of record of a share of Common Stock or
Series A Preferred Stock converted pursuant to Section 2.1(c)(i) or Section
2.1(d)(i), (A) a letter of transmittal in customary form, specifying that
delivery shall be effected, and risk of loss and title to such holder's shares
shall pass, only upon proper delivery of Certificates to the Exchange Agent
or, in the case of Book-Entry Shares, upon adherence to the procedures set
forth in the letter of transmittal and (B) instructions for surrendering such
Certificates or Book-Entry Shares.

  

  

(ii) Surrender of Shares. Upon surrender of a Certificate or of a Book-Entry
Share for cancellation to the Exchange Agent, together with a duly executed
letter of transmittal and any other documents reasonably required by the
Exchange Agent, the holder of that Certificate or Book-Entry Share shall be
entitled to receive, and the Exchange Agent shall deliver in exchange
therefor, the Closing Consideration deliverable in respect of the number of
shares formerly evidenced by that Certificate or Book-Entry Share. Any
Certificates and Book-Entry Shares so surrendered shall be canceled
immediately. No interest shall accrue or be paid on the Closing Consideration
deliverable upon surrender of Certificates or Book-Entry Shares.

  

  

(iii) Unregistered Transferees. If any Closing Consideration is to be
delivered to a Person other than the Person in whose name the

  

  

  

 

 

 

  

 

5  

  

 

 

 

  

  

  

surrendered Certificate is registered, then the Closing Consideration may be
delivered to such a transferee so long as (A) the surrendered Certificate is
accompanied by all documents required by Parent to evidence and effect that
transfer and (B) the Person requesting such delivery (1) pays any applicable
transfer Taxes or (2) establishes to the reasonable satisfaction of Parent and
the Exchange Agent that any such transfer Taxes have already been paid or are
not applicable.

  

  

(iv) No Other Rights. Until surrendered in accordance with this Section
2.2(c), each Certificate and each Book-Entry Share shall be deemed, from and
after the Effective Time, to represent only the right to receive the Closing
Consideration. Any Closing Consideration delivered upon the surrender of any
Certificate or Book-Entry Share shall be deemed to have been delivered in full
satisfaction of all rights pertaining to such Certificate or Book-Entry Share
and the shares of Common Stock or Series A Preferred Stock, as applicable,
formerly represented by it.

  

  

(d) Lost, Stolen or Destroyed Certificates. If any Certificate is lost, stolen
or destroyed, upon the making of an affidavit of that fact by the Person
claiming such Certificate to be lost, stolen or destroyed and, if required by
the Surviving Corporation, the posting by such Person of a bond, in such
reasonable amount as the Surviving Corporation may direct, as indemnity
against any claim that may be made against it with respect to such
Certificate, the Exchange Agent shall deliver, in exchange for such affidavit
claiming such Certificate is lost, stolen or destroyed, the Closing
Consideration to such Person in respect of the shares of Common Stock or
Series A Preferred Stock, as applicable, represented by such Certificate.

  

  

(e) No Further Transfers. At the Effective Time, the stock transfer books of
the Company shall be closed and there shall be no further registration of
transfers of the shares of Common Stock and Series A Preferred Stock that were
outstanding immediately before the Effective Time.

  

  

(f) Required Withholding. Parent, Merger Sub, the Surviving Corporation and
the Exchange Agent shall be entitled to deduct and withhold from any
consideration otherwise deliverable under this Agreement such amounts as may
be required to be deducted or withheld therefrom under the Internal Revenue
Code of 1986 (the "Code"), or any applicable state, local or foreign Tax Law.
To the extent that any amounts are so deducted and withheld and paid to the
appropriate Governmental Authorities, those amounts shall be treated as having
been delivered to the Person in respect of whom such deduction or withholding
was made for all purposes under this Agreement.

  

  

(g) No Liability. None of Parent, the Surviving Corporation, Newco or the
Exchange Agent shall be liable to any holder of Certificates or Book-Entry
Shares for any amount properly paid to a public official under any applicable
abandoned property, escheat or similar Law.

  

  

(h) Investment of Exchange Fund. The Exchange Agent shall invest the cash
portion of the Exchange Fund as directed by Parent; provided, that such

  

  

  

 

 

 

  

 

6  

  

 

 

 

  

  

  

investment shall be in obligations of, or guaranteed by, the United States of
America, in commercial paper obligations of issuers organized under the Law of
a state of the United States of America, rated A-1 or P-1 or better by Moody's
Investors Service, Inc. or Standard and Poor's Ratings Service, respectively, or
in certificates of deposit, bank repurchase agreements or bankers' acceptances
of commercial banks with capital exceeding $10 billion, or in mutual funds
investing in such assets. Any such investment shall be for the benefit, and at
the risk, of Parent, and any interest or other income resulting from such
investment shall be for the benefit of Parent; provided, that no such
investment or losses thereon shall affect the Per Share Merger Consideration
deliverable to former shareholders of the Company, and Parent shall promptly
provide, or shall cause the Surviving Corporation to promptly provide,
additional funds to the Exchange Agent for the benefit of the former
shareholders of the Company in the amount of any such losses to the extent
necessary to satisfy the obligations of Parent and the Surviving Corporation
under this Article II.

  

  

(i) Termination of Exchange Fund.

  

  

(i) Any portion of the Exchange Fund that remains unclaimed by the holders of
Certificates or Book-Entry Shares one year after the Effective Time shall be
delivered by the Exchange Agent (A) in the case of the Fractional Shares Fund
and shares of Newco Common Stock deposited in the Exchange Fund by the
Company, to Newco and (B) in the case of the cash portion of the Exchange Fund
(other than the Fractional Shares Fund), to Parent, in each case upon demand.

  

  

(ii) Thereafter, any holder of Certificates or Book-Entry Shares who has not
theretofore complied with this Article II shall look only to (A) Newco for,
and Newco shall remain liable for, delivery of the Split-Off Consideration and
(B) Parent for, and Parent shall remain liable for, delivery of the Per Share
Merger Consideration, in each case pursuant to the terms of this Article II.

  

  

(j) No Fractional Shares.

  

  

(i) No fractional shares of Newco Common Stock shall be delivered upon the
surrender for exchange of Certificates or Book-Entry Shares.

  

  

(ii) In the event that the Company amends the Newco Exchange Ratio in
accordance with Section 8.8 such that fractional shares of Newco Common Stock
would be delivered to holders of Common Stock, as promptly as practicable
following the Effective Time, Newco and Parent shall cause the Exchange Agent
to aggregate all fractional share interests of Newco Common Stock, rounded
down to the nearest whole share, and deliver such fractional share interests
to its designated broker for sale on the open market at the then prevailing
market prices, which sale or sales shall be completed as promptly as
practicable following the Effective Time. Newco and Parent shall cause the
Exchange Agent to, upon receipt of the proceeds of such sale or sales from
such designated broker, distribute the proceeds of such sale or sales to the
holders of surrendered Certificates or Book-Entry Shares in lieu of fractional
shares of Newco Common Stock. Until the proceeds of such sale or sales have
been distributed to

  

  

  

 

 

 

  

 

7  

  

 

 

 

  

  

  

the former holders of Certificates or Book-Entry Shares, the Exchange Agent
shall hold such proceeds in an account for the benefit of such former holders
(the "Fractional Shares Fund"). The portion of the Fractional Shares Fund (net
of any brokerage commissions retained by the Exchange Agent's designated
broker) to which each former holder of Certificates or Book-Entry Shares shall
be entitled, if any, shall be determined by multiplying the amount of the
aggregate proceeds comprising the Fractional Shares Fund (net of any brokerage
commissions retained by the Exchange Agent's designated broker) by a fraction,
the numerator of which is the amount of the fractional share interests in
Newco Common Stock to which such holder is entitled (after taking into account
all shares of Common Stock held at the Effective Time by such holder
(including shares of Common Stock issuable upon conversion of the Series A
Preferred Stock)) and the denominator of which is the aggregate amount of
fractional share interest in Newco Common Stock (after taking into account all
shares of Common Stock held at the Effective Time by all holders (including
shares of Common Stock issuable upon conversion of the Series A Preferred
Stock)) to which all former holders of shares of Common Stock and Series A
Preferred Stock are entitled. Cash payments are being made to holders of
Common Stock and Series A Preferred Stock in lieu of fractional shares of
Newco Common Stock for the purpose of saving Newco the expense and
inconvenience of issuing and transferring fractional shares. Such cash
payments do not represent separately bargained-for consideration.

  

  

Section 2.3 Part D Options; Part D Employee Restricted Shares; and Part D
Employee Performance Shares.

  

  

(a) The Company shall use reasonable best efforts so that, at the Effective
Time, each Company Option that is outstanding immediately before the Effective
Time and held by a Part D Employee or Former Part D Employee (as such term is
defined in the Separation Agreement) (each, a "Part D Option"), whether or not
vested and exercisable, by virtue of the Merger and without any action by
Parent, Merger Sub, the Company or the holder of that Part D Option, shall be
cancelled and converted at the Effective Time into the right to receive an
amount from Parent in cash, without interest, that is equal to the excess, if
any, of (i) the sum of (x) the Per Share Merger Consideration and (y) the
value of the Split-Off Consideration (which shall be deemed for such purpose
to be equal to the product of (A) the closing price of one share of Newco
Common Stock on NASDAQ or the national securities exchange on which the shares
of Newco Common Stock are traded on the first full day of trading after the
Closing Date and (B) the Newco Exchange Ratio (the product of (A) and (B), the
"Split-Off Consideration Value" and the sum of (x) and (y), the "Pre-Split-Off
Common Stock Value") over (ii) the per share exercise or purchase price of the
applicable Part D Option (the "Exercise Price"), multiplied by the aggregate
number of shares of Common Stock in respect of such Part D Option immediately
before the Effective Time. For the avoidance of doubt, if the Exercise Price
of a Part D Option is equal to or exceeds the Pre-Split-Off Common Stock
Value, such Part D Option shall be cancelled and terminated at the Effective
Time without payment or consideration therefor and the holder of such Part D
Option shall have no rights whatsoever with respect thereto.

  

  

  

 

 

 

  

 

8  

  

 

 

 

  

  

  

(b) Each Restricted Share that is outstanding immediately prior to the
Effective Time and held by a Part D Employee or Former Part D Employee (each,
a "Part D Employee Restricted Share") shall, at the Effective Time, be
cancelled and converted into the right to receive an amount in cash equal to
(i) the Per Share Merger Consideration plus (ii) the Split-Off Consideration
Value, on the same dates and subject to the same conditions on vesting as
applied to the Part D Employee Restricted Share immediately prior the
Effective Time, without any crediting of interest for the period from the
Effective Time until vesting; provided, that if the Part D Employee's
employment with Parent and its Affiliates is terminated other than for "Cause"
or by the Part D Employee for "Good Reason," as such terms are defined on
Section 5.7(d) of the Company Disclosure Letter, then such vesting shall be
accelerated to the date of such termination (the "Converted Restricted Share
Award").

  

  

(c) Each Earned Performance Share that is outstanding immediately prior to the
Effective Time and held by a Part D Employee or Former Part D Employee (each,
a "Part D Employee Performance Share") shall, at the Effective Time, be
cancelled and converted into the right to receive an amount in cash equal to
(i) the Per Share Merger Consideration plus (ii) the Split-Off Consideration
Value, in each case of clauses (i) and (ii) on the first to occur of (x) the
first anniversary of the date on which the Effective Time occurs and (y) the
date the Part D Employee's employment with Parent and its Affiliates is
terminated other than for "Cause" or by the Part D Employee for "Good Reason,"
as such terms are defined on Section 5.7(d) of the Company Disclosure Letter,
without any crediting of interest for the period from the Effective Time until
vesting (the "Converted Performance Share Award"). The Company shall use
reasonable best efforts so that, at the Effective Time, each Performance Share
held by a Part D Employee or a Former Part D Employee that is not an Earned
Performance Share is cancelled without consideration being due therefor.

  

  

(d) As of and following the Effective Time, the Company shall retain all
Liabilities in respect of the Part D Employee Restricted Shares, the Part D
Employee Performance Shares and the Part D Options.

  

  

(e) Parent and the Company shall, or shall cause their respective Affiliates
to, take such action (including adopting, if appropriate, equity award plans)
as is necessary or appropriate to effect the foregoing.

  

  

(f) Except as described in clauses (a) through (e) above, all terms of the
Part D Employee Performance Shares and the Part D Employee Restricted Shares
as in existence on the Effective Time, including, in the case of the Part D
Employee Restricted Shares, the vesting schedule and restrictions on transfer,
shall continue to apply to the Converted Performance Share Awards and the
Converted Restricted Share Awards, as applicable.

  

  

(g) In addition to the payments made pursuant to this Section 2.3, Parent
shall pay all accrued dividends and other distributions (including dividend
equivalents) in respect of each Part D Employee Restricted Share and Part D
Employee Performance Share with a record date prior to the Effective Time
which have

  

  

  

 

 

 

  

 

9  

  

 

 

 

  

  

  

been authorized by the Company and which remain unpaid at the Effective Time
as set forth on Section 2.3(g) of the Company Disclosure Letter. Such payments
shall be made to the holders thereof simultaneously with the payments made in
respect of the Converted Restricted Share Awards and Converted Performance
Share Awards pursuant to Section 2.3(b) and Section 2.3(c), respectively.

  

  

(h) Any payments made to Part D Employees pursuant to this Section 2.3 shall
be reduced by any income or employment tax withholding required under (A) the
Code, (B) any applicable state, local or foreign tax Law, and (C) any other
applicable Laws. To the extent that any amounts are so withheld and paid to
the appropriate Governmental Authorities, those amounts shall be treated as
having been paid to the holder of the applicable award, as applicable, for all
purposes under this Agreement.

  

  

(i) For the avoidance of doubt, the treatment of each Company Option,
Restricted Share and Performance Share not held by a Part D Employee or a
Former Part D Employee is set forth in Article VII of the Separation
Agreement.

  

  

ARTICLE III

  

  

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

  

  

As used in this Agreement, the term "Part D Entities" means the Company, Penn
Life, UAC Holding Inc., MemberHealth LLC, Universal American Statutory Trust
II, Universal American Financial Corp. Statutory Trust III, Universal American
Statutory Trust IV, Universal American Financial Corp. Statutory Trust V and
Universal American Statutory Trust VI, taken as a whole, assuming for the
representations and warranties set forth in this Article III, other than
Section 3.22, 3.26 and 3.29 that the Part D Entities had operated the Medicare
Part D Business separately from the other businesses of the Company and its
Subsidiaries since formation of the Company. Except (i) as set forth in the
corresponding sections of the disclosure letter delivered by the Company to
Parent before the execution of this Agreement (the "Company Disclosure
Letter"), it being agreed that disclosure of any item in any section of the
Company Disclosure Letter (whether or not an explicit cross reference appears)
shall be deemed to be disclosure with respect to any other section to which
the relevance of such item is reasonably apparent or (ii) as disclosed in the
Company SEC Reports filed after December 31, 2008 and before the date of this
Agreement (excluding all disclosures in any "Risk Factors" sections and any
other prospective or forward-looking information), the Company represents and
warrants to Parent and Merger Sub that:

  

  

Section 3.1 Organization and Power. Each of the Company and its Subsidiaries
is duly organized, validly existing and in good standing under the Law of its
jurisdiction of organization. The Company has the requisite power and
authority to own, lease and operate its assets and properties and to carry on
its business as now conducted. Each of the Company's Subsidiaries has the
requisite power and authority to own, lease and operate its assets and
properties and to carry on its business as now conducted, except where the
failure to have such requisite power or authority would not, individually or
in

  

  

  

 

 

 

  

 

10  

  

 

 

 

  

  

  

the aggregate, reasonably be expected to have a Company Material Adverse
Effect. Each of the Company and its Subsidiaries is duly qualified to do
business as a foreign corporation, limited liability company or other legal
entity and is in good standing in each jurisdiction where such qualification
is necessary, except where failures to be so qualified or in good standing
would not, individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect.

  

  

Section 3.2 Organizational Documents. The Company has made available to Parent
true and complete copies of the certificate of incorporation and bylaws of the
Company as in effect on the date of this Agreement (collectively, the "Company
Organizational Documents").

  

  

Section 3.3 Governmental Authorizations. The execution, delivery and
performance of this Agreement and the Split-Off Agreements by the Company and
the consummation by the Company of the transactions contemplated hereby and
thereby do not and will not require any consent, approval or other
authorization of, or filing with or notification to (collectively,
"Governmental Authorizations"), any Governmental Authority, other than:

  

  

(a) the filing of the Certificate of Merger with the Department of State of
the State of New York;

  

  

(b) the filing with the Securities and Exchange Commission (the "SEC") of (i)
a proxy statement (the "Company Proxy Statement") relating to the special
meeting of the shareholders of the Company to be held to consider the adoption
of this Agreement (the "Company Shareholders Meeting") and (ii) a registration
statement on Form S-4 to be filed by Newco in connection with the distribution
of Newco Common Stock in the Split-Off (the "Newco Form S-4");

  

  

(c) any other filings and reports that may be required in connection with this
Agreement and the transactions contemplated by this Agreement under the
Securities Exchange Act of 1934 (the "Exchange Act") or state securities Laws
or "blue sky" Laws;

  

  

(d) compliance with the Applicable Exchange rules and regulations;

  

  

(e) any filings with and approvals of a national securities exchange or The
Nasdaq Stock Market LLC ("NASDAQ") to permit the shares of Newco Common Stock
that are to be distributed in the Split-Off to be approved for listing on such
national securities exchange, or approved for quotation on NASDAQ, as the case
may be, in either case subject to official notice of issuance;

  

  

(f) the pre-merger notification required under the Hart-Scott-Rodino Antitrust
Improvements Act of 1976 (the "HSR Act");

  

  

  

 

 

 

  

 

11  

  

 

 

 

  

  

  

(g) compliance with the notice requirements of the Centers for Medicare and
Medicaid Services (" CMS") applicable to the transactions contemplated by this
Agreement (the "CMS Notice Requirements");

  

  

(h) approvals, consents, exemptions, filings and/or notices required by
federal and state insurance departments, departments of health and/or other
Governmental Authorities having jurisdiction over the Governmental
Authorizations or the Part D Entities as set forth on Section 3.3 of the
Company Disclosure Letter (exclusively as indicated thereon, the "Required
Consents"); and

  

  

(i) where the failure to obtain such Governmental Authorizations would not,
individually or in the aggregate, reasonably be expected to have a Company
Material Adverse Effect.

  

  

Section 3.4 Corporate Authorization. Assuming that the representations and
warranties of Parent and Merger Sub contained in Section 4.5(c) are true and
correct, the Company has all necessary corporate power and authority to enter
into this Agreement and the Split-Off Agreements and, subject (in the case of
this Agreement) to the receipt of the Requisite Company Vote, to consummate
the transactions contemplated hereby and thereby. The Company Board at a
meeting duly called and held has unanimously (a) approved and declared
advisable this Agreement, the Merger, the Split-Off and the transactions
contemplated by this Agreement and the Split-Off Agreements, (b) declared that
it is in the best interests of the shareholders of the Company that the
Company enter into this Agreement and the Split-Off Agreements and consummate
the Merger and the Split-Off on the terms and subject to the conditions set
forth in this Agreement and the Split-Off Agreements, (c) directed that the
adoption of this Agreement be submitted to a vote at a meeting of the
shareholders of the Company and (d) recommended to the shareholders of the
Company that they adopt this Agreement. Assuming that the representations and
warranties of Parent and Merger Sub contained in Section 4.5(c) are true and
correct and the Requisite Company Vote is received, the execution, delivery
and performance of this Agreement and the Split-Off Agreements by the Company
and the consummation by the Company of the transactions contemplated hereby
and thereby have been duly and validly authorized by all necessary corporate
action on the part of the Company. This Agreement constitutes a legal, valid
and binding agreement of the Company enforceable against the Company in
accordance with its terms (except as such enforceability may be limited by
bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and
other similar laws of general applicability relating to or affecting
creditor's rights, and to general equitable principles).

  

  

Section 3.5 Non-Contravention. The execution, delivery and performance of this
Agreement and the Split-Off Agreements by the Company and the consummation of
the transactions contemplated hereby and thereby do not and will not (a)
contravene or conflict with, or result in any violation or breach of, any
provision of the organizational or governing documents of (i) any of the
Company or (ii) any of its Subsidiaries, (b) assuming that the representations
and warranties of Parent and Merger Sub contained in Section 4.5(c) are true
and correct, contravene or conflict with, or result

  

  

  

 

 

 

  

 

12  

  

 

 

 

  

  

  

in any material violation or breach of, any Law applicable to the Company or
any of its Subsidiaries or by which any assets of the Company or any of its
Subsidiaries are bound, assuming that all Governmental Authorizations
described in Section 3.3 have been obtained or made, (c) result in any
violation, termination, cancellation or breach of, or constitute a default
(with or without notice or lapse of time or both) under, any Contracts to
which the Company or any of its Subsidiaries is a party or by which any assets
of the Company or any of its Subsidiaries are bound or (d) result in the
creation of any Liens upon any of the assets of the Company or any of its
Subsidiaries, except, in the case of clauses (c) and (d), as would not,
individually or in the aggregate, reasonably be expected to have a Company
Material Adverse Effect.

  

  

Section 3.6 Capitalization.

  

  

(a) The Company's authorized capital stock consists solely of (i) 200,000,000
shares of Common Stock, (ii) 30,000,000 shares of non-voting Common Stock par
value $0.01 per share (the "Non-Voting Common Stock") and (iii) 3,000,000
shares of Preferred Stock, par value $1.00 per share (the "Preferred Stock"),
consisting of 300,000 shares of Series A Preferred Stock and 300,000 shares of
Series B Preferred Stock, par value $1.00 per share (the "Series B Preferred
Stock"). As of December 30, 2010, (A) 74,019,140 shares of Common Stock were
issued and outstanding, (B) no shares of Non-Voting Common Stock were issued
and outstanding, (C) 897,203 shares of restricted Common Stock (each, a
"Restricted Share") were reserved for issuance and (D) 42,105 shares of
Preferred Stock were issued and outstanding, consisting of 42,105 shares of
Series A Preferred Stock and no shares of Series B Preferred Stock. As of
December 30, 2010, (1) options to purchase 5,594,943 shares of Common Stock
(each, a "Company Option") at a weighted average per share exercise price of
$13.00 were outstanding and (2) performance shares that convey the right to
acquire 761,000 shares of Common Stock (each, a "Performance Share") were
awarded but not issued, as may be increased or decreased pursuant to the
authorization of the Compensation Committee of the Company Board.

  

  

(b) Except as set forth in this Section 3.6, as of the date of this Agreement
(x) there are no outstanding shares of capital stock of the Company and (y)
there are no outstanding subscriptions, options, warrants, calls, convertible
securities, rights of first refusal, preemptive rights, or other similar
rights, agreements or commitments (other than this Agreement) relating to the
issuance or acquisition of capital stock to which the Company or any of its
Subsidiaries is a party (collectively, "Securities") obligating the Company or
any of its Subsidiaries to (i) issue, transfer or sell any shares of capital
stock or other equity interests of the Company or any of its Subsidiaries or
securities convertible into or exchangeable for such shares or equity
interests or (ii) provide an amount of funds to, or make any investment (in
the form of a loan, capital contribution or otherwise) in the Company or any
of its Subsidiaries.

  

  

(c) All outstanding shares of Common Stock and Series A Preferred Stock have
been duly authorized and are validly issued, fully paid and non-assessable and
not subject to any pre-emptive rights.

  

  

  

 

 

 

  

 

13  

  

 

 

 

  

  

  

(d) Each outstanding share of capital stock of each Subsidiary of the Company
that is a corporation is duly authorized, validly issued, fully paid and non-
assessable and not subject to any pre-emptive rights.

  

  

(e) There are no outstanding contractual obligations of the Company or any of
its Subsidiaries to repurchase, redeem or otherwise acquire any shares of
Common Stock or Series A Preferred Stock or capital stock of any Subsidiary of
the Company.

  

  

(f) There are no voting trusts, proxies or similar agreements, arrangements or
commitments to which the Company or any of its Subsidiaries is a party with
respect to the voting of any shares of capital stock of the Company or any of
its Subsidiaries, other than the Stockholders Agreement and the Voting
Agreements. There are no bonds, debentures, notes or other instruments of
indebtedness of the Company or any of its Subsidiaries that entitle the holder
of such instruments of indebtedness to vote together with shareholders of the
Company on any matters with respect to the Company or any Subsidiary.

  

  

(g) Section 3.6(g) of the Company Disclosure Letter sets forth a true,
complete and correct list of all persons who, as of December 30, 2010, held
Part D Options, Part D Employee Restricted Shares and Part D Employee
Performance Shares, indicating, with respect to each such holder, the type of
award granted, the number of shares of Common Stock subject to such award, the
exercise price of each Part D Option, and date of grant.

  

  

Section 3.7 Subsidiaries. Each of the Subsidiaries of the Company is wholly
owned by the Company, directly or indirectly, free and clear of any Liens. The
Company does not own, directly or indirectly, any capital stock of, or any
other securities convertible or exchangeable into or exercisable for capital
stock of, any Person other than the Subsidiaries of the Company. No Subsidiary
of the Company owns any shares of capital stock or Securities of the Company.

  

  

Section 3.8 Voting. Assuming that the representations and warranties of Parent
and Merger Sub contained in Section 4.5(c) are true and correct, the Requisite
Company Vote is the only vote of the holders of any class or series of the
capital stock of the Company necessary to approve and adopt (x) this
Agreement, the Merger and the transactions contemplated by this Agreement and
(y) the Split-Off Agreements and the transactions contemplated by the Split-
Off Agreements.

  

  

Section 3.9 SEC Reports. The Company has timely filed with the SEC (including
following any extensions of time for filing provided by Rule 12b-25
promulgated under the Exchange Act) all forms, reports, schedules, statements
and other documents required to be filed by the Company with the SEC since
December 31, 2008 (collectively, the "Company SEC Reports"). The Company SEC
Reports (a) were prepared in all material respects in accordance with the
applicable requirements of the Securities Act of 1933 (the "Securities Act"),
the Exchange Act and other applicable Law and (b) did not, at the time they
were filed, or if amended or restated, at the time of such

  

  

  

 

 

 

  

 

14  

  

 

 

 

  

  

  

later amendment or restatement, contain any untrue statement of a material
fact or omit to state a material fact required to be stated therein or
necessary in order to make the statements therein, in the light of the
circumstances under which such statements were made, not misleading in any
material respect. No Subsidiary of the Company is subject to the periodic
reporting requirements of the Exchange Act or is otherwise required to file
any periodic forms, reports, schedules, statements or other documents with the
SEC.

  

  

Section 3.10 Financial Statements; Internal Controls.

  

  

(a) The audited consolidated financial statements and unaudited consolidated
interim financial statements of the Company and its consolidated Subsidiaries
included in the Company SEC Reports:

  

  

(i) complied in all material respects with applicable accounting requirements
and the rules and regulations of the SEC;

  

  

(ii) were prepared in accordance with United States generally accepted
accounting principles ("GAAP") applied on a consistent basis (except as may be
indicated in the notes to those financial statements); and

  

  

(iii) fairly presented in all material respects the consolidated financial
position of the Company and its consolidated Subsidiaries as of the dates
thereof and their consolidated results of operations and cash flows for the
periods then ended (subject, in the case of any unaudited interim financial
statements, to normal year-end adjustments and the absence of notes).

  

  

(b) The unaudited financial statements for the Medicare Part D Business set
forth in Section 3.10(b) of the Company Disclosure Letter (the "Interim Part D
Financial Statements") fairly present in all material respects the financial
position of the Medicare Part D Business as of September 30, 2010 and the
results of operations of the Medicare Part D Business for the period then
ended (subject to normal year-end adjustments and the absence of notes).
Parent acknowledges that the Interim Part D Financial Statements (i) have been
prepared by the Company at the request of Parent as a basis for presenting the
financial condition of the Medicare Part D Business as of September 30, 2010
and (ii) have not been reviewed by the Company's auditors.

  

  

(c) The Company maintains disclosure controls and procedures required by Rule
13a-15 or Rule 15d-15 under the Exchange Act. Such disclosure controls and
procedures are reasonably effective to ensure that all material information
relating to the Company and its Subsidiaries required to be disclosed in the
Company's periodic reports under the Exchange Act is made known to the
Company's principal executive officer and its principal financial officer by
others within the Company or any of its Subsidiaries, and such disclosure
controls and procedures are effective in timely alerting the Company's
principal executive officer and its principal financial officer to such
information required to be included in the Company's periodic reports required
under the Exchange Act. The Company has disclosed, based on the most recent
evaluation of its principal executive officer and its principal financial
officer prior to the

  

  

  

 

 

 

  

 

15  

  

 

 

 

  

  

  

date of this Agreement, to the Company's auditors and the audit committee of
the Company Board (i) all significant deficiencies and material weaknesses in
the design or operation of internal controls over financial reporting which
are reasonably likely to adversely affect the Company's or any of its
Subsidiaries' ability to record, process, summarize and report financial
information in any material respect and (ii) any fraud, whether or not
material, that involves management or other employees who have a significant
role in the Company internal controls.

  

  

Section 3.11 Undisclosed Liabilities. There are no liabilities or obligations
of any kind, whether accrued, contingent, absolute, inchoate or otherwise
(collectively, "Liabilities") of the Company or any of its Subsidiaries, other
than:

  

  

(a) Liabilities reflected or reserved against in the consolidated balance
sheet of the Company and its consolidated Subsidiaries as of September 30,
2010 (the "Balance Sheet Date") or the footnotes thereto set forth in the
Company SEC Reports;

  

  

(b) Liabilities incurred since the Balance Sheet Date in the ordinary course
of business; or

  

  

(c) Liabilities that would not, individually or in the aggregate, reasonably
be expected to have a Company Material Adverse Effect.

  

  

Section 3.12 Absence of Certain Changes. Except as otherwise expressly
contemplated or required by this Agreement or the Split-Off Agreements, since
the Balance Sheet Date to the date of this Agreement, (a) the Medicare Part D
Business has been conducted, in all material respects, in the ordinary course,
(b) there has not been any event, circumstance, development, change or effect
that, individually or in the aggregate, has had or would reasonably be
expected to have a Company Material Adverse Effect, and (c) there has not been
any action taken by the Company or any of its Subsidiaries that, if such
action had been taken during the period from the date of this Agreement
through the Effective Time without Parent's consent, would constitute a breach
of Section 5.1(a) through (d), (f) or (k).

  

  

Section 3.13 Litigation. As of the date of this Agreement, (a) there are no
legal actions, claims, demands, arbitrations, hearings, charges, complaints,
sanctions, investigations, examinations, indictments, litigations, suits or
other civil, criminal, administrative or investigative proceedings
(collectively, "Legal Actions") pending or, to the Knowledge of the Company,
threatened against the Company or any of its Subsidiaries that would,
individually or in the aggregate, reasonably be expected to have a Company
Material Adverse Effect and (b) there are no Orders outstanding against the
Company or any of its Subsidiaries that would, individually or in the
aggregate, reasonably be expected to have a Company Material Adverse Effect.

  

  

  

 

 

 

  

 

16  

  

 

 

 

  

  

  

Section 3.14 Material Contracts.

  

  

(a) Section 3.14 of the Company Disclosure Letter sets forth a list of each
Contract to which, as of the date of this Agreement, the Company or any of its
Subsidiaries is a party and which is primarily related to the Medicare Part D
Business, organized under captions representing each subsection set forth
below (each, a "Material Contract"):

  

  

(i) each Contract to which the Medicare Part D Business is (or, after the
Effective Time, any Part D Entity will be) a party and filed as an exhibit to
the Company's Annual Report on Form 10-K for the year ended December 31, 2009
pursuant to Item 601(b)(10) of Regulation S-K under the Securities Act or
disclosed by the Company in a Current Report on Form 8-K since the Balance
Sheet Date and before the date of this Agreement (in each case, other than any
Company Benefit Plan);

  

  

(ii) each Contract containing covenants of the Medicare Part D Business (A)
not to (or otherwise restricting or limiting the ability of the Medicare Part
D Business, the Part D Entities or any of their respective Affiliates, to)
compete in any line of business or geographic area or (B) to restrict the
ability of the Medicare Part D Business, the Part D Entities or any of their
respective Affiliates, to conduct business in any geographic area;

  

  

(iii) each Contract providing for or resulting in payments by or to the
Medicare Part D Business in excess of $1,000,000 annually or $3,000,000 over
the remaining term of the contract;

  

  

(iv) all material agreements with CMS or any other federal or state healthcare
program;

  

  

(v) all material agreements with any State insurance department;

  

  

(vi) all contracts and agreements granting to any Person an option or a first
refusal, first offer or similar preferential right to purchase or acquire any
of the assets of a Part D Entity;

  

  

(vii) material contracts and agreements for the granting or receiving of a
license, sublicense or franchise or under which any Person is obligated to pay
or has the right to receive a royalty, license fee, franchise fee or similar
payment;

  

  

(viii) all material reinsurance agreements for ceded reinsurance or material
marketing agreements;

  

  

(ix) all partnership, joint venture or other similar agreements or
arrangements;

  

  

(x) all material settlement agreements;

  

  

  

 

 

 

  

 

17  

  

 

 

 

  

  

  

(xi) any agreement with any director, officer or shareholder of the Company or
any Subsidiary that is required to be described under Item 404 of the
Regulation S-K of the SEC in the Company SEC Reports;

  

  

(xii) any agreement relating to indebtedness for borrowed money or the
deferred purchase price of property (in either case, whether incurred,
assumed, guaranteed or secured by any asset), except any such agreement with
an aggregate outstanding principal amount not exceeding $500,000 and which may
be prepaid on not more than 30 days' notice without the payment of any
penalty; and

  

  

(xiii) to the extent not set forth in Section 3.14(a) of the Company
Disclosure Letter pursuant to another subsection of this Section 3.14(a), all
material agreements with any Governmental Authority.

  

  

(b) A true and complete copy of each Material Contract entered into prior to
the date of this Agreement has been made available to Parent prior to the date
of this Agreement. Each Material Contract is a valid and binding agreement of
the Medicare Part D Business, except where failures to be valid and binding
would not, individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect. Except as would not, individually or in the
aggregate, reasonably be expected to have a Company Material Adverse Effect,
(i) neither the Medicare Part D Business nor, to the Knowledge of the Company,
any other party thereto, is in breach of or default under any such Material
Contract, and (ii) as of the date of this Agreement, no party under any
Material Contract has given written notice of its intent to terminate or
otherwise seek a material amendment to such Material Contract.

  

  

Section 3.15 Benefit Plans.

  

  

(a) Section 3.15(a) of the Company Disclosure Letter lists all material
Company Benefit Plans. For purposes of this Agreement a "Company Benefit Plan"
is, whether or not written, (i) any "employee benefit plan" within the meaning
of Section 3(3) of the Employee Retirement Income Security Act of 1974, as
amended ("ERISA"), (ii) any compensation, stock purchase, stock option, equity
or equity-based compensation, severance, employment, consulting, change-of-
control, bonus, incentive, deferred compensation and other employee benefit
plan, agreement, program or policy, whether or not subject to ERISA, (iii) any
plan, agreement, program or policy providing vacation benefits, insurance
(including any self-insured arrangements), medical, dental, vision or
prescription benefits, disability or sick leave benefits, life insurance,
employee assistance program, workers' compensation, supplemental unemployment
benefits and post-employment or retirement benefits (including compensation,
pension or insurance benefits) or (iv) any material loan to or for the benefit
of an officer of any Part D Entity, in each case (A) under which any current
or former director, officer, employee or independent contractor of any of the
Part D Entities has any right to benefits, (B) which are maintained, sponsored
or contributed to by any of the Part D Entities or to which any of the Part D
Entities makes or is required to make contributions with respect to such
directors, officers, employees or independent contractors and (C) under which
any of the

  

  

  

 

 

 

  

 

18  

  

 

 

 

  

  

  

Part D Entities has any liability. All such plans, agreements, programs and
policies are collectively referred to as the "Company Benefit Plans."

  

  

(b) With respect to each Company Benefit Plan, if applicable, the Company has
made available to Parent true and complete copies of (i) the plan document and
any amendments thereto, (ii) the most recent summary plan description, (iii)
the most recent annual report on Form 5500 (including all schedules) and tax
return on Form 990, (iv) the most recent annual audited financial statements
and opinion, (v) if the Company Benefit Plan is intended to qualify under
Section 401(a) of the Code, the most recent determination letter received from
the Internal Revenue Service (the "IRS") and (vi) any related trust or funding
agreements or insurance policies.

  

  

(c) Neither the Company nor any of its ERISA Affiliates maintains, sponsors,
administers or contributes to (or is required to sponsor, maintain administer
or contribute to), and has not within the preceding six years maintained,
sponsored or contributed to, any employee benefit plan subject to Section 412
of the Code or Title IV of ERISA.

  

  

(d) Each Company Benefit Plan has been maintained in compliance with ERISA,
the Code and other applicable Law in all material respects. With respect to
each Company Benefit Plan that is intended to qualify under Section 401(a) of
the Code (i) a favorable determination or opinion letter has been issued by
the IRS with respect to such qualification, (ii) its related trust has been
determined to be exempt from taxation under Section 501(a) of the Code and
(iii) except as would not, individually or in the aggregate, reasonably be
material, no event has occurred since the date of such qualification or
exemption that would adversely affect such qualification or exemption.

  

  

(e) Neither the Company nor any of its Subsidiaries has any current or
projected liability with respect to, and no Company Benefit Plan provides,
health, medical, life insurance or death benefits with respect to current or
former employees of the Medicare Part D Business beyond their retirement or
other termination of service, other than coverage mandated by COBRA or Section
4980B of the Code, or any similar state group health plan continuation Law,
the cost of which is fully paid by such current or former employees or their
dependents.

  

  

(f) The execution and delivery of this Agreement and the consummation of the
transactions contemplated by this Agreement will not (either alone or in
combination with another event) (i) result in any payment from any of the Part
D Entities becoming due, or increase the amount of any compensation due, to
any current or former employee, director or independent contractor of any of
the Part D Entities, (ii) increase any benefits otherwise payable under any
Company Benefit Plan, (iii) result in the acceleration of the time of payment
or vesting of any compensation or benefits from any of the Part D Entities to
any current or former employee, director or independent contractor of the Part
D Entities, or (iv) result in any funding, through a grantor trust or
otherwise, of any compensation or benefits to any current or former

  

  

  

 

 

 

  

 

19  

  

 

 

 

  

  

  

employee, director or independent contractor of any of the Part D Entities
under any Company Benefit Plan.

  

  

(g) No Company Benefit Plan could give rise to the payment of any amount that
would not be deductible pursuant to Section 280G of the Code.

  

  

(h) There are no pending, or, to the Knowledge of the Company, threatened,
material claims, investigations, audits or litigation against or involving any
Company Benefit Plan, other than ordinary claims for benefits by participants
and beneficiaries.

  

  

(i) Section 3.15(i) of the Company Disclosure Letter lists each individual
who, as of the date hereof, is an employee of the Medicare Part D Business
(each, a "Part D Employee") and each individual's title, annual salary and
most recent target annual bonus, date of hire, work location, vacation and
paid time off accrual, active status, severance entitlement and outstanding
equity.

  

  

(j) Section 3.15(j) of the Company Disclosure Letter lists all new hires into
the Medicare Part D Business and any employee transfers into or out of the
Medicare Part D Business within the six months prior to the date of this
Agreement.

  

  

Section 3.16 Labor Relations.

  

  

(a) As of the date of this Agreement, (i) no employee of the Medicare Part D
Business is represented by a union and, to the Knowledge of the Company, no
union organizing efforts are currently being conducted, (ii) the Medicare Part
D Business is not a party to, and is not currently negotiating in connection
with entering into, any material collective bargaining agreement or other
labor contract, and (iii) except as would not, individually or in the
aggregate, reasonably be expected to be material to the Company and its
Subsidiaries, taken as a whole, the Medicare Part D Business does not
currently have, and, to the Knowledge of the Company, has not been threatened
with, a strike, picket, work stoppage, work slowdown or other organized labor
dispute.

  

  

(b) Except as would not, individually or in the aggregate, reasonably be
expected to be material to the Medicare Part D Business, (i) each of the Part
D Entities is in compliance with all applicable Laws relating to the
employment of labor, including all applicable Law relating to wages, hours,
collective bargaining, employment discrimination, civil rights, safety and
health, workers' compensation, pay equity, continuation coverage with respect
to group health plans, immigration control and the collection and payment of
withholding or social security taxes, and (ii) none of the Part D Entities
have incurred any liability or obligation under the Worker Adjustment and
Retraining Notification Act (the "WARN Act") or any similar state or local Law
within the last six months that remains unsatisfied.

  

  

(c) Except as would not, individually or in the aggregate, reasonably be
expected to be material to the Medicare Part D Business, since the Balance

  

  

  

 

 

 

  

 

20  

  

 

 

 

  

  

  

Sheet Date, the Medicare Part D Business has not effectuated (i) a "plant
closing" (as defined in the WARN Act) affecting any site of employment or one
or more facilities or operating units within any site of employment or
facility of the Company or any of its Subsidiaries, (ii) a "mass layoff" (as
defined in the WARN Act) or (iii) such other transaction, layoff, reduction in
force or employment terminations sufficient in number to trigger application
of any similar foreign, state or local Law.

  

  

Section 3.17 Taxes.

  

  

(a) All material Tax Returns required to be filed by or with respect to the
Company or any of its Subsidiaries have been timely filed (taking into account
all applicable extensions), and all such Tax Returns are true, complete and
correct in all material respects.

  

  

(b) The Company and its Subsidiaries have fully and timely paid (or have had
paid on their behalf) all material Taxes due and owing (whether or not shown
on any of the Tax Returns referred to in Section 3.17(a)).

  

  

(c) There are no outstanding agreements extending or waiving the statutory
period of limitations applicable to any claim for, or the period for the
collection, assessment or reassessment of, any material Taxes due from the
Company or any of its Subsidiaries for any taxable period and no request for
any such waiver or extension is currently pending.

  

  

(d) No audit or other proceeding or investigation by any Governmental
Authority is pending or, to the Knowledge of the Company, threatened with
respect to any material Taxes due from or with respect to the Company or any
of its Subsidiaries.

  

  

(e) All deficiencies for material Taxes asserted or assessed in writing
against the Company or any of its Subsidiaries have been fully and timely
paid, settled or properly reflected in the most recent financial statements
contained in the Company SEC Reports.

  

  

(f) There are no material Liens for Taxes on any assets of the Company or any
of its Subsidiaries, other than Permitted Liens.

  

  

(g) During the two-year period ending on the date hereof, neither the Company
nor any of its Subsidiaries was a "distributing corporation" or a "controlled
corporation" in a transaction intended to be governed by Section 355 of the
Code.

  

  

(h) Since December 31, 2008, to the Knowledge of the Company, neither the
Company nor any of its Subsidiaries has participated in any "listed
transaction" within the meaning of Treasury Regulations Section 1.6011-4.

  

  

  

 

 

 

  

 

21  

  

 

 

 

  

  

  

(i) (i) Neither the Company nor any of its Subsidiaries is or has been a
member of an affiliated group of corporations within the meaning of Section
1504 of the Code or any group that has filed a combined, consolidated or
unitary Tax Return (other than the group of which the Company is or was the
common parent), and (ii) neither the Company nor any of its Subsidiaries has
any liability for any material Taxes of any Person (other than the Company or
its Subsidiaries) under Treasury Regulations Section 1.1502-6 (or any similar
provision of state, local or foreign law), as a transferee or successor, by
contract or otherwise.

  

  

(j) There are no material Tax sharing agreements or similar arrangements
(including Tax indemnity arrangements other than customary commercial or
financial arrangements entered into in the ordinary course of business
consistent with past practice) with respect to or involving the Company or any
of its Subsidiaries.

  

  

Section 3.18 Environmental Matters. Except as would not, individually or in
the aggregate, reasonably be expected to have a Company Material Adverse
Effect, (a) the Company and each of its Subsidiaries comply with all
applicable Environmental Laws, (b) the Company and each of its Subsidiaries
possess all Permits required under Environmental Law necessary for their
respective operations, and are in compliance with such Permits and all such
Permits are in full force and effect, (c) no Legal Action, arising under,
relating to, or pursuant to Environmental Law is pending, or to the Knowledge
of the Company, threatened, against the Company or any of its Subsidiaries (d)
no condition, fact or set of circumstances relating to the Company or any of
its Subsidiaries or any property currently or formerly owned, or, to the
Knowledge of the Company, leased or operated by the Company or any of its
Subsidiaries exists or has existed which has given rise to, or would
reasonably be expected to give rise to, any Liability under any Contract
relating to environmental or Hazardous Substances matters or Environmental
Law, and (e) the execution, delivery, and performance of this Agreement and
the Split-Off Agreements and the consummation of the transactions contemplated
hereby and thereby, by the Company, does not and will not require any
Governmental Authorizations under any Environmental Law.

  

  

Section 3.19 Intellectual Property.

  

  

(a) As of the Effective Time and after giving effect to the transactions
contemplated by the Split-Off Agreements (excluding the Transition Services
Agreement and assuming the receipt of the consents listed on Section 3.3 and
Section 3.5 of the Company Disclosure Letter) the Part D Entities will own or
will be licensed to use pursuant to valid, enforceable and binding Contracts,
all Intellectual Property used, held for use or necessary for the operation of
the Medicare Part D Business (collectively, the "Company Intellectual
Property"), except as would not, individually or in the aggregate, reasonably
be expected to have a Company Material Adverse Effect. Section 3.19(a) of the
Company Disclosure Letter sets forth a true and complete list of all
Intellectual Property owned by the Part D Entities that is registered, issued
or the subject of a pending application for registration. Except as would not,
individually or in the aggregate, reasonably be expected to have a Company
Material

  

  

  

 

 

 

  

 

22  

  

 

 

 

  

  

  

Adverse Effect, the execution, delivery and performance of this Agreement by
the Company and the consummation by the Company of the transactions
contemplated by this Agreement do not and will not encumber, impair or
extinguish any of the Company Intellectual Property.

  

  

(b) Except as would not, individually or in the aggregate, reasonably be
expected to have a Company Material Adverse Effect, (i) none of the
Intellectual Property owned by the Part D Entities (A) has been adjudged
invalid or unenforceable in whole or in part, or (B) is the subject of any
cancellation or reexamination proceeding or any other proceeding challenging
its validity and enforceability, and (ii) to the Knowledge of the Company, all
Intellectual Property owned by the Part D Entities is valid and enforceable.
There exist no material restrictions on the disclosure, use, license or
transfer of any Intellectual Property owned by the Part D Entities.

  

  

(c) Except as would not, individually or in the aggregate, reasonably be
expected to have a Company Material Adverse Effect, (i) the conduct of the
Medicare Part D Business does not infringe upon, misappropriate or otherwise
violate the Intellectual Property rights of any third party and (ii) no claim
is pending, asserted in writing, or to the Knowledge of the Company,
threatened against any of the Part D Entities that the conduct of the Medicare
Part D Business infringes upon, misappropriates or otherwise violates the
Intellectual Property rights of any third party. To the Knowledge of the
Company, no Person is infringing upon, misappropriating or otherwise violating
any Intellectual Property owned by the Part D Entities in any respect.

  

  

(d) Except as would not, individually or in the aggregate, reasonably be
expected to have a Company Material Adverse Effect, the Company and the Part D
Entities have taken reasonable steps in accordance with normal industry
practice to maintain the confidentiality of all Company Intellectual Property
that is material to the Medicare Part D Business and the value of which is
contingent upon maintaining the confidentiality thereof. Except as would not,
individually or in the aggregate, reasonably be expected to have a Company
Material Adverse Effect, none of the Company Intellectual Property that is
material to the Medicare Part D Business and the value of which is contingent
upon maintaining the confidentiality thereof, has been disclosed other than to
third parties that are bound by customary written confidentiality agreements
entered into in the ordinary course of business consistent with past practice.

  

  

(e) As of the Effective Time and after giving effect to the transactions
contemplated by this Agreement and the Split-Off Agreements (excluding the
Transition Services Agreement and assuming the receipt of the consents listed
on Section 3.3 and Section 3.5 of the Company Disclosure Letter), the Part D
Entities will own or possess, adequate licenses or other rights from third
parties pursuant to valid, binding and enforceable Contracts (except as such
enforceability may be limited by bankruptcy, insolvency, fraudulent transfer,
reorganization, moratorium and other similar laws of general applicability
relating to or affecting creditor's rights, and to general equitable
principles), to use all material computer software used or held for use in

  

  

  

 

 

 

  

 

23  

  

 

 

 

  

  

  

connection with the operation of the Medicare Part D Business (collectively,
the "Computer Software"), except as would not, individually or in the
aggregate, reasonably be expected to have a Company Material Adverse Effect.
Without limiting the foregoing, to the extent that any Computer Software has
been developed or created by a third party (including any current or former
employee of any of the Part D Entities) for any of the Part D Entities, the
Part D Entities have a written agreement with such third party with respect
thereto, and the Part D Entities thereby either (i) have obtained ownership or
and are the exclusive owner of, or (ii) have obtained a valid and unrestricted
right to exploit, sufficient for the conduct of the Medicare Part D Business,
such Computer Software, except as would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect.

  

  

(f) The IT Assets operate and perform in a manner that permits the Part D
Entities to conduct the Medicare Part D Business as currently conducted and in
compliance with applicable Medicare Part D requirements, in each case, in all
material respects, and, to the Knowledge of the Company, (i) no Person has
gained unauthorized access to any of the IT Assets and (ii) there has been no
failure of the IT Assets within the past two (2) years, except in the case of
clauses (i) and (ii) as would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect. The Part D
Entities have implemented reasonable backup and disaster recovery technology
consistent with normal industry practice, except as would not, individually or
in the aggregate, reasonably be expected to have a Company Material Adverse
Effect.

  

  

(g) Except as would not, individually or in the aggregate, reasonably be
expected to have a Company Material Adverse Effect, the Company and the Part D
Entities have at all times complied with all applicable Laws relating to
privacy, data protection and the collection and use of personal information
and user information gathered or accessed in the course of conduct of the
Medicare Part D Business. Except as would not, individually or in the
aggregate, reasonably be expected to have a Company Material Adverse Effect,
no claims have been asserted or, to the Knowledge of the Company, threatened
against the Part D Entities by any Person alleging a violation of such
Person's privacy, personal or confidentiality rights under any such applicable
Laws.

  

  

Section 3.20 Real Property; Personal Property.

  

  

(a) Except as would not, individually or in the aggregate, reasonably be
expected to have a Company Material Adverse Effect, (i) the Part D Entities
have good and marketable title to, or have a valid and enforceable right to
use or a valid and enforceable leasehold interest in, all real property
(including all buildings, fixtures and other improvements thereto) used by the
Medicare Part D Business and (ii) the ownership of or leasehold interest in
any such property of the Medicare Part D Business is not subject to any Lien
(except in all cases for Permitted Liens).

  

  

(b) Except as would not, individually or in the aggregate, reasonably be
expected to have a Company Material Adverse Effect, each of the material
leases, subleases and other agreements under which any of the Medicare Part D
Business uses or occupies or has the right to use or occupy, now or in the
future, any material real

  

  

  

 

 

 

  

 

24  

  

 

 

 

  

  

  

property (the "Real Property Leases") is valid and binding (except as may be
limited by bankruptcy, insolvency, fraudulent transfer, reorganization,
moratorium and other similar laws of general applicability relating to or
affecting creditor's rights, and to general equitable principles), and no
termination event or condition or uncured default on the part of the Medicare
Part D Business exists under any Real Property Lease.

  

  

(c) Except as would not, individually or in the aggregate, reasonably be
expected to have a Company Material Adverse Effect, (i) the Part D Entities
have good and marketable title to, or a valid and enforceable leasehold
interest in, all personal assets of the Medicare Part D Business and (ii) the
ownership of or leasehold interest by the Part D Entities in any such personal
assets of the Medicare Part D Business is not subject to any Liens (except in
all cases for Permitted Liens).

  

  

Section 3.21 Permits; Compliance with Law.

  

  

(a) The Part D Entities are in possession of all material franchises, grants,
authorizations, licenses, easements, variances, exceptions, consents,
certificates, approvals and other permits of any Governmental Authority
("Permits") necessary for the Part D Entities to own, lease and operate their
respective properties and assets or to carry on their respective business as
it is now being conducted (all Permits held by the Part D Entities shall be
hereinafter referred to as the "Company Permits"). All such Company Permits
are in full force and effect, no suspension or cancellation by a Governmental
Authority of any of the Company Permits is pending or, to the Knowledge of the
Company, has been threatened by a Governmental Authority against a Part D
Entity. Since December 31, 2008, no Part D Entity has received written notice
of any action pending or recommended by any Governmental Authority to revoke,
withdraw or suspend any Company Permit.

  

  

(b) Each Part D Entity is, and since December 31, 2008 has been, in compliance
in all material respects with (i) all Laws applicable to the Medicare Part D
Business or by which any of its assets is bound and (ii) all Laws applicable
to, and the terms and conditions of, any Company Permits.

  

  

(c) No representation is made under this Section 3.21 with respect to the
matters specifically addressed in Section 3.18.

  

  

Section 3.22 Regulatory Matters.

  

  

(a) Each of the Part D Entities is, and since December 31, 2008 has been, in
compliance in all material respects with all applicable Health Care Laws and
any Orders to which it is a party or is subject. Except for matters arising in
the ordinary course of business consistent with past practice, at all times
since December 31, 2008, no Part D Entity has received any written notice,
citation, suspension, revocation, limitation, warning, or request for
repayment or refund issued by a Governmental Authority which alleges or
asserts that any of the Part D Entities have violated any applicable Health
Care Laws in any material respect or which requires or seeks to adjust, modify
or alter in any material respect the Medicare Part D Business' operations,
activities, services or financial

  

  

  

 

 

 

  

 

25  

  

 

 

 

  

  

  

condition that has not been fully and finally resolved to the Governmental
Authority's satisfaction without further liability to any of the Part D
Entities. There are no restrictions imposed by any Governmental Authority upon
any of the Medicare Part D Business', activities or services which would
restrict or prevent the Medicare Part D Business from operating as it
currently operates, in all material respects.

  

  

(b) As of the date of this Agreement, none of the Part D Entities is currently
the subject of any material Legal Actions, or to the Knowledge of the Company,
material investigations or focused reviews by a Governmental Authority
regarding its compliance with applicable Health Care Laws.

  

  

(c) Each Part D entity is in compliance in all material respects with the (i)
Benefits and Benefit Protection Requirements set forth at 42 C.F.R. Part 423,
Subpart C, (ii) Cost Control and Quality Improvement Requirements set forth at
42 C.F.R. Part 423, Subpart D, (iii) Grievance, Coverage Determinations and
Appeals Requirements set forth at 42 C.F.R. Part 423, Subpart M, (iv) rules
regarding beneficiary premiums set forth at 42 C.F.R. 423.286 and 423.293,
(v) coordination of benefit requirements set forth at 42 C.F.R. 423.464, (vi)
Part D Marketing Requirements set forth at 42 C.F.R. Part 423, Subpart V,
(vii) Requirements for Submission of Bids, 42 C.F.R. Part 423, Subpart F,
(viii) Premium and Cost Sharing Requirements, 42 C.F.R. Part 423, Subpart P,
and (ix) the terms, conditions and requirements of Chapter 9 of the Centers
for Medicare and Medicaid Services Prescription Drug Benefit Manual (Part D.
Program to Control Fraud, Waste and Abuse). With respect to the Medicare Part
D Business, there is not currently in effect, and for the past twelve months
prior to the date of this Agreement there has not been imposed, any sanction
or civil monetary penalty in accordance with 42 C.F.R. 423.752.

  

  

(d) Each Part D Entity has established and implemented programs, policies,
procedures, contracts and systems reasonably designed to cause its and its
employees and agents to comply in all material respects with the applicable
provisions of the Health Insurance Portability and Accountability Act of 1996
(Pub. L. No. 104-191), as amended, and the Health Information Technology for
Economic and Clinical Health Act (Pub. L. No. 111-5), and any state privacy or
medical information Laws applicable to the Medicare Part D Business
(collectively, the "Healthcare Information Laws"). Each Part D Entity is in
compliance in all material respects with the applicable Healthcare Information
Laws.

  

  

(e) The Part D Entities have developed and implemented a compliance program
including policies and procedures reasonably designed to cause the Part D
Entities and its agents and employees to be in compliance with all applicable
Health Care Laws in all material respects. The compliance program meets the
requirements of Chapter 9 of the Centers for Medicare and Medicaid Services'
Prescription Drug Benefit Manual in all material respects.

  

  

(f) None of the Part D Entities or, to the Knowledge of the Company, any of
their directors, officers, agents, or employees, in their individual
capacities, has directly or indirectly made or offered to make any
contribution, gift, bribe,

  

  

  

 

 

 

  

 

26  

  

 

 

 

  

  

  

rebate, payoff, influence payment, kickback to any Person, regardless of form:
(i) in violation of the federal Anti-Kickback Statute, 42 U.S.C. 1320a-7b, or
(ii) to obtain or maintain favorable treatment in securing business in
material violation of any applicable Health Care Law.

  

  

Section 3.23 Takeover Statutes. Assuming that the representations and
warranties of Parent and Merger Sub contained in Section 4.5(c) are true and
correct, the Company Board has taken all necessary action to ensure that the
restrictions on business combinations contained in Section 912 of the NYBCL
will not apply to this Agreement, the Merger or the other transactions
contemplated by this Agreement, including by approving this Agreement, the
Merger and the other transactions contemplated by this Agreement. There is no
shareholder rights plan, "poison pill" anti-takeover plan or other similar
plan, device or arrangement to which the Company or any of its Subsidiaries is
a party or by which it or they are bound with respect to any capital stock of
the Company or any of its Subsidiaries.

  

  

Section 3.24 Transactions with Affiliates. Except for any agreements entered
into after the date of this Agreement as permitted by Section 5.1(m), other
than the rights to receive the Closing Consideration, there are no
transactions, arrangements or contracts, between the Company or any Subsidiary
of the Company, on the one hand, and any Affiliate of the Company (other than
the Company's wholly owned Subsidiaries), on the other hand, that are required
to be described under Item 404 of the Regulation S-K of the SEC in the Company
SEC Reports, which are not described therein.

  

  

Section 3.25 Insurance. The Part D Entities are covered by valid and currently
effective insurance policies and all premiums payable under such policies have
been duly paid to date. None of the Part D Entities have received any written
notice of cancellation of any such policy. All material fire and casualty,
general liability, business interruption, product liability, and sprinkler and
water damage insurance policies maintained by or on behalf of the Part D
Entities ("Insurance Policies") provide adequate coverage for all normal risks
incident to the business of the Part D Entities and their properties and
assets, except for any such failures to maintain Insurance Policies that,
individually or in the aggregate, would not reasonably be expected to have a
Company Material Adverse Effect.

  

  

Section 3.26 Insurance Reports. Each of the Part D Entities through which the
Company conducts insurance operations is listed in Section 3.26 of the Company
Disclosure Letter (the "Part D Insurance Entities"). Since December 31, 2008,
each of the Part D Insurance Entities has filed all annual and quarterly
statements, together with all material exhibits, interrogatories, notes,
schedules and any actuarial opinions, affirmations or certifications or other
supporting documents in connection therewith, in each case required to be
filed by such Part D Entity with or submitted by such Part D Entity to the
appropriate insurance regulatory authorities of the jurisdiction in which it
is domiciled or commercially domiciled on forms prescribed or permitted by
such authority (collectively, the "SAP Statements"). The Company has delivered
or made available to the Parent, to the extent permitted by applicable Laws,
copies of all such

  

  

  

 

 

 

  

 

27  

  

 

 

 

  

  

  

annual SAP Statements for the periods beginning January 1, 2008 and through
the date hereof and all such quarterly SAP Statements for the quarterly
periods ended March 31, 2010, June 30, 2010 and September 30, 2010, each in
the form (including exhibits, annexes and any amendments thereto) filed with
state insurance regulatory authorities and true and complete copies of all
examination reports of insurance departments and any insurance regulatory
authorities received by the Company on or after January 1, 2008 and through
the date hereof relating to the Part D Insurance Entities. The financial
statements included in SAP Statements and prepared on a statutory accounting
basis, including the notes thereto, were prepared in all material respects in
conformity with statutory accounting practices ("SAP") prescribed or permitted
by the applicable state insurance regulatory authority, in each case,
consistently applied for the periods covered thereby and fairly present in all
material respects the statutory financial position of the relevant Part D
Insurance Entity as at the respective dates thereof and the results of
operations of such Part D Insurance Entity for the respective periods then
ended. SAP Statements complied in all material respects with all applicable
Law when filed. Any financial statements of any Part D Insurance Entity that
were prepared in accordance with GAAP and filed with any insurance regulatory
authority were prepared in conformity with GAAP consistently applied for the
periods covered thereby and present fairly in all material respects in
accordance with GAAP the financial position of the relevant Part D Insurance
Entity as at the respective dates thereof and the results of operations of
such Part D Insurance Entity for the respective periods then ended
(collectively, the "GAAP Statements"). No material deficiency has been
asserted to the Part D Insurance Entities by any Governmental Authority with
respect to any SAP Statements or GAAP Statements. Except as indicated therein,
all assets that are reflected as admitted assets on SAP Statements or GAAP
Statements comply in all material respects with all applicable Law (including
the filing of any required reports) regulating the business and products of
insurance and all applicable orders and directives of insurance regulatory
authorities and market conduct recommendations resulting from market conduct
examinations of insurance regulatory authorities (collectively, the "Insurance
Laws") with respect to admitted assets, as applicable. The statutory balance
sheets and income statements included in SAP Statements and or GAAP Statements
have been audited by the Company's independent auditors, and the Company has
delivered or made available to Parent true and complete copies of all audit
opinions related thereto for periods beginning January 1, 2009. The Part D
Insurance Entities comply in all material respects with all applicable
solvency requirements, including risk-based capital requirements under
applicable Insurance Laws.

  

  

Section 3.27 Insurance Laws. Since December 31, 2008, the business and
operations of the Part D Insurance Entities (including business, marketing,
operations, sales and issuances of Insurance Contracts conducted by or through
Agents) have been conducted in compliance with Insurance Laws in all material
respects. In addition, (i) there is no pending or, to the Knowledge of the
Company, threatened, charge by any state insurance regulatory authority that
any of the Part D Insurance Entities has materially violated, nor is there any
pending or, to the Knowledge of the Company, threatened investigation by any
state insurance regulatory authority with respect to possible material
violations by the Part D Insurance Entities of, any applicable Insurance

  

  

  

 

 

 

  

 

28  

  

 

 

 

  

  

  

Laws; (ii) each Part D Insurance Entity has been duly authorized by the
relevant state insurance regulatory authorities to issue the policies and/or
contracts of insurance related to the Medicare Part Business that it is
currently writing and in the states in which it conducts its business; and
(iii) since December 31, 2008, the Part D Insurance Entities have filed all
material reports required to be filed by the Part D Insurance Entities with
any state insurance regulatory authority. None of the Part D Insurance
Entities is subject to any order or decree of any insurance regulatory
authority relating to such Part D Insurance Entity which (A) would,
individually or in the aggregate, be reasonably likely to have a Company
Material Adverse Effect, or (B) except as would not, individually or in the
aggregate, reasonably be expected to be material to the Medicare Part D
Business, (1) relates to material marketing, sales, trade or underwriting
practices (other than routine correspondence) from and after January 1, 2008
or (2) seeks the revocation or suspension of any license or other permit
issued pursuant to applicable Insurance Laws. No action or proceeding is
pending or, to the Knowledge of the Company, threatened which would reasonably
be expected to result in the revocation or suspension of any such material
license or permit.

  

  

Section 3.28 Insurance Business. All policies, binders, slips, certificates,
guaranteed insurance contracts, annuity contracts and other agreements of
insurance, whether individual or group, in effect as of the date of this
Agreement (including all applications, supplements, endorsements, riders and
ancillary documents forming a part of the contract in connection therewith)
that have been issued by a Part D Insurance Entity (collectively, the
"Insurance Contracts"), and any and all marketing materials which were used
for the sale of the Insurance Contracts, to the extent required under
applicable Insurance Laws, were on forms and at rates approved or deemed to
have been approved by the insurance regulatory authority of the jurisdiction
where issued or, to the extent required by applicable laws, have been filed
with and not objected to by such authority within the period provided for
objection, in each case, in all material respects. The Company has delivered
or made available to Parent the most recent reports reflecting the results of
the most recent triennial, market conduct and financial examinations of the
Part D Insurance Entities by state insurance regulatory authority and all
material deficiencies or violations Known to the Company in such reports for
any prior year have been resolved to the satisfaction of such state insurance
regulatory authority.

  

  

Section 3.29 Reinsurance. Each Part D Insurance Entity is entitled to take
full credit in its SAP Statements pursuant to Insurance Laws for all
reinsurance, coinsurance or excess insurance ceded by such Part D Insurance
Entity pursuant to any reinsurance, coinsurance, excess insurance, ceding of
insurance, assumption of insurance or indemnification with respect to
insurance or similar arrangements to which it is a party.

  

  

Section 3.30 Agents. Except as would not, individually or in the aggregate,
reasonably be expected to be material to the Medicare Part D Business (a) to
the Knowledge of the Company, each insurance agent or broker (each, an
"Agent"), at the time such Agent wrote, sold, or produced Insurance Contracts
related to the Medicare Part D Business on behalf of the Part D Insurance
Entities was duly licensed for such

  

  

  

 

 

 

  

 

29  

  

 

 

 

  

  

  

business and duly appointed by the applicable Part D Insurance Entity in
accordance with applicable Insurance Laws and (b) to the Knowledge of the
Company, no such Agent violated any term or provision of any law applicable to
the writing, sale, production or management of business for any Part D
Insurance Entity.

  

  

Section 3.31 Opinion of Financial Advisor. Goldman Sachs and Co. (the "Company
Financial Advisor") has delivered to the Company Board its opinion to the
effect that, as of the date of this Agreement, and subject to the various
limitations, assumptions, factors and matters set forth therein, the Closing
Consideration is fair to the shareholders of the Company from a financial
point of view.

  

  

Section 3.32 Brokers. No broker, finder, adviser, or investment banker other
than the Company Financial Advisor is entitled to any brokerage, success,
finder's or other similar fee or commission in connection with the Merger or
the other transactions contemplated by this Agreement based upon arrangements
made by or on behalf of the Company or any of its Subsidiaries.

  

  

Section 3.33 Sufficiency of Assets. As of the Effective Time and after giving
effect to the transactions contemplated by this Agreement and the Split-Off
Agreements (excluding the Transition Services Agreement and assuming the
receipt of the consents listed on Section 3.3 and Section 3.5 of the Company
Disclosure Letter), the assets of the Part D Entities shall constitute all of
the assets, tangible and intangible, necessary for the operation of the
Medicare Part D Business as currently conducted as of the date of this
Agreement.

  

  

ARTICLE IV 
 

  

  

REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB

  

  

Except as set forth in the corresponding sections of the disclosure letter
delivered by Parent to the Company before the execution of this Agreement (the
"Parent Disclosure Letter"), it being agreed that disclosure of any item in
any section of the Parent Disclosure Letter shall be deemed to be disclosure
with respect to any other section to which the relevance of such item is
reasonably apparent, Parent and Merger Sub represent and warrant to the
Company that:

  

  

Section 4.1 Organization and Power. Each of Parent and Merger Sub is duly
organized, validly existing and in good standing under the Law of its
jurisdiction of organization. Each of Parent and Merger Sub has the requisite
power and authority to own, lease and operate its assets and properties and to
carry on its business as now conducted.

  

  

Section 4.2 Governmental Authorizations. The execution, delivery and
performance of this Agreement by Parent and Merger Sub and the consummation by
Parent and Merger Sub of the transactions contemplated by this Agreement do
not and will not require any Governmental Authorization, other than:

  

  

  

 

 

 

  

 

30  

  

 

 

 

  

  

  

(a) the filing of the Certificate of Merger with the Department of State of
the State of New York;

  

  

(b) the filing with the SEC of any filings or reports that may be required in
connection with this Agreement and the transactions contemplated by this
Agreement under the Exchange Act or state securities Laws or "blue sky" Laws;

  

  

(c) compliance with the Applicable Exchange rules and regulations;

  

  

(d) the pre-merger notification required under the HSR Act;

  

  

(e) compliance with the CMS Notice Requirements;

  

  

(f) the Required Consents; and

  

  

(g) where the failure to obtain such Governmental Authorizations would not,
individually or in the aggregate, reasonably be expected to have a Parent
Material Adverse Effect.

  

  

Section 4.3 Authorization. Each of Parent and Merger Sub has all necessary
power and authority to enter into this Agreement and to consummate the
transactions contemplated by this Agreement. A duly authorized committee of
the board of directors of Parent has unanimously adopted resolutions approving
this Agreement and the transactions contemplated by this Agreement. The sole
member of Merger Sub has approved and adopted this Agreement, the Merger and
the transactions contemplated by this Agreement. The execution, delivery and
performance of this Agreement by each of Parent and Merger Sub and the
consummation by each of Parent and Merger Sub of the transactions contemplated
by this Agreement have been duly and validly authorized by all necessary
action on the part of Parent and Merger Sub. This Agreement constitutes a
legal, valid and binding agreement of Parent and Merger Sub enforceable
against Parent and Merger Sub in accordance with its terms (except as such
enforceability may be limited by bankruptcy, insolvency, fraudulent transfer,
reorganization, moratorium and other similar laws of general applicability
relating to or affecting creditor's rights, and to general equitable
principles). No vote or consent of the shareholders of Parent is required by
any applicable Law, or the certificate of incorporation or bylaws or other
equivalent organizational documents of Parent in connection with the Merger or
the other transactions contemplated by this Agreement.

  

  

Section 4.4 Non-Contravention. The execution, delivery and performance of this
Agreement by Parent and Merger Sub and the consummation by Parent and Merger
Sub of the transactions contemplated by this Agreement do not and will not:

  

  

(a) contravene or conflict with, or result in any violation or breach of, any
provision of the organizational documents of Parent or Merger Sub;

  

  

  

 

 

 

  

 

31  

  

 

 

 

  

  

  

(b) contravene or conflict with, or result in any violation or breach of, any
Law applicable to Parent or any of its Subsidiaries or by which any assets of
Parent or any of its Subsidiaries ("Parent Assets") are bound, assuming that
all Governmental Authorizations described in Section 3.3 and Section 4.2 have
been obtained or made;

  

  

(c) result in any violation or breach of, or constitute a default (with or
without notice or lapse of time or both) under, any Contracts to which Parent
or any of its Subsidiaries is a party or by which any Parent Assets are bound
(collectively, "Parent Contracts"), other than as would not, individually or
in the aggregate, reasonably be expected to have a Parent Material Adverse
Effect; or

  

  

(d) require any consent, approval or other authorization of, or filing with or
notification to, any Person under any Parent Contracts, other than as, if not
obtained, would not, individually or in the aggregate, reasonably be expected
to have a Parent Material Adverse Effect.

  

  

Section 4.5 Capitalization; Interim Operations of Merger Sub; Ownership of
Common Stock; Section 912 of the NYBCL.

  

  

(a) All of the issued and outstanding membership interests of Merger Sub are,
and at the Effective Time will be, owned by Parent or one of Parent's wholly
owned Subsidiaries. Merger Sub has no outstanding option, warrant, right or
any other agreement pursuant to which any Person other than Parent may acquire
any equity security of Merger Sub.

  

  

(b) Merger Sub was formed solely for the purpose of engaging in the
transactions contemplated by this Agreement and has not engaged in any
business activities or conducted any operations other than in connection with
the transactions contemplated by this Agreement. No shares of Common Stock or
securities that are convertible, exchangeable or exercisable into Common Stock
are beneficially owned (as defined by Rule 13d-3 under the Exchange Act) by
Parent or Merger Sub, or any direct or indirect wholly owned Subsidiary of
Parent or Merger Sub. Merger Sub has no Subsidiaries.

  

  

(c) None of Parent, Merger Sub or their respective Affiliates owns (directly
or indirectly, beneficially or of record) any shares of Common Stock, and none
of Parent, Merger Sub or their respective Affiliates holds any rights to
acquire or vote any shares of Common Stock except pursuant to this Agreement.
Before the action of the Company Board taken on December 30, 2010, neither
Parent nor Merger Sub, alone or together with any other Person, was at any
time, or became, an "interested shareholder" of the Company as defined in
Section 912 of the NYBCL, or has taken any action that would cause the
restrictions on business combinations with interested shareholders set forth
in Section 912 of the NYBCL to be applicable to this Agreement, the Merger or
any transactions contemplated by this Agreement.

  

  

  

 

 

 

  

 

32  

  

 

 

 

  

  

  

(d) None of Parent, Merger Sub and their respective Affiliates has any
agreement, arrangement or understanding concerning the transactions
contemplated by this Agreement with any director of the Company, other than
the Voting Agreements.

  

  

Section 4.6 Sufficient Funds. Parent's and Merger Sub's obligations hereunder
are not subject to any conditions regarding Parent's, Merger Sub's or any
other Person's ability to obtain financing for the consummation of the Merger
and the other transactions contemplated by this Agreement. Parent and Merger
Sub will have as of the Effective Time and the Closing sufficient cash
available to pay all amounts to be paid by Parent and Merger Sub in connection
with this Agreement and the transactions contemplated by this Agreement,
including Parent's and Merger Sub's costs and expenses, the aggregate Per
Share Merger Consideration, and the payments contemplated by Section 2.3 on
the terms and conditions contained in this Agreement, and as of the Effective
Time and the Closing there will not be any restriction on the use of such cash
or cash equivalents for such purpose.

  

  

Section 4.7 Litigation. As of the date of this Agreement, (a) there is no
Legal Action pending or, to the Knowledge of Parent, threatened, against
Parent or any of its Subsidiaries before any Governmental Authority that would
or seeks to materially delay or prevent the consummation of the Merger or the
transactions contemplated by this Agreement and (b) neither Parent nor any of
its Subsidiaries is subject to any Order of, or, to the Knowledge of Parent,
continuing investigation by, any Governmental Authority, in each case that
would or seeks to materially delay or prevent the consummation of any of the
transactions contemplated by this Agreement.

  

  

Section 4.8 Absence of Arrangements with Management. Other than this Agreement
and the Voting Agreements and the Split-Off Agreements, there are no
contracts, undertakings, commitments, agreements or obligations or
understandings between Parent or Merger Sub or any of their respective
Affiliates, on the one hand, and any member of the Company's management or the
Company Board, on the other hand, relating to the transactions contemplated by
this Agreement or the operations of the Company after the Effective Time.

  

  

Section 4.9 Brokers. The Company, Newco and the Part D Entities will not be
responsible for any brokerage, finder's, success or other fee or commission to
any broker, finder, adviser or investment banker in connection with the
transactions contemplated by this Agreement based on arrangements made by or
on behalf of Parent or Merger Sub.

  

  

Section 4.10 Independent Investigation. Parent and Merger Sub acknowledge and
agree (a) that, except for the specific representations and warranties of the
Company contained in Article III (which, to the extent provided for in this
Agreement, include and are subject to the Company Disclosure Letter and the
Company SEC Reports) and the representations and warranties of the Company and
its Subsidiaries in the Split-Off Agreements, none of the Company, the Part D
Entities, their respective Subsidiaries or Affiliates and their respective
shareholders, controlling persons and

  

  

  

 

 

 

  

 

33  

  

 

 

 

  

  

  

Representatives makes or has made any representation or warranty, either
express or implied, with respect to the Company, the Part D Entities or their
respective Subsidiaries or Affiliates and their business, operations,
technology, assets, liabilities, results of operations, financial condition,
prospects, projections, budgets, estimates or operational metrics, or as to
the accuracy or completeness of any of the information (including any
financial statements and any projections, estimates or other forward-looking
information) provided (including in any management presentations, information
or descriptive memorandum, certain "data rooms" maintained by the Company,
supplemental information or other materials or information with respect to any
of the above) or otherwise made available to Parent and Merger Sub or any of
their respective Affiliates, shareholders or Representatives and (b) that, to
the fullest extent permitted by applicable Law, none of the Company, the Part
D Entities, their respective Affiliates or Subsidiaries, shareholders or
Representatives shall have any liability or responsibility whatsoever to
Parent or Merger Sub, their Affiliates or their Subsidiaries, stockholders or
Representatives on any basis (including in contract or tort, under federal or
state securities laws or otherwise) based upon any such information provided
or made available, or statements made (or any omissions therefrom), to Parent,
Merger Sub, their respective Affiliates or any of their respective
Subsidiaries, stockholders or Representatives, except (x) as and only to the
extent expressly set forth in this Agreement, the Voting Agreements and the
Split-Off Agreements or (y) in the case of fraud.

  

  

ARTICLE V

  

  

COVENANTS

  

  

Section 5.1 Conduct of Business of the Company. From and after the date of
this Agreement and prior to the Effective Time or the date, if any, on which
this Agreement is earlier terminated pursuant to Article VII, except as
expressly contemplated by this Agreement or any of the Split-Off Agreements,
as set forth in Section 5.1 of the Company Disclosure Letter or as required by
Law, without the prior written consent of Parent, such consent not to be
unreasonably withheld or delayed, the Company shall, and shall cause each of
its Subsidiaries to, use reasonable best efforts to (x) conduct the operations
of the Medicare Part D Business only in the ordinary course of business
consistent with past practice, (y) maintain and preserve intact the Medicare
Part D Business' business organization, to retain the services of its current
officers and key employees (it being understood that no increases in any
compensation, including any incentive, retention or similar compensation shall
be required in respect thereof except to the extent such increase is required
in the ordinary course of business and is permitted by this Section 5.1) and
to preserve the good will of its material customers, suppliers, agents,
employees and other Persons with whom it has material business relationships
and (z) except as would not, individually or in the aggregate, be expected to
result in a Company Material Adverse Effect, maintain compliance with all
Health Care Laws. Without limiting the generality of the foregoing, and except
as otherwise expressly contemplated by this Agreement or any of the Split-Off
Agreements, as set forth in Section 5.1 of the Company Disclosure Letter or as
required by Law, from and after the

  

  

  

 

 

 

  

 

34  

  

 

 

 

  

  

  

date of this Agreement and prior to the Effective Time or the date, if any, on
which this Agreement is earlier terminated pursuant to Article VII, the
Company shall not, and shall not permit any of its Subsidiaries to, take any
of the following actions, without the prior written consent of Parent, such
consent not to be unreasonably withheld or delayed:

  

  

(a) Organizational Documents. Amend any of the Company Organizational
Documents or any of the comparable organizational documents of any of the
Company's Subsidiaries;

  

  

(b) Dividends. Make, declare or pay any dividend or distribution on any shares
of its capital stock, other than dividends and distributions by wholly owned
Subsidiaries of the Company; provided that no Part D Entity shall make any
dividend or distribution to any member of the Newco Group (as defined in the
Separation Agreement);

  

  

(c) Capital Stock. (i) Adjust, split, combine or reclassify its capital stock,
(ii) redeem, purchase or otherwise acquire, directly or indirectly, any shares
of its capital stock or any securities convertible or exchangeable into or
exercisable for any shares of its capital stock, (iii) grant any Part D
Employee any right or option to acquire any shares of its capital stock, (iv)
issue, deliver or sell to any Part D Employee any additional shares of its
capital stock or any securities convertible or exchangeable into or
exercisable for any shares of its capital stock or such securities or issue
any awards to any Part D Employee referenced to any security of the Company
(other than pursuant to (A) the exercise of Company Options, (B) the vesting
of Restricted Shares and/or Performance Shares and (C) the conversion of
Preferred Stock, in each case outstanding as of the date of this Agreement) or
(v) enter into any Contract with respect to the sale, voting, registration or
repurchase of its capital stock, except, in the case of each of clauses (i)
through (v), as permitted under Section 5.1(d);

  

  

(d) Compensation and Benefits. (i)(A) Increase the compensation or benefits
payable or to become payable to any Part D Employee or grant or modify any
compensation awards to any Part D Employee, (B) grant or increase any
severance or termination pay to any Part D Employee, (C) renew, enter into or
amend any employment, service or severance agreement with any Part D Employee
or (D) establish, adopt, enter into, amend or terminate any Company Benefit
Plan or any employee benefit plan, agreement, policy or program that, if in
effect on the date of this Agreement, would be a Company Benefit Plan, except,
in the case of each of clauses (A) through (D), (w) to the extent required by
applicable Law, any Company Benefit Plan or other agreement as in effect on
the date of this Agreement; (x) in the ordinary course of business consistent
with past practice; (y) to comply with Section 409A of the Code and guidance
applicable thereunder; or (z) in connection with the acceleration of certain
payments as set forth in Section 5.1(d) of the Company Disclosure Letter or
(ii) hire or transfer individuals into or out of the Medicare Part D Business,
except for new hires at an annualized compensation level of $100,000 or less
in the ordinary course of business consistent with past practice;

  

  

(e) Acquisitions. Acquire, by merger, consolidation, acquisition of equity
interests or assets, or otherwise, any business, any material assets or

  

  

  

 

 

 

  

 

35  

  

 

 

 

  

  

  

properties, or any corporation, partnership, limited liability company, joint
venture or other business organization or division thereof that would (i)
after the Effective Time, constitute a portion of the Medicare Part D
Business, (ii) otherwise be material to the Company and its Subsidiaries,
taken as a whole, or (iii) reasonably be expected to materially delay or
prevent the consummation of the transactions contemplated by this Agreement
and the Split-Off Agreements, except, in the case of clause (i), the
acquisition of Investment Assets in the ordinary course of business consistent
with past practice;

  

  

(f) Dispositions. Sell, lease, license, transfer, pledge, encumber, grant or
dispose of any assets of the Medicare Part D Business, including the capital
stock of Subsidiaries of the Company, other than (i) in the ordinary course of
business consistent with past practice, or (ii) pursuant to existing
agreements in effect prior to the date of this Agreement as set forth on
Section 5.1(f) of the Company Disclosure Letter;

  

  

(g) Contracts. (i) Enter into any Contract which if in effect as of the date
of this Agreement would be a Material Contract, other than in the ordinary
course of business consistent with past practice or as permitted under another
subsection of this Section 5.1, (ii) enter into any Contract that would limit
or otherwise restrict the Medicare Part D Business or any of its successors,
or that would, after the Effective Time, limit or otherwise restrict Parent or
any of its controlled Affiliates or any of their successors, in each case from
engaging or competing in any line of business or in any geographic area or
(iii) terminate, cancel or request any material change in any Material
Contract other than the expiration of any Material Contracts in accordance
with its terms or in the ordinary course of business consistent with past
practice;

  

  

(h) Indebtedness; Guarantees. Incur, assume or guarantee any indebtedness for
borrowed money in excess of $10,000,000, other than in the ordinary course of
business consistent with past practice pursuant to the Credit Agreement
outstanding on the date of this Agreement (and referred to in the definition
of Company Indebtedness), or in connection with interest rate hedges on terms
in the ordinary course of business consistent with past practice;

  

  

(i) Loans. Make any loans, advances or capital contributions to (other than
the extension of trade credit in the ordinary course of business), or
investments in, any other Person in respect of the Medicare Part D Business,
other than (i) subject to the terms of the Separation Agreement, by the
Company or a Subsidiary of the Company to the Company or any of its
Subsidiaries or (ii) to third-party agents in the ordinary course of business
consistent with past practice;

  

  

(j) Tax. Make or change any material Tax election, change any annual Tax
accounting period, adopt or change any material method of Tax accounting,
materially amend any Tax Returns or file any claim for material Tax refunds,
enter into any closing agreement, enter into any material Tax allocation
agreement, Tax sharing agreement or Tax indemnity agreement (other than any
customary commercial or financing agreements, entered into in the ordinary
course of business consistent with past practices), settle any material Tax
claim, audit or assessment, or surrender any right to

  

  

  

 

 

 

  

 

36  

  

 

 

 

  

  

  

claim a material Tax refund (including any such refund to the extent it is
used to offset or otherwise reduce Tax liability);

  

  

(k) Accounting. Change its accounting policies or procedures to the extent
primarily related to or affecting the Medicare Part D Business, other than as
required by GAAP or applicable Law;

  

  

(l) Legal Actions. Waive, release, assign, settle or compromise any material
Legal Action that is primarily related to or materially affects the Medicare
Part D Business, or enter into any material settlement agreement or other
understanding or agreement with any Governmental Authority with respect to any
Legal Action relating to the Medicare Part D Business other than any such
waiver, release, assignment, settlement or compromise that is limited only to
the payment of money not in excess of $500,000, individually, or $2,000,000,
in the aggregate;

  

  

(m) Affiliate Transactions. Enter into or amend any arrangement or Contract
with any Affiliate or shareholder of the Company that (i) will be binding on
any Part D Entity on or after the Effective Time or obligate any Part D Entity
to make any payments after the date hereof to any such Affiliate or
shareholder of the Company or (ii) would reasonably be expected to materially
delay or prevent the consummation of the transactions contemplated by this
Agreement;

  

  

(n) Other Actions. Take any action that would reasonably be expected to result
in any of the conditions to the Split-Off or the Merger set forth in Article
VI of this Agreement not being satisfied or satisfaction of those conditions
being materially delayed, except in connection with a Takeover Proposal or a
Company Adverse Recommendation Change, in each case in accordance with the
terms of this Agreement; or

  

  

(o) Related Actions. Agree or commit to do any of the foregoing.

  

  

Section 5.2 Conduct of Business of Parent. Until (x) the expiration or
termination of the waiting period under the HSR Act (in the case of Section
5.2(a)) or (y) the Effective Time (in the case of Section 5.2(b)), Parent
shall not, and shall not permit Merger Sub or any of its other Subsidiaries or
Affiliates to, take any of the following actions, without the prior written
consent of the Company, such consent not to be unreasonably withheld or
delayed:

  

  

(a) Enter into, or permit any Subsidiary to enter into, any definitive
agreement to acquire, by merger, consolidation, acquisition or equity
interests or assets, or otherwise, any Part D lives or any Person engaged in
the Medicare Part D prescription drug business, if the entering into of a
definitive agreement relating to, or the consummation of, such acquisition,
merger, consolidation, acquisition of equity interests or assets, or otherwise
would reasonably be expected to (A) impose any material delay in the obtaining
of, or materially increase the risk of not obtaining, any Required Consent or
the expiration or termination of the waiting period under the HSR Act, (B)
materially

  

  

  

 

 

 

  

 

37  

  

 

 

 

  

  

  

increase the risk of any Governmental Authority entering an Order prohibiting
the consummation of the transactions contemplated by this Agreement, (C)
materially increase the risk of not being able to remove any such Order on
appeal or otherwise, (D) materially increase the likelihood that any relevant
Governmental Authority may (i) require the divestiture of any assets of
Parent, the Company or any of their respective Affiliates, (ii) limit in any
respect Parent's freedom of action with respect to, or its ability to
consolidate and control, the Medicare Part D Business following the Effective
Time or (iii) require taking any other action that would reasonably be
expected to diminish the benefits reasonably expected to be derived by Parent
on the date of this Agreement, in each case, as a result of the consummation
of the transactions contemplated by this Agreement or (E) materially delay or
prevent the consummation of the transactions contemplated by this Agreement;
or

  

  

(b) Take any action that would reasonably be expected to result in any of the
conditions to the Split-Off or the Merger set forth in Article VI of this
Agreement not being satisfied or satisfaction of those conditions being
materially delayed; provided that in no event shall Parent be deemed to have
breached this Section 5.2(b) by reason of any action permitted to be taken by
Parent under Section 5.9 or Section 5.23 of this Agreement.

  

  

Section 5.3 Access to Information; Confidentiality.

  

  

(a) The Company shall, and shall cause its Subsidiaries to, (i) provide to
Parent and its Representatives access at reasonable times upon prior notice to
the officers, employees, properties, books and records of (A) the Medicare
Part D Business and the Part D Entities and (B) as reasonably necessary, the
Non-Medicare Part D Business and Newco and the other Subsidiaries of the
Company, and (ii) furnish promptly such information concerning (A) the
Medicare Part D Business and the Part D Entities and (B) as reasonably
necessary, Newco and the other Subsidiaries of the Company, as Parent or its
Representatives may reasonably request. Notwithstanding the foregoing, the
Company shall not be required to provide such access if it determines that it
would (i) cause a violation of any Material Contract, (ii) constitute a
violation of any applicable Law or (iii) cause a material risk of disclosure
of any information that in the reasonable judgment of the Company would result
in the disclosure of any trade secrets of third parties. Nothing herein shall
require the Company or any of its Subsidiaries to disclose information to the
extent such information would result in a waiver of attorney-client privilege,
work product doctrine or similar privilege or violate any confidentiality
obligation of such party existing as of the date of this Agreement or entered
into in the ordinary course of business consistent with past practice after
the date of this Agreement (provided that such party shall use reasonable best
efforts to permit such disclosure to be made in a manner consistent with the
protection of such privilege or to obtain any consent required to permit such
disclosure to be made without violation of such confidentiality obligations,
as applicable).

  

  

(b) Parent and the Company shall comply with, and shall cause their respective
Representatives to comply with, all of their respective obligations under

  

  

  

 

 

 

  

 

38  

  

 

 

 

  

  

  

the Confidentiality Agreement, dated August 9, 2010 (the "Confidentiality
Agreement"), between Parent and the Company with respect to the information
disclosed under this Section 5.3(b).

  

  

(c) Nothing contained in this Agreement shall give Parent, directly or
indirectly, rights to conduct or cause to be conducted any intrusive
environmental investigation of the current or former operations or facilities
of the Company or any of its Subsidiaries without the written consent of the
Company in its reasonable discretion.

  

  

(d) Nothing contained in this Agreement shall give Parent, directly or
indirectly, rights to control or direct the operations of the Company and its
Subsidiaries (including the Medicare Part D Business) before the Effective
Time. Before the Effective Time, the Company shall, consistent with the terms
and conditions of this Agreement, exercise complete control and supervision
over the operations of the Company and its Subsidiaries (including the
Medicare Part D Business).

  

  

Section 5.4 Solicitation.

  

  

(a) From the date of this Agreement until the date on which the Requisite
Company Vote has been obtained, except as expressly permitted by Section
5.4(b), the Company shall not, nor shall the Company permit any of its
Subsidiaries or any of its or their respective Representatives to, directly or
indirectly, (i) solicit, initiate or knowingly facilitate or encourage
(including by way of furnishing non-public information or providing access to
its properties, books, records or personnel) any inquiries regarding, or the
making of any proposal or offer with respect to a Takeover Proposal, or (ii)
have any discussions (other than to state that the Company is not permitted to
have discussions) or participate in any negotiations regarding a Takeover
Proposal, or execute or enter into any Contract with respect to a Takeover
Proposal, or approve or recommend a Takeover Proposal or any agreement,
understanding or arrangement relating to a Takeover Proposal. Immediately
following the execution of this Agreement, the Company shall cease and cause
to be terminated all discussions or negotiations conducted heretofore with any
Person other than Parent with respect to any Takeover Proposal.

  

  

(b) Notwithstanding Section 5.4(a), if, before obtaining the Requisite Company
Vote and following the receipt by the Company of a Takeover Proposal from any
Person, which Takeover Proposal was made after the date of this Agreement and
did not result from a breach of this Section 5.4, the Company Board
determines, in consultation with its legal and financial advisors, that such
Takeover Proposal constitutes or would reasonably be expected to lead to a
Superior Proposal, the Company may, in response to such Takeover Proposal,
subject to compliance with this Section 5.4, (x) furnish access and
information with respect to the Company and any of its Subsidiaries to the
Person who has made such Takeover Proposal pursuant to one or more
confidentiality agreements on terms no less favorable to the Company than
those contained in the Confidentiality Agreement ("Acceptable Confidentiality
Agreements") (provided that all such access and information has previously
been provided to Parent or

  

  

  

 

 

 

  

 

39  

  

 

 

 

  

  

  

is provided to Parent substantially concurrently with the time it is provided
to such Person except to the extent the provision of such information would
constitute a violation of applicable Law) and (y) participate in discussions
and negotiations regarding such Takeover Proposal. The Company shall advise
Parent orally and in writing of the receipt of any Takeover Proposal or any
inquiry with respect to, or that could reasonably be expected to lead to, any
Takeover Proposal (in each case within 24 hours of receipt thereof) and
specify the terms and conditions thereof and the identity of the Person(s)
making such Takeover Proposal. The Company shall notify Parent (within 24
hours) orally and in writing of any material modifications to the financial or
other material terms of such Takeover Proposal or inquiry.

  

  

(c) Except as set forth in Sections 5.4(d) or (e), the Company Board shall
not, directly or indirectly, (i) withdraw, modify or amend the Company Board
Recommendation in any manner adverse to Parent (or take any action or make any
statement that is inconsistent with the Company Board Recommendation) (a
"Company Adverse Recommendation Change"), (ii) approve, endorse or recommend a
Takeover Proposal or (iii) approve, recommend or allow the Company to enter
into a Contract relating to a Takeover Proposal (other than an Acceptable
Confidentiality Agreement to the extent permitted by Section 5.4(b)).

  

  

(d) Notwithstanding Section 5.4(c), the Company Board may, before obtaining
the Requisite Company Vote, in response to a Superior Proposal received by the
Company Board after the date of this Agreement, make a Company Adverse
Recommendation Change, but only if:

  

  

(i) the Company Board has concluded in good faith, following consultation with
its outside legal counsel, that, in light of such Superior Proposal, its
failure to make a Company Adverse Recommendation Change would be inconsistent
with its fiduciary duties under applicable Law;

  

  

(ii) such Superior Proposal did not result, directly or indirectly, from a
breach by the Company of this Section 5.4;

  

  

(iii) the Company shall have first provided prior written notice to Parent of
its intention to make a Company Adverse Recommendation Change, which notice
shall include the most recent version of the proposed agreement under which
the transaction contemplated by such Superior Proposal is proposed to be
consummated and the identity of the Person(s) making such Superior Proposal;
and

  

  

(iv) Parent does not make, within five Business Days after the receipt of such
notice, a binding, written and complete (including any schedules or exhibits)
proposal that the Company Board determines in good faith, after consultation
with its financial advisor, causes the Takeover Proposal that constituted a
Superior Proposal to no longer constitute a Superior Proposal (it being
understood that any amendment to the financial terms or other material terms
of such Superior Proposal shall require a new written notification pursuant to
the foregoing clause (iii) and a new five-Business Day period under this
clause (iv)).

  

  

  

 

 

 

  

 

40  

  

 

 

 

  

  

  

(e) Nothing contained in this Section 5.4 shall prohibit the Company from
complying with Rules 14a-9, 14d-9, 14e-2 and Item 1012(a) of Regulation M-A
promulgated under the Exchange Act, or from issuing a "stop, look and listen"
statement pending disclosure of its position thereunder, or making any
required disclosure to the Company's shareholders if, in the good faith
judgment of the Company Board, after consultation with its outside legal
counsel, the failure to do so would be inconsistent with its fiduciary duties
under applicable Law or such disclosure is otherwise required under applicable
Law; provided, in each case, that (x) any such action taken or disclosure made
is consistent with this Section 5.4 and (y) unless the Company Board reaffirms
the Company Board Recommendation in connection therewith within ten Business
Days of the event that gave rise to such "stop, look and listen" statement,
any such action or disclosure shall be deemed to constitute a breach of this
Section 5.4(e); provided, further, that the foregoing proviso shall not apply
following a Company Adverse Recommendation Change.

  

  

(f) Notwithstanding Section 5.4(a), following the receipt by the Company of a
bona fide, unsolicited written Takeover Proposal relating solely to the Non-
Medicare Part D Business from any Person, which Takeover Proposal was made
after the date of this Agreement and did not result from a breach of Section
5.4(a) or this Section 5.4(f), the Company may, in response to such Takeover
Proposal, (x) furnish access and information with respect to the Non-Medicare
Part D Business (but not any non-public information with respect to the
Medicare Part D Business) to the Person who has made such Takeover Proposal
pursuant to an Acceptable Confidentiality Agreement and (y) participate in
discussions and negotiations regarding such Takeover Proposal; provided, that,
prior to the Effective Time, the Company (i) shall not enter into any
agreement, understanding or arrangement with respect to any such Takeover
Proposal (other than an Acceptable Confidentiality Agreement) and (ii) shall
not participate in discussions or negotiations regarding such Takeover
Proposal if such participation would reasonably be expected to (A) adversely
affect the Medicare Part D Business following the Effective Time or (B)
materially delay or prevent the consummation of the transactions contemplated
by this Agreement. For purposes of this Section 5.4(f) only, the definition of
the term "Takeover Proposal" shall be interpreted solely by reference to the
Non-Medicare Part D Business.

  

  

Section 5.5 Preparation of the Newco Form S-4 and Company Proxy Statement.

  

  

(a) As promptly as practicable following the date of this Agreement, the
Company and Newco shall prepare a draft of the Newco Form S-4 (of which the
Company Proxy Statement shall be a part). Parent shall provide to the Company
all information concerning Parent and Merger Sub as may be reasonably
requested by the Company in connection with the Newco Form S-4 and the Company
Proxy Statement and shall otherwise assist and cooperate with the Company in
the preparation of the Newco Form S-4 and the Company Proxy Statement and
resolution of any comments referred to below.

  

  

  

 

 

 

  

 

41  

  

 

 

 

  

  

  

(b) The Company agrees that none of the information to be included or
incorporated by reference in (i) the Newco Form S-4 will, at the time it is
filed with the SEC, contain any untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary in order to
make the statements therein, in light of the circumstances under which they
are made, not misleading or (ii) the Company Proxy Statement will, at the date
it is first mailed to the shareholders of the Company or at the time of the
Company Shareholders Meeting or at the time of any amendment or supplement
thereof, contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary in order to make the
statements therein, in light of the circumstances under which they are made,
not misleading; provided, however, that no representation or warranty is made
by the Company with respect to statements made or incorporated by reference in
the Newco Form S-4 or the Company Proxy Statement to the extent based on
information supplied by or on behalf of Parent or Merger Sub or any Affiliate
of Parent or Merger Sub in connection with the preparation of the Newco Form
S-4 or the Company Proxy Statement for inclusion or incorporation by reference
therein. Parent and Merger Sub hereby covenant and agree that none of the
information to be supplied by or on behalf of Parent or Merger Sub or any
Affiliate of Parent or Merger Sub for inclusion or incorporation by reference
in (i) the Newco Form S-4 will, at the time it is filed with the SEC, contain
any untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they are made, not
misleading or (ii) the Company Proxy Statement shall, at the date it is first
mailed to the shareholders of the Company or at the time of the Company
Shareholders Meeting or at the time of any amendment or supplement thereof,
contain any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary in order to make the
statements therein, in light of the circumstances under which they are made,
not misleading; provided, however, that no representation or warranty is made
by either Parent or Merger Sub with respect to statements made or incorporated
by reference in either the Newco Form S-4 or the Company Proxy Statement to
the extent based on information supplied by the Company or any Affiliate of
the Company in connection with the preparation of the Newco Form S-4 or the
Company Proxy Statement for inclusion or incorporation by reference therein.

  

  

(c) The Company shall use reasonable best efforts to (i) respond to any
comments on the Newco Form S-4 and the Company Proxy Statement or requests for
additional information from the SEC as soon as practicable after receipt of
any such comments or requests and (ii) cause the Company Proxy Statement to be
mailed to the shareholders of the Company as promptly as practicable following
the date of this Agreement. The Company shall promptly (A) notify Parent upon
the receipt of any such comments or requests and (B) provide Parent with
copies of all correspondence relating to the Newco Form S-4 and the Company
Proxy Statement between the Company and its Representatives, on the one hand,
and the SEC and its staff, on the other hand.

  

  

(d) Before the filing or mailing of the Newco Form S-4 and the Company Proxy
Statement or responding to any such comments or requests, the Company (x)
shall provide Parent with a reasonable opportunity to review and comment

  

  

  

 

 

 

  

 

42  

  

 

 

 

  

  

  

on any drafts of the Newco Form S-4 and the Company Proxy Statement and
related correspondence and filings and (y) shall include in such drafts,
correspondence and filings all comments reasonably proposed by Parent.

  

  

(e) The Company Proxy Statement shall include the Company Board Recommendation
unless the Company Board has made a Company Adverse Recommendation Change in
accordance with this Agreement.

  

  

Section 5.6 Company Shareholders Meeting. Subject to Section 5.4, following
the clearance of the Company Proxy Statement by the SEC and following such
time as the Newco Form S-4 is declared effective under the Securities Act, the
Company shall call and hold the Company Shareholders Meeting as promptly as
practicable following the mailing of the definitive Company Proxy Statement
for the purpose of voting on adoption of this Agreement; provided, however,
for the avoidance of doubt, the Company may (at the reasonable request of
Parent, will) postpone or adjourn the Company Shareholders Meeting: (i) with
the consent of Parent; (ii) for the absence of a quorum; or (iii) to allow
reasonable additional time for the filing and distribution of any supplemental
or amended disclosure with respect to the transactions contemplated by this
Agreement or the Split-Off Agreements which the Company Board has determined
in good faith (after consultation with its outside legal counsel) is necessary
under applicable Laws and for such supplemental or amended disclosure to be
disseminated to and reviewed by the Company's shareholders prior to the
Company Shareholders Meeting. Except following a Company Adverse
Recommendation Change, the Company shall (a) use reasonable best efforts to
solicit or cause to be solicited from its shareholders proxies in favor of
adoption of this Agreement and (b) take all other action reasonably necessary
or advisable to secure the Requisite Company Vote. Notwithstanding anything to
the contrary contained herein, the adoption of this Agreement shall be
submitted to a vote of the Company's shareholders at the Company Shareholders
Meeting whether or not the Company Board has made a Company Adverse
Recommendation Change.

  

  

Section 5.7 Employees; Benefit Plans.

  

  

(a) For a period of one year following the Closing Date (the "Continuation
Period"), Parent shall, or shall cause the Surviving Corporation or any of
their respective Subsidiaries or Affiliates to, provide to each Part D
Employee (i) salary, hourly wage rate, short-term (annual or more frequent)
bonus or commission opportunity and other compensation (excluding equity and
equity-based awards which will remain discretionary) that are no less
favorable and (ii) benefits that are no less favorable, in the aggregate, than
those provided to such Part D Employee under the Company's and its
Subsidiaries' compensation and benefit plans, programs, policies, agreements
and arrangements in effect immediately prior to the Effective Time. For the
sake of clarity, and without limiting the generality of the foregoing, Parent
shall provide each Part D Employee with the opportunity to enroll in the
compensation and benefit plans of Parent, the Surviving Corporation or any of
their respective Affiliates as of the Effective Time; provided that Parent
shall have received all information necessary to effectuate such enrollment.

  

  

  

 

 

 

  

 

43  

  

 

 

 

  

  

  

(b) 2010 Bonus Plan. The Company may pay bonuses to Part D Employees and other
Company employees in respect of calendar year 2010 in the ordinary course of
business consistent with past practice.

  

  

(c) 2011 Bonus Plan. The target bonus opportunity for the year ended December
31, 2011 for each Part D Employee shall be not less than such Part D
Employee's target bonus opportunity for the year ended December 31, 2010.
Pursuant to the Company Severance Plan, each Part D Employee will be entitled
to receive a pro-rated bonus applicable to such Part D Employee in the event
such Part D Employee is terminated without Cause (as defined in Section 5.7(d)
of the Company Disclosure Letter) or resigns for Good Reason (as defined in
Section 5.7(d) of the Company Disclosure Letter) prior to the twelve (12)
month anniversary of the Closing Date (provided that (x) the provisions of
this sentence shall not result in the duplication of bonus payments to such
Part D Employee and (y) for the avoidance of doubt, the pro-rated portion of
any bonus payment for an Part D Employee shall assume a target bonus payout
for such pro-rated period).

  

  

(d) As to each Part D Employee, Parent shall honor the Company severance
program set forth on Section 5.7(d) of the Company Disclosure Letter (the
"Company Severance Plan").

  

  

(e) [Reserved].

  

  

(f) The Company may establish a retention pool (the "Retention Pool") prior to
the Effective Time providing for the payment of retention bonuses to certain
Part D Employees in connection with the Merger for the purpose of retaining
the services of such Part D Employees, on the terms set forth on Section
5.7(f) of the Company Disclosure Letter. Following the Effective Time, the
Surviving Corporation and/or Parent shall pay or cause to be paid the
retention bonuses pursuant to the terms set forth on Section 5.7(f) of the
Company Disclosure Letter.

  

  

(g) For all purposes under all employee benefit plans of Parent, the Surviving
Corporation and their respective Subsidiaries and Affiliates providing
benefits to any Part D Employee after the Effective Time (the "New Plans"),
each Part D Employee shall receive full credit for such Part D Employee's
years of service with the Company and its Subsidiaries before the Effective
Time (including predecessor or acquired entities or any other entities for
which the Company and its Subsidiaries have given credit for prior service),
to the same extent as such Part D Employee was entitled, prior to the
Effective Time, to credit for such service under any similar or comparable
Company Benefit Plan (except to the extent such credit would result in a
duplication of accrual of benefits). In addition, where applicable, and
without limiting the generality of the foregoing, subject only to (i) Parent
receiving all information necessary with respect to Part D Employees and (ii)
any required approval of the applicable insurer, which Parent agrees to use or
cause the Surviving Corporation or any Subsidiaries and Affiliates to use,
commercially reasonable efforts to obtain, if any: (1) at the Effective Time,
each Part D Employee immediately shall be eligible to participate, without any
waiting time, in each New Plan to the extent such waiting time was satisfied
under a similar or

  

  

  

 

 

 

  

 

44  

  

 

 

 

  

  

  

comparable Company Benefit Plan in which such Part D Employee participated
immediately before the Effective Time (such plans, collectively, the "Old
Plans"); (2) Parent shall cause all pre-existing condition exclusions or
limitations and actively-at-work requirements of each New Plan to be waived or
satisfied for such Part D Employee and his or her covered dependents to the
extent waived or satisfied under the analogous Old Plan as of the Effective
Time; and (3) Parent shall cause all eligible expenses incurred by each Part D
Employee and his or her covered dependents during the portion of the plan year
of the Old Plan ending on the date such Part D Employee's participation in the
corresponding New Plan begins to be taken into account under such New Plan for
purposes of satisfying all deductible, coinsurance and maximum out-of-pocket
requirements applicable to such Part D Employee and his or her covered
dependents for the applicable plan year as if such amounts had been paid in
accordance with such New Plan.

  

  

(h) With respect to any accrued but unused paid time off to which any Part D
Employee is entitled pursuant to the paid time off policy applicable to such
Part D Employee immediately prior to the Effective Time, Parent shall, or
shall cause the Surviving Corporation or any of their respective Subsidiaries
or Affiliates to, (i) allow such Part D Employee to use such accrued paid time
off and, (ii) if any Part D Employee's employment terminates during the
Continuation Period under circumstances entitling the Part D Employee to
severance pay under the Company Severance Plan, pay the Part D Employee, in
cash, an amount for a number of days of paid time off calculated as follows:
(A) the number of accrued days of paid time off to which the Part D Employee
is entitled as of the date of such termination, and (B) reducing this number
by the number of days of paid time off actually used by the Part D Employee
prior to the date of termination.

  

  

(i) The Company shall, and shall cause its Subsidiaries to, provide to Parent
and its Representatives access at all reasonable times to the Part D Employees
and the employment and personnel records and data relating to the Part D
Employees to the maximum extent permitted under applicable Law.

  

  

(j) Nothing in this Section 5.7, whether express or implied, shall confer upon
any current or former employee of the Company, Parent, the Surviving
Corporation or any of their respective Subsidiaries or Affiliates, any rights
or remedies including any right to employment or continued employment for any
specified period, of any nature or kind whatsoever under or by reason of this
Section 5.7.

  

  

Section 5.8 Reasonable Best Efforts. Upon the terms and subject to the
conditions set forth in this Agreement and in accordance with applicable Law
(but subject, for the avoidance of doubt, to the limitations set forth in
Section 5.9) each of the parties to this Agreement shall use its reasonable
best efforts to take, or cause to be taken, all actions and to do, or cause to
be done, all things necessary, proper or advisable to ensure that the
conditions set forth in Article VI are satisfied and to consummate the
transactions contemplated by this Agreement as promptly as practicable. The
terms of this Section 5.8 shall not limit the rights of the Company set forth
in Section 5.4 or

  

  

  

 

 

 

  

 

45  

  

 

 

 

  

  

  

impose any obligations on Parent or Merger Sub that are not specifically
provided for in this Agreement.

  

  

Section 5.9 Consents; Filings; Further Action.

  

  

(a) Upon the terms and subject to the conditions of this Agreement and in
accordance with applicable Law, each of Parent and the Company shall use its
best efforts to promptly (i) obtain any consents, approvals or other
authorizations, and make any filings and notifications required in connection
with the transactions contemplated by this Agreement, (ii) make any other
submissions either required or deemed appropriate by either Parent or the
Company, in connection with the transactions contemplated by this Agreement
under the Securities Act, the Exchange Act, the HSR Act, the NYBCL, the rules
and regulations of the Applicable Exchange, any other national securities
exchange or NASDAQ, CMS, state insurance Laws and any other applicable Law,
(iii) take or cause to be taken all other actions necessary, proper or
advisable consistent with this Section 5.9 to (x) cause the expiration of the
applicable waiting periods, or (y) obtain receipt of required consents,
approvals or authorizations, including the Required Consents, as applicable,
under such Laws, rules and regulations as soon as practicable, and (iv) defend
any Legal Actions, including with respect to matters involving any Section
5.23 Person, whether judicial or administrative, challenging this Agreement or
the consummation of the transactions contemplated by this Agreement, including
seeking to have any stay or temporary restraining Order or any other Order
entered by any court or other Governmental Authority vacated or reversed.
Parent and the Company shall cooperate and consult with each other in
connection with the making of all such filings and notifications, including by
providing copies of all relevant documents to the non-filing party's outside
antitrust or applicable regulatory counsel (and to the non-filing party upon
consent of the filing party, such consent not to be unreasonably withheld or
delayed) before filing. Neither Parent nor the Company shall consent to any
voluntary extension of any statutory deadline or waiting period or to any
voluntary delay of the consummation of the transactions contemplated by this
Agreement at the behest of any Governmental Authority without the consent of
the other party, which consent shall not be unreasonably withheld or delayed.

  

  

(b) As promptly as practicable after the date of this Agreement and in any
event no later than ten Business Days after the date of this Agreement, unless
the parties agree to file at a later date, each of Parent and the Company
shall file and not withdraw any Notification and Report Forms and related
material required to be filed by it with the Federal Trade Commission and the
United States Department of Justice under the HSR Act, as applicable, to
request early termination of the applicable waiting period under the HSR Act
with respect to the transactions contemplated by this Agreement, and shall
promptly make any further filings pursuant thereto that may be necessary,
proper or advisable.

  

  

(c) Each of Parent and the Company shall promptly inform the other party upon
receipt of any communication from any Governmental Authority regarding any of
the transactions contemplated by this Agreement. If Parent or the

  

  

  

 

 

 

  

 

46  

  

 

 

 

  

  

  

Company (or any of their respective Affiliates) receives a request for
additional information from any Governmental Authority that is related to the
transactions contemplated by this Agreement, then such party shall endeavor in
good faith to make, or cause to be made, to the extent practicable and after
consultation with the other party, an appropriate response to such request.
Prior to delivery of such response, to the extent practicable, such party
shall provide the other party with a reasonable opportunity to review and
comment on such response. No party shall participate in any meeting, or engage
in any material substantive conversation, with any Governmental Authority
without giving the other party prior notice of the meeting or conversation
and, unless prohibited by such Governmental Authority, the opportunity to
attend or participate. Parent shall advise the Company promptly of any
understandings, undertakings or agreements (oral or written) which Parent
proposes to make or enter into with any Governmental Authority in connection
with the transactions contemplated by this Agreement.

  

  

(d) Without limiting the foregoing, but subject to Section 5.9(e), each of
Parent and the Company shall promptly take, in order to consummate the
transactions contemplated hereby, all actions necessary to (i) avoid the entry
of, or to effect the dissolution of or vacate or lift, any Order of or sought
by a Governmental Authority that would have the effect of preventing or
delaying the Closing and (ii) resolve any objections asserted by any
Governmental Authority with respect to the transactions contemplated by this
Agreement under any applicable Law, including (A) executing settlements,
undertakings, consent decrees, stipulations or other agreements with any
Governmental Authority, (B) selling, divesting or otherwise conveying
particular assets or categories of assets or businesses of Parent and its
Subsidiaries and (C) agreeing to sell, divest or otherwise convey any
particular assets or categories of assets or businesses of the Company and its
Subsidiaries contemporaneously with or subsequent to the Effective Time.

  

  

(e) Notwithstanding anything herein to the contrary, Parent shall not be
required and the Company shall not be permitted by this Section 5.9 to take or
agree to undertake any action, including entering into any consent decree,
hold separate order or other arrangement, that would (i) require the
divestiture of any assets (of Parent, the Company or any of their respective
Affiliates) collectively representing in excess of the amount of premium
revenues set forth on Section 5.9(e) of the Company Disclosure Letter
(measured on the basis of premium revenues attributable to such assets for the
2010 fiscal year) (the "Maximum Divestiture Amount"), (ii) limit in any
respect Parent's freedom of action with respect to, or its ability to
consolidate and control, the Medicare Part D Business following the Effective
Time or (iii) require taking any other action that would reasonably be
expected to diminish the benefits reasonably expected to be derived by Parent
on the date of this Agreement from the acquisition (whether by reason of
impact on Parent's existing businesses or assets or on the Medicare Part D
Business), in such a manner that Parent would not have entered into this
Agreement in the face of such diminished benefits unless in the case of
clauses (ii) and (iii) such actions would not, individually or in the
aggregate, reasonably be expected to have a Company

  

  

  

 

 

 

  

 

47  

  

 

 

 

  

  

  

Material Adverse Effect or a Parent Material Adverse Effect at or following
the Effective Time (a "Regulatory Material Adverse Effect").

  

  

Section 5.10 Public Announcements. Parent and the Company shall consult with
each other before issuing any press release or otherwise making any public
statements about (i) this Agreement or any of the transactions contemplated by
this Agreement or (ii) the Split-Off Agreements or any of the transactions
contemplated by the Split-Off Agreements. Neither Parent nor the Company shall
issue any such press release or make any such public statement prior to such
consultation, except to the extent required by applicable Law or the
Applicable Exchange requirements, in which case that party shall use its
reasonable best efforts to consult with the other party before issuing any
such release or making any such public statement; provided, however, that
Parent's consent shall not be required, and the Company shall not be required
to consult with Parent in connection with, or provide Parent an opportunity to
review or comment upon, any press release or other public statement or comment
to be issued or made with respect to any Takeover Proposal or with respect to
any actions contemplated by Section 5.4(d) and Section 5.4(e). Notwithstanding
the foregoing, without the prior consent of the other parties, the Company may
(a) communicate with customers, vendors, suppliers, financial analysts,
investors and media representatives in a manner consistent with its past
practice in compliance with applicable Law to the extent such communications
consist of information included in a press release or other document
previously approved for external distribution by Parent and (b) issue public
statements or disseminate information to the extent solely related to the
Newco Group or the operation of the Non-Medicare Part D Business; provided,
however, that Parent's consent shall not be required, and the Company shall
not be required to consult with Parent in connection with, or provide Parent
an opportunity to review or comment upon, any press release or other public
statement or comment to be issued or made with respect to any Takeover
Proposal or with respect to any actions contemplated by Section 5.4(d) and
Section 5.4(e). Each of Parent and the Company will issue a separate (but
mutually agreed upon) press release announcing the execution of this
Agreement.

  

  

Section 5.11 Applicable Exchange De-listing. Parent shall cause the Common
Stock to be de-listed from the Applicable Exchange and de-registered under the
Exchange Act at or as soon as practicable following the Effective Time.

  

  

Section 5.12 Newco Common Stock Listing. The Company shall use reasonable best
efforts to cause the shares of Newco Common Stock to be distributed in the
Split-Off to be approved for listing on a national securities exchange, or
approved for quotation on NASDAQ, in each case subject to official notice of
issuance, prior to the Effective Time.

  

  

Section 5.13 Fees and Expenses.

  

  

(a) Except as explicitly provided otherwise in this Agreement, all Transaction
Expenses incurred by any party to this Agreement or on its behalf shall be
paid by the party incurring such Transaction Expenses.

  

  

  

 

 

 

  

 

48  

  

 

 

 

  

  

  

(b) [Reserved.]

  

  

(c) Regardless of whether the Merger is consummated, Parent shall pay (i) all
Consent Expenses and (ii) all Transaction Litigation Expenses.

  

  

Section 5.14 Takeover Statutes. Unless the Company Board has made a Company
Adverse Recommendation Change in accordance with this Agreement, if any
takeover statute is or becomes applicable to this Agreement, the Merger or the
other transactions contemplated by this Agreement, each of Parent, the Company
and their respective boards of directors shall use reasonable best efforts (a)
to ensure that such transactions may be consummated as promptly as practicable
upon the terms and subject to the conditions set forth in this Agreement and
(b) to otherwise act to eliminate or minimize the effects of such takeover
statute.

  

  

Section 5.15 Obligations of Merger Sub. Parent shall cause Merger Sub to
perform its obligations under this Agreement and to consummate the Merger on
the terms and conditions set forth in this Agreement.

  

  

Section 5.16 Rule 16b-3. Prior to the Effective Time, the Company may take
such further actions, if any, as may be necessary or appropriate to ensure
that the dispositions of equity securities of the Company (including
derivative securities) pursuant to the transactions contemplated by this
Agreement by any officer or director of the Company who is subject to Section
16 of the Exchange Act are exempt under Rule 16b-3 promulgated under the
Exchange Act.

  

  

Section 5.17 Resignation of Directors. The Company shall deliver to Parent
evidence reasonably satisfactory to Parent of the resignation of all directors
of any of the Part D Entities in writing reasonably in advance of the Closing
(such resignations to be effective at the Effective Time).

  

  

Section 5.18 Split-Off and Related Matters.

  

  

(a) Prior to the Effective Time and pursuant to the terms of the Separation
Agreement, (i) the Company shall, and shall cause Newco to, enter into a Tax
Matters Agreement (the "Tax Matters Agreement") in the form attached to the
Separation Agreement as Exhibit A thereto, and (ii) the Company and its
Subsidiaries shall consummate the Separation (as defined in the Separation
Agreement) upon the terms and subject to the conditions set forth in the
Split-Off Agreements.

  

  

(b) Prior to the Effective Time and pursuant to the terms of the Separation
Agreement, the Company and a Subsidiary of Newco shall enter into a
Reinsurance Agreement (the "Reinsurance Agreement") and a Pharmacy Benefits
Management Agreement (the "PBM Agreement"), in each case in accordance with
the terms set forth in the Exhibits A and B, respectively, and in a form that
is otherwise mutually satisfactory to the Company and Parent.

  

  

  

 

 

 

  

 

49  

  

 

 

 

  

  

  

(c) Within thirty (30) days of the date of this Agreement, the Company shall
cause American Progressive Life and Health Insurance Company of New York, a New
York domiciled insurance company and Subsidiary of the Company ("American
Progressive"), to (i) enter into a Novation Agreement with Parent or a
Subsidiary of Parent in the form required by CMS (the "Novation Agreement")
and (ii) submit the Novation Agreement to CMS for approval, in each case in
accordance with the CMS novation regulations. In addition, within forty-five
(45) days of the date of this Agreement, the Company shall cause American
Progressive to (i) enter into a customary reinsurance agreement (the "Part D
Reinsurance Agreement") with Parent or a Subsidiary of Parent (the "Part D
Reinsurer") pursuant to which the Part D Reinsurer will reinsure on a 100% co-
insurance basis all of the Liabilities and receive the benefit of all of the
rights of the Medicare Part D Business held by American Progressive (the
"AmPro Part D Business"), including the right to control the operation of that
business; and (ii) seek any required approval from the New York Department of
Insurance. Subject to CMS approval, the Novation Agreement shall be effective
as of January 1, 2012 or such earlier date as directed by the Part D Reinsurer
(the "Novation Effective Date"), in either case, with economic effect as of
January 1, 2011. The Novation Agreement, or such other agreement as may be
determined by the parties to this Agreement, shall provide that, on the
Novation Effective Date, the Part D Reinsurer shall pay to American
Progressive the Novation Allocation Amount plus the amount of any loss by
American Progressive in respect AmPro Part D Business since January 1, 2011 to
such effective date minus any gains by American Progressive in respect of the
AmPro Part D Business since January 1, 2011 to such effective date, but only
to the extent that such gains and losses have not been determined to be gains
and losses pursuant to the Part D Reinsurance Agreement. Subject to any
required New York Department of Insurance approval, the Part D Reinsurance
Agreement shall take effect as of the Effective Time and terminate as of the
Novation Effective Date.

  

  

(d) Immediately prior to the Effective Time, the Company and Newco shall enter
into a transition services agreement upon the terms set forth on Exhibit C
(the "Transition Services Agreement"), which shall set forth the provision of
transition support and other transition services after the Effective Time
between the Newco Group and the Part D Group (as such terms are defined in the
Separation Agreement).

  

  

(e) As soon as practicable following the date of this Agreement, the Company
and Parent shall work together in good faith to complete the Reinsurance
Agreement, the PBM Agreement, the Novation Agreement and the Transition
Services Agreement upon the terms contemplated by this Agreement. In
furtherance and not in limitation of the foregoing, each of the Company and
Parent shall use reasonable best efforts to make available and cause the
necessary personnel to work together in good faith to finalize the terms of
each such Split-Off Agreement no later than March 15, 2011 (the "Split-Off
Agreement Date"). In the event that the Company and Parent fail to agree upon
the terms of any such Split-Off Agreement by the Split-Off Agreement Date, the
Company and Parent shall appoint a mutually acceptable arbitrator with
experience resolving commercial disputes and commercial agreements within the

  

  

  

 

 

 

  

 

50  

  

 

 

 

  

  

  

healthcare insurance industry (the "Requisite Experience") to assist in
resolving any disputes between parties relating to the terms of such Split-Off
Agreement (the "Split-Off Agreement Arbitrator"). If the Company and Parent
cannot agree upon a mutually acceptable arbitrator to be the Split-Off
Agreement Arbitrator, then each of the Company and Parent shall select an
arbitrator possessing the Requisite Experience, which two arbitrators shall
mutually agree upon a third arbitrator possessing the Requisite Experience,
who shall be appointed the Split-Off Agreement Arbitrator. Within fifteen (15)
days of such appointment, each of the Company and Parent shall submit to the
Split-Off Arbitrator such Person's proposed terms of such Split-Off Agreement,
including such Person's proposed final form of Split-Off Agreement. The Split-
Off Agreement Arbitrator shall as promptly as practicable, and in no event
more than forty-five (45) days follow its receipt of such submissions, review
the terms of this Agreement and the terms of such Split-Off Agreement set
forth in the applicable Exhibit and determine the final form of Split-Off
Agreement in accordance with the terms thereof. Such decision by the Split-Off
Agreement Arbitrator shall be final and binding upon the Company and Parent.
The cost of such review and determination shall be borne equally by the
Company and Parent.

  

  

(f) From and after the date of this Agreement and prior to the Effective Time
or the date, if any, on which this Agreement is earlier terminated pursuant to
Article VII, without the prior written consent of Parent, such consent shall
not be unreasonably withheld or delayed, the Company shall not (i) enter into
any Contract (other than a Contract that is expressly contemplated by the
Separation Agreement) between any of the Part D Entities, on the one hand, and
Newco or any other Subsidiary of the Company (other than the Part D Entities),
on the other hand, or (ii) amend, waive any rights under, or otherwise modify,
or terminate, any Split-Off Agreement.

  

  

Section 5.19 Notification of Certain Matters.

  

  

(a) The Company shall give prompt notice to Parent, and Parent shall give
prompt notice to the Company, of (a) the occurrence of any event known to it
which would reasonably be expected to, individually or in the aggregate, (i)
in the case of the Company, have a Company Material Adverse Effect, or, in the
case of Parent, have a Parent Material Adverse Effect, (ii) cause any
condition set forth in Article VI to be unsatisfied in any material respect at
any time prior to the Effective Time or (iii) cause any authorization,
consent, Order, declaration or approval of any Governmental Authority or third
party necessary for the consummation of the transactions contemplated by this
Agreement to not be obtained by the Termination Date or (b) any action, suit,
proceeding, inquiry or investigation pending or, to the Knowledge of the
Company or Parent, threatened which questions or challenges the validity of
this Agreement or any Split-Off Agreement or the ability of any party to
consummate the transactions contemplated hereby or thereby; provided, however,
that the delivery of any notice pursuant to this Section 5.19 shall not limit
or otherwise affect the remedies available hereunder to the party receiving
such notice nor shall the party giving such notice be prejudiced with respect
to any such matters solely by virtue of having given such notice.

  

  

  

 

 

 

  

 

51  

  

 

 

 

  

  

  

(b) Subject to applicable Law, the Company shall provide to Parent copies of
(x) all material written notices received from any Governmental Authority by
the Company or any of its Subsidiaries to the extent such notice is primarily
related to the Medicare Part D Business and (y) all material written notices
received from CMS by the Company or any of its Subsidiaries, in each case from
and after the date of this Agreement until the Effective Time, provided that
the foregoing shall not apply to the Company's communications with CMS
concerning the resolution of matters set forth in the November 2010 CMS Letter
(as defined in Section 3.12 of the Company Disclosure Letter), except to the
extent related, directly or indirectly, to the Medicare Part D Business.

  

  

Section 5.20 Adjustment Certificates.

  

  

(a) No later than March 14, 2011, the Company shall deliver to Parent a
certificate executed by the Chief Financial Officer of the Company (the
"Statutory Capital Adjustment Certificate") setting forth the amount of each
of (i) the Statutory Capital of Penn Life relating to the Medicare Part D
Business as of December 31, 2010 (as adjusted, if at all, pursuant to Section
5.20(e), the "Statutory Capital 12/31 Amount"), (ii) the 2010 Annual Statement
of Penn Life as filed with the Insurance Department of the State of
Pennsylvania and (iii) the Authorized Control Level of Penn Life relating to
the Medicare Part D Business as of December 31, 2010 (as adjusted, if at all,
pursuant to Section 5.20(e), the "Authorized Control Level Amount"), in each
case as calculated in accordance with the methodologies set forth in Section
5.20 of the Company Disclosure Letter. No later than three Business Days prior
to the Effective Time, the Company shall deliver to Parent a certificate
executed by the Chief Financial Officer of the Company (the "Closing Date
Indebtedness Certificate") setting forth the amount of the Company
Indebtedness (the "Closing Date Indebtedness Amount").

  

  

(b) From and after the date of the delivery of the Closing Date Indebtedness
Certificate to the Effective Time, the Company shall not incur, assume or
guarantee any indebtedness for borrowed money in excess of the amount of
Company Indebtedness set forth in the Closing Date Indebtedness Certificate.

  

  

(c) Within fifteen (15) days after Parent's receipt of the Statutory Capital
Adjustment Certificate, Parent shall deliver to the Company a written
statement either accepting the Statutory Capital Adjustment Certificate or
specifying any objections thereto (including therein Parent's calculations of
such amounts and Parent's grounds for such disagreement in reasonable detail)
(a "Statutory Capital Objections Statement"). The Statutory Capital Objections
Statement shall specify those items or amounts as to which Parent disagrees,
and Parent shall be deemed to have agreed with all other items and amounts
contained in the calculations delivered by the Company pursuant to Section
5.20(a).

  

  

(d) If Parent shall have delivered a Statutory Capital Objections Statement,
the Company and Parent shall, during the fifteen (15) days following such
delivery, negotiate in good faith to reach agreement on the disputed items

  

  

  

 

 

 

  

 

52  

  

 

 

 

  

  

  

or amounts in order to determine, as may be required, the amounts set forth in
the Statutory Capital Adjustment Certificate. If the Company and Parent are
unable to reach such agreement during such period, they shall promptly
thereafter appoint an independent accountant of nationally recognized standing
reasonably satisfactory to the Company and Parent (the "Statutory Capital
Accounting Firm") to promptly review this Agreement and the disputed items or
amounts for the purpose of calculating the amounts set forth in the Statutory
Capital Adjustment Certificate. In making such calculations, the Statutory
Capital Accounting Firm shall consider only those items or amounts in the
Statutory Capital Objections Statement. The Statutory Capital Accounting Firm,
acting as experts and not as arbitrators, shall determine in accordance with
the methodologies set forth in Section 5.20 of the Company Disclosure Letter,
the actual Statutory Capital 12/31 Amount and the Authorized Control Level
Amount and shall deliver to the Company and Newco a written report setting
forth such calculations. Such report shall be final and binding upon the
Company and Parent. The cost of such review and report shall be borne equally
by the Company and Parent.

  

  

(e) The parties agree that they will, and agree to cause their respective
independent accountants and Subsidiaries to, cooperate and assist in the
preparation of the calculations of the amounts set forth in the Statutory
Capital Adjustment Certificate and in the conduct of the reviews referred to
in this Section 5.20, including by making available to the extent necessary
their respective books, records, work papers and personnel.

  

  

(f) The Statutory Capital 12/31 Amount and the Authorized Control Level Amount
as of the Effective Time shall equal the amount determined under this Section
5.20 by agreement of the parties pursuant to Section 5.20(d) or by the
Statutory Capital Accounting Firm pursuant to Section 5.20(e).

  

  

Section 5.21 Termination of Medco Agreement. On the date of this Agreement,
the Company shall deliver to Medco Health Solutions, Inc. a notice of
termination of that certain Subcontract for Medicare Part D Prescription
Benefits Management Services, dated January 1, 2009, between Medco Health
Solutions, Inc. and MemberHealth, LLC, pursuant to Section 8.2.6 thereof and
otherwise in accordance with the terms thereof.

  

  

Section 5.22 2012 CMS Bid Process.

  

  

(a) The Company shall, and shall cause the Part D Entities to, use
commercially reasonable efforts consistent with past practice to participate
in the Medicare Part D bid process for the 2012 plan year. If the Closing has
not occurred on or prior to May 1, 2011, the Company and Parent shall
immediately thereafter jointly appoint an actuarial firm from among those
firms set forth on Section 5.22 of the Company Disclosure Letter, which firm
shall be reasonably acceptable to the Company and Parent (the "Actuarial
Firm"), to review the bid submission(s) of the Company and/or the Part D
Entities for the 2012 plan year (the "Bid Submission") solely for the purpose
of determining whether the Bid Submission constitutes a good faith bid
consistent with the Company's past practice in all material respects (a "Good
Faith Bid"). The Actuarial

  

  

  

 

 

 

  

 

53  

  

 

 

 

  

  

  

Firm shall not be permitted to disclose to Parent or any of its Affiliates any
information relating to the Bid Submission other than to state whether or not
the Bid Submission constitutes a Good Faith Bid.

  

  

(b) Within five Business Days from the date of appointment, the Company shall
deliver the Bid Submission to the Actuarial Firm and the Actuarial Firm shall
as soon as practicable, but in any event within seven days after receipt
thereof, notify the Company of its determination as to whether the Bid
Submission constitutes a Good Faith Bid. To the extent that the Actuarial Firm
determines that the Bid Submission is not a Good Faith Bid, the Company shall
work together with the Actuarial Firm in good faith to resolve any material
issues identified by the Actuarial Firm in respect of the Bid Submission.

  

  

(c) Nothing in this Section 5.22 shall be deemed to give Parent or any of its
Affiliates any direct or indirect control of any bid submission of the Company
or the Part D Entities prior to the Effective Time.

  

  

Section 5.23 Relationships with Certain Parties. From the date hereof until
the Effective Time, each of the Company and Parent shall, and shall cause
their respective Subsidiaries to, consult and cooperate with each other
concerning the communications of the Company and Parent with the Persons set
forth on Section 5.23 of the Company Disclosure Letter (the "Section 5.23
Persons") relating (a) to the Contracts between the Company and its
Affiliates, on the one hand, and the Section 5.23 Persons, on the other hand,
and (b) in any material respect to this Agreement, the Split-Off Agreements or
the transactions contemplated hereby or thereby ((a) and (b) collectively, the
"Section 5.23 Matters"). In furtherance of the foregoing, neither the Company
nor Parent shall participate in any meeting, or engage in any material
substantive conversation, in each case relating to the Section 5.23 Matters,
with any Section 5.23 Person without giving the other party prior notice of
the meeting or conversation and the opportunity to attend or participate. Each
of Parent and the Company shall promptly inform the other party upon receipt
of any communication from any Section 5.23 Person relating to the Section 5.23
Matters, and neither party shall enter into any understandings, undertakings
or agreements (oral or written) with any Section 5.23 Person without the prior
consent of the other party, in each case relating to the Section 5.23 Matters.
Prior to any written communication with a Section 5.23 Person relating to the
Section 5.23 Matters, the Company or Parent, as the case may be, shall provide
the other party with a reasonable opportunity to review and comment on such
communication and shall include in such communication all comments reasonably
proposed by such other party. Neither the Company nor Parent shall take any
actions with respect to the Section 5.23 Matters that, to the Knowledge of the
Company or Parent, as applicable, would reasonably be expected to prevent or
to materially impede, delay or interfere with the Merger, the Split-Off or the
other transactions contemplated by this Agreement or the Split-Off Agreements.
Promptly following the date of this Agreement, Parent and the Company shall
meet jointly with the Section 5.23 Persons and Parent shall communicate the
matters set forth on Section 5.23 of the Company Disclosure Letter to the
Section 5.23 Persons. For the avoidance of doubt, each of the Company and
Parent acknowledges that the other

  

  

  

 

 

 

  

 

54  

  

 

 

 

  

  

  

party maintains an ongoing business relationship with Section 5.23 Persons,
and this Section 5.23 shall not prohibit the Company or Parent from engaging
in communications or meetings with Section 5.23 Persons in the ordinary course
of business consistent with past practice that are unrelated to the Section
5.23 Matters. Neither Parent nor the Company shall be entitled to participate
in, or receive notice of, any such excluded communications.

  

  

Section 5.24 Certain Litigation.

  

  

(a) Parent shall assume the control and defense at its own expense of all
shareholder litigation against (i) the Parent, any of their respective
Subsidiaries or any directors or officers of Parent or its Subsidiaries or
(ii) the Company, any of its Subsidiaries or any of directors or officers of
the Company or its Subsidiaries (such Persons set forth in this clause (ii),
the "Covered Persons"), in each case, arising out of or in connection with the
Separation, the Split-Off or the Merger (collectively, the "Shareholder
Litigation"); provided that the Covered Persons shall have the right to
participate in (but not control) such proceedings and to be represented by one
counsel for all Covered Persons of their choosing. The reasonable fees and
expenses of such separate counsel shall constitute Transaction Litigation
Expenses. Whether or not the Merger is consummated, Parent shall reimburse,
indemnify and hold harmless each Covered Person for all costs and expenses
incurred by the Company, its Subsidiaries and the Covered Persons in
connection with the Shareholder Litigation (including, for the avoidance of
doubt, all Transaction Litigation Expenses, which may include only the
reasonable fees and expenses of one counsel for all Covered Persons). Each
Covered Person shall be a third-party beneficiary of this Section 5.24.

  

  

(b) Parent shall obtain the prior written consent of the Company and the
Covered Persons (which shall not be unreasonably withheld or delayed) before
entering into any settlement, understanding or other agreement relating to
such Shareholder Litigation.

  

  

(c) Each party shall cooperate, and cause its Affiliates to cooperate, in the
defense of any Shareholder Litigation and shall furnish or cause to be
furnished such records, information and testimony, and attend, at Parent's
expense, such conferences, discovery proceedings, hearings, trials or appeals,
as may be reasonably requested in connection therewith.

  

  

Section 5.25 Designated Bonds.

  

  

(a) From time to time following the date of this Agreement (but no more than
two (2) times prior to the Designation Date (as defined below)), the Company
shall deliver to Parent at Parent's request a schedule setting forth all bonds
held by the Company and its Subsidiaries. Such schedule shall set forth the
material terms of each bond held by the Company and its Subsidiaries as of
such date, including such bond's outstanding principal amount, maturity date,
original purchase price, investment credit rating and whether such bonds
relate to the Medicare Part D Business or the Non-Medicare Part D Business.

  

  

  

 

 

 

  

 

55  

  

 

 

 

  

  

  

(b) Subject to the terms and conditions in this Section 5.25, Parent shall be
entitled to designate one or more bonds held by the Company and its
Subsidiaries (other than the Newco Bonds (as defined in the Separation
Agreement)) with an investment credit rating of A2/A or lower to be sold by
the Company prior to the Effective Time (such bond(s), the "Designated Part D
Bonds"). No less than 30 Business Days and no more than 60 Business Days prior
to the Effective Time (the "Designation Date"), Parent shall identify by
irrevocable written notice to the Company all Part D Designated Bonds.
Following receipt of such notice, the Company shall, prior the Effective Time,
(i) sell (at the Company's option) such Part D Designated Bonds to (A) a third
party or (B) a member of the Newco Group (in the case of this clause (B) for a
price equal to the fair market value of such Part D Designated Bond (valued as
if such Part D Designated Bond were sold in an arm's length transaction) and
(ii) thereafter acquire, with the proceeds of such sale, bonds with an
individual investment credit rating of A1/A+ or above (the "Designated Bond
Exchange"). Any gain or loss arising out of the Designated Bond Exchange
(calculated by applying the value of the Part D Designated Bonds on a basis
consistent with the Company's historical valuation methods) shall be taken
into account for purposes of determining Newco Cash in accordance with the
terms of the Separation Agreement.

  

  

Section 5.26 Parent Standstill. From the date of this Agreement until the
Closing, Parent shall not, and shall not permit any person acting on behalf of
Parent to, directly or indirectly, acquire (i) any Securities of the Company
or (ii) any derivative contracts or derivative securities that give Parent or
any Person acting on behalf of Parent the economic or voting equivalent of
ownership of Securities of the Company.

  

  

ARTICLE VI 
 

  

  

CONDITIONS

  

  

Section 6.1 Conditions to Each Party's Obligation to Effect the Split-Off and
the Merger. The respective obligation of each party to this Agreement to
effect the Merger is subject to the satisfaction or waiver on or before the
Closing Date of each of the following conditions:

  

  

(a) Company Shareholder Approval. This Agreement shall have been duly adopted
by the Requisite Company Vote.

  

  

(b) Antitrust. The waiting period applicable to the consummation of the Merger
under the HSR Act shall have expired or been terminated.

  

  

(c) Required Regulatory Approvals. All Required Consents shall have been
obtained or, in the case of notices, made.

  

  

(d) Newco Form S-4. The Newco Form S-4 shall have become effective under the
Securities Act and shall not be the subject of any stop order or proceedings
seeking a stop order.

  

  

  

 

 

 

  

 

56  

  

 

 

 

  

  

  

(e) No Orders. No Governmental Authority shall have enacted, issued,
promulgated, enforced or entered any Law or Order that enjoins or otherwise
prohibits consummation of the Merger, the Separation or the Split-Off.

  

  

(f) Split-Off Transactions. Except as set forth in Section 2.01(b) of the
Separation Agreement, the transactions contemplated by Section 5.18, including
the Separation, shall have been consummated in accordance with the terms of
this Agreement and the Split-Off Agreements (including the satisfaction of all
conditions to the Separation set forth in the Separation Agreement).

  

  

Section 6.2 Conditions to Obligations of Parent and Merger Sub. The
obligations of each of Parent and Merger Sub to effect the Merger are also
subject to the satisfaction or waiver by Parent on or before the Closing Date
of the following conditions:

  

  

(a) Representations and Warranties. (i) The representations and warranties of
the Company set forth in Section 3.1 (Organization and Power), Section 3.4
(Corporate Authorizations), Section 3.23 (Takeover Statutes), Section 3.31
(Opinion of Financial Advisor) and Section 3.32 (Brokers) shall be true and
correct in all material respects, (ii) the representation and warranty set
forth in Section 3.12(b) (Absence of Certain Changes) shall be true and
correct in all respects, and (iii) the remaining representations and
warranties of the Company contained in Article III (Representations and
Warranties of the Company) shall be true and correct, in each case as of the
Closing (except to the extent any such representation and warranty expressly
speaks as of a specified date, in which case as of such date), except, in the
case of clause (iii) only, where the failure of any such representations and
warranties to be so true and correct (without regard to any materiality or
Company Material Adverse Effect qualifications set forth in any such
representation or warranty) would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect.

  

  

(b) Performance of Obligations. The Company shall have performed in all
material respects all obligations required to be performed by it under this
Agreement, and the Company and its Subsidiaries shall have performed in all
material respects all obligations required to be performed by them under the
Split-Off Agreements, in each case at or before the Closing Date.

  

  

(c) Absence of Company Material Adverse Effect. No event, circumstance,
development, change or effect shall have occurred since the date of this
Agreement that would, individually or in the aggregate, reasonably be expected
to have a Company Material Adverse Effect.

  

  

(d) Officer's Certificate. Parent shall have received a certificate, signed by
an executive officer of the Company, certifying as to the matters set forth in
Section 6.2(a) and Section 6.2(b).

  

  

  

 

 

 

  

 

57  

  

 

 

 

  

  

  

Section 6.3 Conditions to Obligation of the Company. The obligation of the
Company to effect the Merger is also subject to the satisfaction or waiver by
the Company on or before the Closing Date of the following conditions:

  

  

(a) Representations and Warranties. (i) The representations and warranties of
each of Parent and Merger Sub set forth in Section 4.3(a) (Corporate
Authorization) and Section 4.5(c) (Ownership of Common Stock) shall be true
and correct in all material respects, and (ii) the remaining representations
and warranties of each of Parent and Merger Sub contained in Article IV
(Representations and Warranties of Parent and Merger Sub) shall be true and
correct, in each case as of the Closing (except to the extent any such
representation and warranty expressly speaks as of a specified date, in which
case as of such date), except, in the case of clause (ii) only, where the
failure of any such representations and warranties to be so true and correct
(without regard to any materiality or Parent Material Adverse Effect
qualifications set forth in any such representation or warranty) would not,
individually or in the aggregate, reasonably be expected to have a Parent
Material Adverse Effect.

  

  

(b) Performance of Obligations. Each of Parent and Merger Sub shall have
performed in all material respects all obligations required to be performed by
it under this Agreement at or before the Closing Date.

  

  

(c) Officer's Certificate. The Company shall have received a certificate,
signed by an executive officer of Parent, certifying as to the matters set
forth in Section 6.3(a) and Section 6.3(b).

  

  

(d) Newco Common Stock Listing. The shares of Newco Common Stock issuable to
the Company's shareholders pursuant to Article II shall have been approved for
listing on a national securities exchange, or approved for quotation on
NASDAQ, in either case subject only to official notice of issuance.

  

  

Section 6.4 Frustration of Closing Conditions. Neither the Company, on the one
hand, nor Parent or Merger Sub, on the other hand, may rely, either as a basis
for not consummating the Merger or for terminating this Agreement and
abandoning the Merger, on the failure of any condition set forth in Section
6.1, Section 6.2 or Section 6.3, as the case may be, to be satisfied if such
failure was principally caused by such party's breach of any provision of this
Agreement.

  

  

ARTICLE VII 
 

  

  

TERMINATION, AMENDMENT AND WAIVER

  

  

Section 7.1 Termination by Mutual Consent. This Agreement may be terminated at
any time before the Effective Time, whether before or after obtaining the
Requisite Company Vote, by mutual written consent of Parent and the Company.

  

  

  

 

 

 

  

 

58  

  

 

 

 

  

  

  

Section 7.2 Termination by Either Parent or the Company. This Agreement may be
terminated by either Parent or the Company at any time before the Effective
Time:

  

  

(a) whether before or after obtaining the Requisite Company Vote, if the
Merger has not been consummated by December 31, 2011 (the "Termination Date"),
except that the right to terminate this Agreement under this Section 7.2(a)
shall not be available to any party to this Agreement whose breach of this
Agreement has been a principal cause of, or resulted in, the failure to
consummate the Merger by such date;

  

  

(b) if this Agreement has been submitted to the shareholders of the Company
for adoption at a duly convened Company Shareholders Meeting (or adjournment
or postponement thereof) and the Requisite Company Vote is not obtained upon a
vote taken thereon; or

  

  

(c) whether before or after obtaining the Requisite Company Vote, if any Law
or Order is enacted, issued, promulgated, enforced or entered that permanently
enjoins or otherwise prohibits consummation of the Merger, the Separation or
the Split-Off, and (in the case of any Order) such Order has become final and
nonappealable.

  

  

Section 7.3 Termination by Parent. This Agreement may be terminated by Parent
at any time before the Effective Time:

  

  

(a) if the Company Board effects a Company Adverse Recommendation Change;

  

  

(b) if (i) the Company Board approves, endorses or recommends to shareholders
a Superior Proposal or (ii) a tender offer or exchange offer for any
outstanding shares of capital stock of the Company is commenced before
obtaining the Requisite Company Vote and the Company Board fails to recommend
against acceptance of such tender offer or exchange offer by its shareholders
within ten Business Days after commencement;

  

  

(c) if there shall have been an intentional and material breach of Section
5.4;

  

  

(d) if the Company breaches any of its representations, warranties, covenants
or agreements contained in this Agreement, which breach (i) would give rise to
the failure of a condition set forth in Section 6.1 or Section 6.2 and has not
been cured by the Company within 45 Business Days after the Company's receipt
of written notice of such breach from Parent; provided that Parent shall not
have the right to terminate this Agreement pursuant to this Section 7.3(d) if
Parent or Merger Sub is then in breach of any of their representations,
warranties, covenants or agreements contained in this Agreement that would
result in the conditions to Closing set forth in Section 6.1 or Section 6.3
not being satisfied; or

  

  

  

 

 

 

  

 

59  

  

 

 

 

  

  

  

(e) if all of the conditions set forth in Section 6.1 and Section 6.3 have
been satisfied (other than any condition the failure of which to be satisfied
has been principally caused by the breach of this Agreement by the Company or
any of its Affiliates and conditions that, by their nature, are to be
satisfied at Closing and which were, at the time of termination, capable of
being satisfied) and the Company has failed to fulfill its obligation and
agreement herein to consummate the Closing within three Business Days
following written notice of such satisfaction from Parent.

  

  

Section 7.4 Termination by the Company. This Agreement may be terminated by
the Company at any time before the Effective Time:

  

  

(a) if Parent breaches any of its representations, warranties, covenants or
agreements contained in this Agreement, which breach (i) would give rise to
the failure of a condition set forth in Section 6.1 or Section 6.3 and (ii)
has not been cured by Parent within 45 Business Days after Parent's receipt of
written notice of such breach from the Company; provided that the Company
shall not have the right to terminate this Agreement pursuant to this Section
7.4(a) if the Company is then in breach of any of its representations,
warranties, covenants or agreements contained in this Agreement that would
result in the conditions to Closing set forth in Section 6.1 or Section 6.2
not being satisfied; or

  

  

(b) if all of the conditions set forth in Section 6.1 and Section 6.2 have
been satisfied (other than any condition the failure of which to be satisfied
has been principally caused by the breach of this Agreement by Parent or any
of its Affiliates and conditions that, by their nature, are to be satisfied at
Closing and which were, at the time of termination, capable of being
satisfied) and Parent and Merger Sub have failed to fulfill their obligation
and agreement herein to consummate the Closing within three Business Days
following written notice of such satisfaction from the Company.

  

  

Section 7.5 Effect of Termination. If this Agreement is terminated pursuant to
this Article VII, except as set forth in this Section 7.5, it shall become
void and of no further force and effect, with no liability (except as provided
in Section 7.6) on the part of any party to this Agreement (or any shareholder
or Representative of such party), except that, subject to Section 7.6, if such
termination results from the willful (a) failure of any party to perform its
covenants, obligations or agreements contained in this Agreement or (b) breach
by any party of its representations or warranties contained in this Agreement,
then such party shall be fully liable for any Damages incurred or suffered by
the other parties as a result of such failure or breach. The parties
acknowledge that Damages sought by the Company in connection with any such
willful failure or breach by Parent or Merger Sub can be based on, or
otherwise take into account, the consideration that would have otherwise been
payable to the shareholders of the Company pursuant to this Agreement. The
provisions of Section 5.3(b) (Confidentiality), Section 5.13 (Fees and
Expenses), this Section 7.5 (Effect of Termination), Section 7.6 (Fees and
Expenses Following Termination) and Article VIII (Miscellaneous) shall survive
any termination of this Agreement.

  

  

  

 

 

 

  

 

60  

  

 

 

 

  

  

  

Section 7.6 Fees and Expenses Following Termination.

  

  

(a) Except as set forth in this Section 7.6, all Expenses incurred in
connection with this Agreement and the transactions contemplated by this
Agreement shall be paid in accordance with the provisions of Section 5.13.

  

  

(b) The Company shall pay, or cause to be paid, to Parent by wire transfer of
immediately available funds an amount equal to the Company Termination Fee:

  

  

(i) if this Agreement is terminated by Parent pursuant to Section 7.3(a),
Section 7.3(b) or Section 7.3(c), in which case payment shall be made within
two Business Days following such termination; or

  

  

(ii) if (A) this Agreement is terminated by either Parent or the Company
pursuant to Section 7.2(b), (B) after the date of this Agreement and prior to
the date of such termination, a Takeover Proposal shall have been communicated
to the Company Board, publicly made or publicly proposed to the Company or
otherwise publicly announced (which has not been publicly withdrawn), in each
case prior to the Company Shareholders Meeting, and (C) within twelve months
following the date of such termination, the Company consummates, or enters
into a Contract providing for the implementation of, a Takeover Proposal, in
which case payment shall be made concurrently with such consummation or the
entry into such Contract, as applicable. For purposes of the foregoing clause
(C) only, references in the definition of the term "Takeover Proposal" to the
figure "15%" shall be deemed to be replaced by the figure "more than 50%".

  

  

(c) For purposes of this Agreement, the "Company Termination Fee" means an
amount in cash equal to $36,000,000, plus actual and reasonable documented
out-of-pocket costs and expenses incurred prior to the date of termination in
connection with the transactions contemplated by this Agreement and the Split-
Off Agreements in an amount not to exceed $5,000,000.

  

  

(d) If the Company fails to pay the Company Termination Fee as required
pursuant to this Section 7.6, when due, such fee shall accrue interest for the
period commencing on the date such fee became past due, at a rate equal to the
rate of interest publicly announced by Citibank, in the City of New York from
time to time during such period, as such bank's Prime Lending Rate. In
addition, if the Company fails to pay such fee when due, the Company shall
also pay to Parent all of Parent's costs and expenses (including attorneys'
fees) in connection with efforts to collect such fee. Notwithstanding anything
to the contrary in this Agreement, if the Company Termination Fee is required
to be paid as a result of a termination of this Agreement, then, except in the
case of (x) willful breach of this Agreement or (y) fraud, Parent's right to
receive payment of the Company Termination Fee pursuant to this Section
7.6shall be the sole and exclusive remedy (whether at law, in equity, in
contract, tort or otherwise) of Parent, Merger Sub and their respective
Affiliates, if applicable, for (A) the Damages suffered as a result of the
failure of the Merger to be consummated and (B) any other Damages

  

  

  

 

 

 

  

 

61  

  

 

 

 

  

  

  

suffered as a result of or under this Agreement and the transactions
contemplated by this Agreement, and upon payment of the Company Termination
Fee in accordance with this Section 7.6, none of the Company or any of its
Affiliates, respective current or former shareholders, directors, officers,
employees, agents or Representatives shall have any further liability or
obligation relating to or arising out of this Agreement or the transactions
contemplated by this Agreement. Parent and the Company acknowledge that the
fees and the other provisions of this Section 7.6 are an integral part of the
transactions contemplated by this Agreement and that, without these
agreements, Parent, Merger Sub and the Company would not enter into this
Agreement.

  

  

ARTICLE VIII 
 

  

  

MISCELLANEOUS

  

  

Section 8.1 Certain Definitions. For purposes of this Agreement:

  

  

(a) "Affiliate" means, with respect to any Person, any other Person that
directly or indirectly controls, is controlled by or is under common control
with, such first Person. For the purposes of this definition, "control"
(including, with correlative meanings, the terms "controlling," "controlled
by" and "under common control with"), when used with respect to any Person,
means the power to direct or cause the direction of the management or policies
of such Person, directly or indirectly, whether through the ownership of
voting securities, by contract or otherwise.

  

  

(b) "Applicable Exchange" means the New York Stock Exchange.

  

  

(c) "Authorized Control Level" means, with respect to any Person, an amount of
risk-based capital that is equal to the "Authorized Control Level RBC" of such
Person, as such term is defined in Section 221.1-A of Article V-A of the
Insurance Department Act.

  

  

(d) "Business Day" means any day other than Saturday, Sunday or a day on which
commercial banks in New York, New York are authorized or required by Law to
close, and shall consist of the time period from 12:01 a.m. through 12:00
midnight New York time.

  

  

(e) "Company Indebtedness" means, with respect to the Company and its
Subsidiaries as of the close of business on the day immediately prior to the
Effective Time, the outstanding principal amount of, accrued and unpaid
interest thereon and any other amounts due and payable (including, in the case
of clauses (iii) and (iv) below, any termination payments or breakage costs to
be incurred in connection with the repayment of such indebtedness at the
Closing) pursuant to each of (i) the Credit Agreement, dated as of September
18, 2007, among the Company and the lender parties thereto, as amended by the
First Amendment to Credit Agreement, dated as of November 9, 2009, by and
among the Company, the Lenders party thereto and Bank of America, N.A. as
administrative agent for the Lenders and as further amended by the

  

  

  

 

 

 

  

 

62  

  

 

 

 

  

  

  

Second Amendment to Credit Agreement, dated as of July 27, 2010, by and among
the Company, certain lenders party thereto and Bank of America, N.A., as
administrative agent, (ii) the Indentures (A) dated as of May 15, 2003, among
the Company, as Issuer, and US. Bank National Association, as Trustee, for
Fixed/Floating Rate Junior Subordinated Deferrable Interest Debentures Due
2033, (B) dated as of May 22, 2003, among the Company, as Issuer, and
Wilmington Trust Company, as Trustee, for Floating Rate Junior Subordinated
Debt Securities Due 2033, (C) dated as of October 29, 2003, among the Company,
as Issuer, and U.S. Bank National Association, as Trustee, for Floating Rate
Junior Subordinated Deferrable Interest Debentures Due 2033, (D) dated as of
March 27, 2003, among the Company, as Issuer, and Wells Fargo Bank National
Association, as Trustee, for Junior Subordinated Debt Securities Due 2033 and
(E) dated as of March 22, 2007, among the Company, as Issuer, and Wilmington
Trust Company, as Trustee, for Fixed/Floating Rate Junior Subordinated
Deferrable Interest Debentures Due 2037, (iii) the Interest Rate Swap
Agreement (2002 ISDA Master Agreement), dated November 30, 2007, between the
Company and Citibank, N.A., (iv) the Interest Rate Swap Agreement (ISDA Master
Agreement), dated September 18, 2007, between the Company and Calyon and (v)
any indebtedness incurred pursuant to Section 5.1(h) (which, for the avoidance
of doubt, shall not include any incurrence of indebtedness by Newco or any of
its Subsidiaries prior to the Effective Time in accordance with the Separation
Agreement).

  

  

(f) "Company Material Adverse Effect" means a material adverse effect (i) on
the ability of the Company to consummate the transactions contemplated by this
Agreement or the ability of the Company and its Subsidiaries to consummate the
transactions contemplated by the Split-Off Agreements or (ii) on the business,
assets, results of operations or financial condition of the Medicare Part D
Business, taken as a whole; provided that the term "Company Material Adverse
Effect" shall not include any such effect relating to or arising from (A)
conditions (economic, political, regulatory or otherwise) generally affecting
the industries in which the Medicare Part D Business operates, (B) the United
States or foreign economic, financial or geopolitical conditions or events in
general, (C) changes or conditions in the financial, debt, credit or capital
markets, (D) changes or proposed changes in Law, or standards or
interpretations thereof, including changes in Healthcare Laws or CMS written
interpretation and guidance affecting the industries in which the Company and
its Subsidiaries operate or the introduction or enactment of legislation or
the proposal or adoption of any rule or regulation affecting Medicare pricing,
reimbursement, competitive bidding or other aspects of the healthcare
insurance industry, (E) the American Recovery and Reinvestment Act, (F) the
Patient Protection and Affordable Care Act, (G) changes or proposed changes in
GAAP or other accounting principles or requirements, or standards or
interpretations thereof, (H) changes in interest rates, (I) taking any actions
contemplated by this Agreement or failure to take any actions prohibited by
this Agreement, including compliance by the Company and its Subsidiaries with
the terms of this Agreement, (J) any decline in the market price, or change in
trading volume, of the Common Stock, any decrease of the ratings or ratings
outlook for the Company by any of the Rating Agencies and the consequences of
any such ratings or outlook decrease, or the failure of the Company to meet
any projections, forecasts,

  

  

  

 

 

 

  

 

63  

  

 

 

 

  

  

  

budgets, estimates or operational metrics (it being understood that the
underlying causes of any such decline, change, decrease or failure may, if
they are not otherwise excluded from the definition of Company Material
Adverse Effect, be taken into account in determining whether a Company
Material Adverse Effect has occurred), (K) escalation or outbreak of
hostilities, acts of terrorism or military conflicts, (L) the entry into, or
any announcement or disclosure of, this Agreement or the transactions
contemplated by this Agreement, including any effects related to the identity
of Parent and any loss of a material customer, supplier, employee or CMS
contract as a result of the identity of Parent (provided that the exception in
this clause (L) shall not be deemed to apply to references to "Company
Material Adverse Effect" in the representations and warranties set forth in
Section 3.3 and Section 3.5), (M) any actions taken by, or at the request of,
Parent or its Affiliates after the date of this Agreement and on or before the
Closing Date that relate to, or affect, the Medicare Part D Business, (N) any
seasonality associated with the earnings of the Medicare Part D Business
generally consistent with the financial results for such business for the year
ended December 31, 2010, (O) the results of the Medicare Part D bid process
for the 2012 plan year (except to the extent that such results are affected by
any administrative action or sanction applicable to the Company or any of its
Subsidiaries or any breach or violation of Health Care Laws by the Company or
any of its Subsidiaries) or (P) the matters set forth in Section 8.1(d) of the
Company Disclosure Letter, except, in the case of clauses (A) through (H), to
the extent (and only to the extent) that the Medicare Part D Business is
materially disproportionately affected thereby (relative to other similarly
situated participants in the industries in which the Medicare Part D Business
operates but only with respect of such participation (i.e., disregarding any
other operations of such participants)).

  

  

(g) "Consent Expenses" means any fees, costs and expenses or payments payable
in connection with the receipt of any consents, approvals or authorizations of
any Governmental Authority obtained by Parent or any of its Affiliates in
connection with the transactions contemplated by this Agreement (including
pursuant to Section 5.9).

  

  

(h) "Contract" means any contract, agreement, indenture, note, bond, loan,
lease, sublease, mortgage, license, sublicense, obligation or other binding
arrangement.

  

  

(i) "Damages" means any costs or expenses (including legal fees and
disbursements), judgments, fines, losses, claims, damages or Liabilities.

  

  

(j) "Earned Performance Shares" means (i) in the case of each Performance
Share granted in 2010, all such Performance Shares and (ii) in the case of
each Performance Share granted in 2009, the number of Performance Shares
earned, as determined by the Compensation Committee of the Company Board (as
in effect immediately prior to the Effective Time), but in any event no more
than 150% of such Performance Shares granted in 2009.

  

  

(k) "Environmental Laws" means all Laws relating to (i) pollution,
contamination, protection of the (indoor or outdoor) environment or health

  

  

  

 

 

 

  

 

64  

  

 

 

 

  

  

  

and safety, (ii) emissions, discharges, disseminations, releases or threatened
releases of Hazardous Substances into the air (indoor or outdoor), surface
water, groundwater, soil, land surface or subsurface, buildings, facilities,
real or personal property or fixtures or (iii) the manufacture, processing,
distribution, use, treatment, storage, disposal, transport or handling of, or
exposure to, Hazardous Substances.

  

  

(l) "Governmental Authority" means: (i) any federal, state, local, foreign or
international government or governmental authority, regulatory or
administrative agency, governmental commission, department, board, bureau,
agency or instrumentality, court, tribunal, arbitrator or arbitral body
(public or private); (ii) any self-regulatory organization; (iii) any
political subdivision of any of the foregoing and (iv) any Medicare or
Medicaid contractor or intermediary.

  

  

(m) "Hazardous Substances" means all toxic substances, radioactive substances,
hazardous substances, dangerous materials, pollutants, contaminants, chemicals
or wastes, including petroleum, petroleum derivatives and by products,
hydrocarbons, mold, polychlorinated biphenyls, asbestos-containing materials,
and mold.

  

  

(n) "Health Care Laws" means all Laws relating to: (i) the licensure,
certification, qualification or authority to transact business in connection
with the provision of, payment for, or arrangement of, health benefits or
health insurance, including Laws that regulate managed care, third-party
payors and persons bearing the financial risk for the provision or arrangement
of health care services and, without limiting the generality of the foregoing,
the Medicare Program Laws and Laws relating to Medicaid programs; (ii) the
solicitation or acceptance of improper incentives involving persons operating
in the health care industry, including Laws prohibiting or regulating fraud
and abuse, patient referrals or Provider incentives generally or under the
following statutes: the Federal anti-kickback law (42 U.S.C.  1320a-7b), the
Federal False Claims Act (31 U.S.C.  3729, et seq.), the Federal Civil
Monetary Penalties Law (42 U.S.C.  1320a7a), the Federal Program Fraud Civil
Remedies Act (31 U.S.C.  3801 et seq.) and any similar state laws; (iii) the
administration of health care claims or benefits or processing or payment for
health care services, treatment or supplies furnished by Providers, including
third-party administrators, utilization review agents and persons performing
quality assurance, credentialing or coordination of benefits; (iv) billings to
insurance companies, health maintenance organizations and other managed care
plans or otherwise related to insurance fraud; (v) the Consolidated Omnibus
Budget Reconciliation Act of 1985, as amended; (vi) the Health Insurance
Portability and Accountability Act of 1996, as amended; (vii) any Laws
governing the privacy, security, integrity, accuracy, transmission, storage or
other protection of information about or belonging to actual or prospective
Members including the Health Information Technology for Economic and Clinical
Health Act; (viii) any state insurance, health maintenance organization or
managed care Laws (including Laws relating to Medicaid programs); (ix) the
Medicare Program Laws; and (x) the Patient Protection and Affordable Care Act
(Pub. L. 111148) as amended by the Health Care and Education Reconciliation
Act of 2010 (Pub. L. 111152) and the regulations adopted thereunder.

  

  

  

 

 

 

  

 

65  

  

 

 

 

  

  

  

(o) "Insurance Department Act" means the Pennsylvania Insurance Department Act
of 1921 as in effect on December 31, 2010 (40 P.S. et. seq.)

  

  

(p) "Intellectual Property" means any and all (i) inventions, patents and
patent applications; (ii) trademarks, service marks, trade dress, logos, trade
names, corporate names, domain names and other source identifiers (including
all registrations and applications for registration), and all goodwill
associated with any of the foregoing; (iii) copyrights (including all
registrations and applications for registration), original works of
authorship; (iv) trade secrets, including confidential and proprietary
information and know-how; (v) other intellectual property rights in any and
all jurisdictions throughout the world; and (vi) rights to sue and recover and
retain damages, costs and attorneys' fees for the past, present and future
infringement, misappropriation or other violation of any of the foregoing.

  

  

(q) "IT Assets" means the computers, computer software firmware, middleware,
servers, workstations, routers, hubs, switches, data communications lines, and
all other information technology equipment, and all associated documentation,
in each case used or held for use by the Part D Entities in connection with
the Medicare Part D Business.

  

  

(r) "Investment Assets" means certificates of deposit, banker's acceptances,
bonds, notes, debentures, evidences of indebtedness, certificates of interest
or participation in profit-sharing agreements, collateral-trust certificates,
reorganization certificates or subscriptions or investment contracts.

  

  

(s) "Knowledge" means, when used with respect to Parent or the Company, the
actual knowledge, after reasonable inquiry, of the Persons set forth in
Section 8.1(s) of the Parent Disclosure Letter or Company Disclosure Letter,
respectively.

  

  

(t) "Law" means any law, statute, ordinance, code, regulation, rule, the
common law or other requirement of any Governmental Authority, and any Orders,
including Health Care Laws.

  

  

(u) "Liens" means any mortgages, liens, pledges, security interests, claims,
options, rights of first offer or refusal, charges or other encumbrances in
respect of any property or asset.

  

  

(v) "Medicare Part D Business" means the Company's and its Subsidiaries'
business of (i) establishing, underwriting, selling, administering and/or
maintaining Medicare Part D prescription drug plans throughout the United
States and certain United States territories and (ii) operating as a pharmacy
benefit manager servicing Members in such prescription drug benefit plans and
in the Company's and its Subsidiaries' Medicare Advantage plans offering a
Medicare Part D benefit.

  

  

(w) "Medicare Program Laws" means Title XVIII of the Social Security Act, as
amended, as well as any final rules and final regulations adopted

  

  

  

 

 

 

  

 

66  

  

 

 

 

  

  

  

pursuant to such Acts and any written directives, instructions, guidelines,
bulletins, manuals, requirements, policies and standards issued by a
Governmental Authority.

  

  

(x) "Member(s)" means any individual who is properly enrolled in a MA Plan
offered by the Company or any of its Subsidiaries.

  

  

(y) "Non-Medicare Part D Business" means the business of the Company and its
Subsidiaries now or formerly conducted by the Company or its Subsidiaries,
other than the Medicare Part D Business.

  

  

(z) "Novation Allocation Amount" means the amount listed on Section 8.1(z) of
the Company Disclosure Letter.

  

  

(aa) "Orders" means any orders, decisions, judgments, writs, injunctions,
decrees, awards or other determinations of any Governmental Authority.

  

  

(bb) "Outstanding Common Shares" means the sum of (i) the number of shares of
Common Stock outstanding (other than any Excluded Shares), plus (ii) the
number of shares of Common Stock into which shares of Series A Preferred Stock
are convertible in the Split-Off and the Merger, determined in each case as of
immediately prior to the Effective Time.

  

  

(cc) "Parent Material Adverse Effect" means a material adverse effect (i) on
the ability of Parent or Merger Sub to consummate the transactions
contemplated by this Agreement or the ability of the Parent and its
Subsidiaries to consummate the transactions contemplated by the Split-Off
Agreements or (ii) solely for the purposes of Section 5.9(e), on the business,
assets, results of operations or financial condition of Parent and its
Subsidiaries, taken as a whole; provided that the term "Parent Material
Adverse Effect" shall not include any such effect relating to or arising from
(A) conditions (economic, political, regulatory or otherwise) generally
affecting the industries in which Parent and its Subsidiaries operate, (B) the
United States or foreign economic, financial or geopolitical conditions or
events in general, (C) changes or conditions in the financial, debt, credit or
capital markets, (D) changes or proposed changes in Law, or standards or
interpretations thereof, including changes in Healthcare Laws or CMS written
interpretation and guidance affecting the industries in which Parent and its
Subsidiaries operate or the introduction or enactment of legislation or the
proposal or adoption of any rule or regulation affecting Medicare pricing,
reimbursement, competitive bidding or other aspects of the healthcare
insurance industry, (E) the American Recovery and Reinvestment Act, (F) the
Patient Protection and Affordable Care Act, (G) changes or proposed changes in
GAAP or other accounting principles or requirements, or standards or
interpretations thereof, (H) changes in interest rates, (I) any decline in the
market price, or change in trading volume, of the capital stock of Parent, any
decrease of the ratings or ratings outlook for Parent by any applicable rating
agencies and the consequences of any such ratings or outlook decrease, or the
failure of Parent to meet any projections, forecasts, budgets, estimates or
operational metrics (it being understood that the underlying causes of any
such decline, change, decrease or failure may, if they are not otherwise
excluded from the definition of Parent Material Adverse

  

  

  

 

 

 

  

 

67  

  

 

 

 

  

  

  

Effect, be taken into account in determining whether a Parent Material Adverse
Effect has occurred) or (J) any seasonality associated with the earnings of
Parent's existing Medicare Part D prescription drug business generally
consistent with the financial results for such business for the year ended
December 31, 2010, except, in the case of clauses (A) through (H), to the
extent (but only to the extent) that Parent and its Subsidiaries are
materially disproportionately affected thereby (relative to other similarly
situated participants in the industries in which Parent and its Subsidiaries
operate but only with respect of such participation (i.e., disregarding any
other operations of such participants)).

  

  

(dd) "Penn Life" means Pennsylvania Life Insurance Company, a Pennsylvania
corporation.

  

  

(ee) "Per Share Merger Consideration" means an amount equal to the quotient
(rounded to the nearest cent) of (A)(i) the Purchase Price Amount plus (ii)
the Statutory Capital Excess Amount, if any, minus (iii) the Closing Date
Indebtedness Amount, minus (iv) the Novation Allocation Amount, minus (v) the
Statutory Capital Deficit Amount, if any, divided by (B) the number of
Outstanding Common Shares.

  

  

(ff) "Permitted Liens" shall mean (i) statutory Liens for Taxes, assessments
or other charges by Governmental Authorities not yet due and payable or the
amount or validity of which is being contested in good faith and by
appropriate proceedings, (ii) mechanics', materialmen's, carriers', workmen's,
warehouseman's, repairmen's, landlords' and similar Liens granted or which
arise in the ordinary course of business that are not material in amount and
do not materially detract from the value of or materially impair the existing
use of the property affected by such Lien, (iii) zoning, entitlement, building
and other land use Liens applicable to real property which are not violated by
the current use, occupancy or operation of such real property, (iv) covenants,
conditions, restrictions, easements and other non-monetary Liens affecting
title to any real property which would do not materially impair the value,
current use, occupancy or operation of such real property, (v) Liens arising
under worker's compensation, unemployment insurance, social security,
retirement and similar Laws, (vi) Liens on goods in transit incurred pursuant
to documentary letters of credit and (vii) such other Liens that are not
material in amount and do not materially detract from the value of or
materially impair the existing use of the property affected by such Lien.

  

  

(gg) "Person" means any natural person, corporation, company, partnership,
association, limited liability company, limited partnership, limited liability
partnership, trust or other legal entity or organization, including a
Governmental Authority.

  

  

(hh) "Providers" means any all physicians, physician or medical groups,
Independent Practice Associations, Preferred Provider Organizations, exclusive
provider organizations, specialist physicians, dentists, optometrists,
audiologists, pharmacies and pharmacists, radiologists or radiology centers,
laboratories, mental health professionals, chiropractors, physical therapists,
any hospitals, skilled nursing facilities,

  

  

  

 

 

 

  

 

68  

  

 

 

 

  

  

  

extended care facilities, other health care or services facilities, durable
medical equipment suppliers, opticians, home health agencies, alcoholism or
drug abuse centers and any other specialty, ancillary or allied medical,
health or wellness professional or facility.

  

  

(ii) "Purchase Price Amount" means One Billion and Two Hundred and Fifty
Million Dollars ($1,250,000,000.00).

  

  

(jj) "Rating Agencies" means Standard and Poor's Ratings Service and A.M. Best
Company.

  

  

(kk) "Representatives" means, when used with respect to any Person, the
directors, officers, employees, consultants, accountants, legal counsel,
investment bankers or other financial advisors, agents and other
representatives of such Person.

  

  

(ll) "Requisite Company Vote" means the adoption of this Agreement by the
affirmative vote of holders of two-thirds of the outstanding shares of Common
Stock as of the record date for the Company Shareholders Meeting.

  

  

(mm) "Separation" has the meaning given to such term in the Separation
Agreement.

  

  

(nn) "Split-Off Agreements" mean the Separation Agreement, the Tax Matters
Agreement, the Transition Services Agreement, the Reinsurance Agreement, the
Novation Agreement and the PBM Agreement.

  

  

(oo) "Statutory Capital" means with respect to any Person, an amount equal to
the "Total Adjusted Capital" of such Person, as filed with the Insurance
Department of the State of Pennsylvania in accordance with Section 221.1-A of
Article V-A of the Insurance Department Act.

  

  

(pp) "Statutory Capital Deficit Amount" means the amount, if any, by which
200% of the Authorized Control Level Amount exceeds the Statutory Capital
12/31 Amount.

  

  

(qq) "Statutory Capital Excess Amount" means the amount, if any, by which the
Statutory Capital 12/31 Amount exceeds 200% of the Authorized Control Level
Amount.

  

  

(rr) "Stockholders Agreement" means the Stockholders' Agreement, dated of as
September 21, 2007, among the Company and the stockholders listed on the
signature pages thereto.

  

  

(ss) "Subsidiary" means, when used with respect to any Person, any other
Person that such Person directly or indirectly owns or has the power to vote
or control more than 50% of the voting stock or other interests the holders of
which are

  

  

  

 

 

 

  

 

69  

  

 

 

 

  

  

  

generally entitled to vote for the election of the board of directors or other
applicable governing body of such other Person.

  

  

(tt) "Superior Proposal" means a bona fide, unsolicited written Takeover
Proposal for at least a majority of the outstanding shares of Common Stock or
all or substantially all of the consolidated assets of the Company and its
subsidiaries or the Medicare Part D Business on terms which the Company Board
determines in good faith by a majority vote, after considering the advice of a
financial advisor of nationally recognized reputation and outside legal
counsel and taking into account all of the terms and conditions of such
Takeover Proposal, including, if deemed relevant by the Company Board, any
break-up fees, financing arrangements, expense reimbursement provisions and
conditions to consummation, are more favorable to the shareholders of the
Company (in their capacity as such) than those contemplated by this Agreement.

  

  

(uu) "Takeover Proposal" means, any proposal, offer or indication of interest
relating to (i) a merger, consolidation, share exchange or business
combination involving the Company or any of its Subsidiaries representing 15%
or more of the assets of (x) the Company and its Subsidiaries, taken as a
whole, (y) the Part D Entities, or (z) the Non-Medicare Part D Business; (ii)
a direct or indirect sale, lease, exchange, mortgage, transfer or other
disposition, in a single transaction or series of related transactions, of 15%
or more of the assets of (x) the Company and its Subsidiaries, taken as a
whole, (y) the Part D Entities, or (z) the Non-Medicare Part D Business; (iii)
a purchase or sale of shares of capital stock or other securities, in a single
transaction or series of related transactions, representing 15% or more of the
voting power of the capital stock of Company, including by way of a tender
offer or exchange offer, (iv) a reorganization, recapitalization, liquidation
or dissolution of the Company or (v) any other transaction having a similar
effect to those described in clauses (i) through (iv), in each case other than
the transactions contemplated by this Agreement.

  

  

(vv) "Tax Returns" means any and all reports, returns, declarations, claims
for refund, elections, disclosures, estimates, information reports or returns
or statements required to be supplied to a taxing authority in connection with
Taxes, including any schedule or attachment thereto or amendment thereof.

  

  

(ww) "Taxes" means any and all federal, state, provincial, local, foreign and
other taxes, levies, fees, imposts, duties, and similar governmental charges
(including any interest, fines, assessments, penalties or additions to tax
imposed in connection therewith or with respect thereto) including (x) taxes
imposed on, or measured by, income, franchise, profits or gross receipts, and
(y) ad valorem, value added, capital gains, withholdings, sales, goods and
services, use, real or personal property, capital stock, license, branch,
payroll, estimated withholding, employment, social security (or similar),
unemployment, compensation, utility, severance, production, excise, stamp,
occupation, premium, windfall profits, transfer and gains taxes, and customs
duties.

  

  

(xx) "Transaction Expenses" means, as to any Person, any fees, costs and
expenses incurred by such Person, in each case in connection with the

  

  

  

 

 

 

  

 

70  

  

 

 

 

  

  

  

Separation, the Split-Off, the Merger and the transactions contemplated by
this Agreement or the Split-Off Agreements (whether incurred prior to or after
the date of this Agreement and whether paid or not paid prior to the Effective
Time), including: (a) any brokerage fees, costs and expenses, commissions,
finders' fees, costs and expenses or financial advisory fees, costs and
expenses; and (b) any fees, costs and expenses of counsel, accountants or
other advisors or service providers; provided that Transaction Expenses shall
not include (i) any Consent Expenses, (ii) any Transaction Litigation Expenses
or (iii) any Taxes, including Transfer Taxes, arising or in connection with
the Separation.

  

  

(yy) "Transaction Litigation Expenses" means any fees, costs and expenses and
all other Liabilities and Damages relating to any Shareholder Litigation,
including any judgments, settlements or other Liabilities arising out of such
Shareholder Litigation.

  

  

(zz) "Transfer Taxes" shall have the meaning given to such term in the Tax
Matters Agreement.

  

  

Section 8.2 Interpretation. Unless the express context otherwise requires:

  

  

(a) the words "hereof," "herein" and "hereunder" and words of similar import,
when used in this Agreement, shall refer to this Agreement as a whole and not
to any particular provision of this Agreement;

  

  

(b) terms defined in the singular shall have a comparable meaning when used in
the plural, and vice versa;

  

  

(c) the terms "Dollars" and "$" mean U.S. dollars;

  

  

(d) references herein to a specific Section, Subsection, Recital, Schedule or
Exhibit shall refer, respectively, to Sections, Subsections, Recitals,
Schedules or Exhibits of this Agreement;

  

  

(e) wherever the word "include," "includes" or "including" is used in this
Agreement, it shall be deemed to be followed by the words "without
limitation";

  

  

(f) references herein to any gender shall include each other gender;

  

  

(g) references herein to any Person shall include such Person's heirs,
executors, personal representatives, administrators, successors and assigns;
provided, however, that nothing contained in this Section 8.2 is intended to
authorize any assignment or transfer not otherwise permitted by this
Agreement;

  

  

  

 

 

 

  

 

71  

  

 

 

 

  

  

  

(h) references herein to a Person in a particular capacity or capacities shall
exclude such Person in any other capacity;

  

  

(i) with respect to the determination of any period of time, (i) the word
"from" means "from and including" and the words "to" and "until" each means
"to but excluding" and (ii) time is of the essence;

  

  

(j) the word "or" shall be disjunctive but not exclusive;

  

  

(k) references herein to any Law shall be deemed to refer to such Law as
amended, modified, codified, reenacted, supplemented or superseded in whole or
in part and in effect from time to time, and also to all rules and regulations
promulgated thereunder;

  

  

(l) references herein to any Contract mean such Contract as amended,
supplemented or modified (including by any waiver) in accordance with the
terms thereof;

  

  

(m) the headings contained in this Agreement are intended solely for
convenience and shall not affect the rights of the parties to this Agreement;
and

  

  

(n) if the last day for the giving of any notice or the performance of any act
required or permitted under this Agreement is a day that is not a Business
Day, then the time for the giving of such notice or the performance of such
action shall be extended to the next succeeding Business Day.

  

  

Section 8.3 No Survival. None of the representations and warranties contained
in this Agreement or in any instrument delivered under this Agreement shall
survive the Effective Time. This Section 8.3 shall not limit any covenant or
agreement of the parties to this Agreement which, by its terms, contemplates
performance after the Effective Time.

  

  

Section 8.4 Governing Law. This Agreement shall be governed by, and construed
in accordance with, the Law of the State of New York, without regard to
conflict of law principles thereof.

  

  

Section 8.5 Submission to Jurisdiction; Service. Each party to this Agreement
(a) irrevocably and unconditionally submits to the personal jurisdiction of
the federal courts of the United States District Court for the Southern
District of New York or any New York State Court sitting in New York City, (b)
agrees that it will not attempt to deny or defeat such personal jurisdiction
by motion or other request for leave from any such court, (c) agrees that any
actions or proceedings arising in connection with this Agreement or the
transactions contemplated by this Agreement shall be brought, tried and
determined only in such courts, (d) waives any claim of improper venue or any
claim that those courts are an inconvenient forum and (e) agrees that it will
not bring any action relating to this Agreement or the transactions
contemplated hereunder in any court other than the aforesaid courts. The
parties to this Agreement agree that mailing of process or

  

  

  

 

 

 

  

 

72  

  

 

 

 

  

  

  

other papers in connection with any such action or proceeding in the manner
provided in Section 8.7 or in such other manner as may be permitted by
applicable Law, shall be valid and sufficient service thereof.

  

  

Section 8.6 WAIVER OF JURY TRIAL. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY
CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE
COMPLICATED AND DIFFICULT ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY
AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT
OF ANY LEGAL ACTION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS
AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH PARTY TO
THIS AGREEMENT CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE OF ANY
OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY
WOULD NOT SEEK TO ENFORCE THE FOREGOING WAIVER IN THE EVENT OF A LEGAL ACTION,
(B) SUCH PARTY HAS CONSIDERED AND UNDERSTANDS THE IMPLICATIONS OF THIS WAIVER,
(C) SUCH PARTY MAKES THIS WAIVER VOLUNTARILY AND (D) SUCH PARTY HAS BEEN
INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL
WAIVERS AND CERTIFICATIONS IN THIS SECTION 8.6.

  

  

Section 8.7 Notices. All notices and other communications hereunder shall be
in writing and shall be addressed as follows (or at such other address for a
party as shall be specified by like notice):

  

  

If to Parent or Merger Sub, to:

  

  

CVS Caremark Corporation

  

1 CVS Drive

  

Woonsocket, Rhode Island 02895

  

Attention: Douglas Sgarro

  

Facsimile: (401) 770-5415

  

E-Mail Address: dasgarro@cvs.com

  

  

with a copy (which shall not constitute notice) to: 
 

  

  

Davis Polk and Wardwell LLP

  

450 Lexington Avenue

  

New York, New York 10017

  

Attention: Louis Goldberg

  

Facsimile: 212-701-5539

  

E-Mail Address: louis.goldberg@davispolk.com

  

  

If to the Company, to: 
 

  

  

Universal American Corp.

  

  

  

 

 

 

  

 

73  

  

 

 

 

  

  

  

6 International Drive

  

Rye Brook, New York 10573-1068

  

Attention: Tony Wolk

  

Facsimile: (914) 934-2949

  

E-Mail Address: twolk@universalamerican.com

  

  

with a copy (which shall not constitute notice) to:

  

  

Paul, Weiss, Rifkind, Wharton and Garrison LLP

  

1285 Avenue of the Americas

  

New York, NY 10019-6064

  

Attention: Robert B. Schumer

  

Ariel J. Deckelbaum

  

Facsimile: (212) 757-3990

  

E-Mail Address: rschumer@paulweiss.com

  

ajdeckelbaum@paulweiss.com

  


 

  

All such notices or communications shall be deemed to have been delivered and
received: (a) if delivered in person, on the day of such delivery, (b) if by
facsimile or electronic mail, on the day on which such facsimile or electronic
mail was sent; provided, that receipt is personally confirmed by telephone,
(c) if by certified or registered mail (return receipt requested), on the
seventh (7th) Business Day after the mailing thereof or (d) if by reputable
overnight delivery service, on the second (2nd) Business Day after the sending
thereof.

  

  

Section 8.8 Amendment. This Agreement may be amended by the parties to this
Agreement at any time before the Effective Time, whether before or after
obtaining the Requisite Company Vote, so long as (a) no amendment that
requires further shareholder approval under applicable Law after shareholder
approval hereof shall be made without such required further approval and (b)
such amendment has been duly approved by the board of directors of each of
Merger Sub, Parent and the Company. This Agreement may not be amended except
by an instrument in writing signed by each of the parties to this Agreement.
Notwithstanding the foregoing, at any time prior to the Requisite Company
Vote, the Company may, in its sole discretion, unilaterally change the Newco
Exchange Ratio with, if necessary, approval of the Company Board.

  

  

Section 8.9 Extension; Waiver. At any time before the Effective Time, Parent
and Merger Sub, on the one hand, and the Company, on the other hand, may (a)
extend the time for the performance of any of the obligations of the other
party, (b) waive any inaccuracies in the representations and warranties of the
other party contained in this Agreement or in any document delivered under
this Agreement or, (c) subject to applicable Law, waive compliance with any of
the covenants or conditions contained in this Agreement. Any agreement on the
part of a party to any extension or waiver shall be valid only if set forth in
an instrument in writing signed by such party. The failure of any party to
assert any of its rights under this Agreement or otherwise shall not
constitute a waiver of such rights.

  

  

  

 

 

 

  

 

74  

  

 

 

 

  

  

  

Section 8.10 Entire Agreement. This Agreement (and the exhibits hereto), the
Split-Off Agreements, the Company Disclosure Letter, the Parent Disclosure
Letter and the Confidentiality Agreement contain all of the terms, conditions
and representations and warranties agreed to by the parties relating to the
subject matter of this Agreement and the Split-Off Agreements and supersede
all prior or contemporaneous agreements, negotiations, correspondence,
undertakings, understandings, representations and warranties, both written and
oral, among the parties to this Agreement with respect to the subject matter
of this Agreement. Without limiting the generality of Section 4.12, no
representation, warranty, inducement, promise, understanding or condition not
set forth in this Agreement has been made or relied upon by any of the parties
to this Agreement.

  

  

Section 8.11 No Third-Party Beneficiaries. Except for (a) the right to receive
the Per Share Merger Consideration (which, from and after the Effective Time,
shall be for the benefit of holders of Common Stock and Preferred Stock as of
the Effective Time), (b) for the provisions of Section 5.18 (which, from and
after the Effective Time, shall be for the benefit of Newco) and (c) the
rights of Covered Persons under Section 5.24, Parent and the Company hereby
agree that their respective representations, warranties and covenants set
forth herein are solely for the benefit of the other party hereto, in
accordance with and subject to the terms of this Agreement, and this Agreement
is not intended to, and does not, confer upon any Person other than the
parties hereto any rights or remedies hereunder, including the right to rely
upon the representations and warranties set forth herein.

  

  

Section 8.12 Severability. The provisions of this Agreement shall be deemed
severable and the invalidity or unenforceability of any provision shall not
affect the validity or enforceability of the other provisions of this
Agreement. If any provision of this Agreement, or the application of that
provision to any Person or any circumstance, is invalid or unenforceable, (a)
a suitable and equitable provision shall be substituted for that provision in
order to carry out, so far as may be valid and enforceable, the intent and
purpose of the invalid or unenforceable provision and (b) the remainder of
this Agreement and the application of that provision to other Persons or
circumstances shall not be affected by such invalidity or unenforceability,
nor shall such invalidity or unenforceability affect the validity or
enforceability of that provision, or the application of that provision, in any
other jurisdiction. Upon such a determination, the parties shall negotiate in
good faith to modify this Agreement so as to effect the original intent of the
parties as closely as possible in a reasonably acceptable manner so that the
transactions contemplated by this Agreement may be consummated as originally
contemplated to the fullest extent possible.

  

  

Section 8.13 Rules of Construction. The parties have participated jointly in
negotiating and drafting this Agreement. If an ambiguity or a question of
intent or interpretation arises, this Agreement shall be construed as if
drafted jointly by the parties, and no presumption or burden of proof shall
arise favoring or disfavoring any party by virtue of the authorship of any
provision of this Agreement. Subject to and without limiting the introductory
language to Articles III and IV, each party to this Agreement has or may have
set forth information in its respective disclosure letter in a section of

  

  

  

 

 

 

  

 

75  

  

 

 

 

  

  

  

such disclosure letter that corresponds to the section of this Agreement to
which it relates. The fact that any item of information is disclosed in a
disclosure letter to this Agreement shall not constitute an admission by such
party that such item is material, that such item has had or would have a
Company Material Adverse Effect or Parent Material Adverse Effect, as the case
may be, or that the disclosure of such be construed to mean that such
information is required to be disclosed by this Agreement.

  

  

Section 8.14 Assignment. This Agreement shall be binding upon and shall inure
to the benefit of the parties hereto and their permitted successors and
assigns. No party to this Agreement may assign or delegate, by operation of
law or otherwise, all or any portion of its rights or liabilities under this
Agreement without the prior written consent of the other parties to this
Agreement, which any such party may withhold in its absolute discretion,
except that Parent or Merger Sub may transfer or assign its rights and
obligations under this Agreement, in whole or from time to time in part to one
or more Subsidiaries of Parent and, after the Effective Time, to any Person;
provided that no such transfer or assignment shall relieve Parent or Merger
Sub of its obligations hereunder. Any purported assignment in violation of the
foregoing shall be void.

  

  

Section 8.15 Remedies. Any and all remedies expressly conferred upon a party
to this Agreement shall be cumulative with, and not exclusive of, any other
remedy contained in this Agreement, at law or in equity. The exercise by a
party to this Agreement of any one remedy shall not preclude the exercise by
it of any other remedy.

  

  

Section 8.16 Specific Performance. The parties to this Agreement agree that
irreparable damage would occur if any of the provisions of this Agreement were
not performed in accordance with their specific terms or were otherwise
breached. It is accordingly agreed that the parties to this Agreement shall be
entitled to an injunction or injunctions to prevent breaches or threatened
breaches of this Agreement and to enforce specifically the terms and
provisions of this Agreement in the United States District Court for the
Southern District of New York or any New York State Court sitting in New York
City, this being in addition to any other remedy at law or in equity, and the
parties to this Agreement hereby waive any requirement for the posting of any
bond or similar collateral in connection therewith. The parties agree that
they shall not object to the granting of injunctive or other equitable relief
on the basis that there exists adequate remedy at Law.

  

  

Section 8.17 Counterparts; Effectiveness. This Agreement may be executed in
any number of counterparts, as if the signatures to each counterpart were upon
a single instrument, and all such counterparts together shall be deemed an
original of this Agreement. Facsimile signatures or signatures received as a
pdf attachment to electronic mail shall be treated as original signatures for
all purposes of this Agreement. This Agreement shall become effective when,
and only when, each party hereto shall have received a counterpart signed by
all of the other parties hereto.

  

  

Section 8.18 Merger Sub.

  

  

  

 

 

 

  

 

76  

  

 

 

 

  

  

  

(a) At the Company's request no later than five (5) Business Days before the
Closing Date, Parent shall file (or cause Merger Sub to file) an election with
the U.S. Internal Revenue Services ("IRS") on Form 8832 (or successor form)
electing to treat Merger Sub as a corporation for U.S. federal income tax
purposes, which election shall be effective at least one Business Day before
the Closing Date.

  

  

(b) During the period from the date of this Agreement to the Closing Date,
Company and its Subsidiaries shall (x) prepare, in the ordinary course of
business and consistent with Current Practices (as defined in the Tax Matters
Agreement), and timely file all Tax Returns required to be filed by it (or
them) on or before the Closing Date ("Post-Signing Returns") and (y) consult
with Parent with respect to all material Post-Signing Returns and deliver
drafts of such Post-Signing Returns to Parent no later than ten (10) Business
Days prior to the date (including extensions) on which such Post-Signing
Returns are required to be filed; provided that the financial information used
by Newco in the preparation of each such Post-Signing Return shall be based on
information prepared in accordance with either (A) GAAP applied on a
consistent basis or (B) statutory principles, as applicable; provided,
further, that the filing of such Post-Signing Return shall not result in the
Company being required to establish or increase a FASB Interpretation No. 48
("FIN 48") reserve that would, taken together with all other FIN 48 reserves
established or increased pursuant to this section and Sections 2.1(a)(i),
2.3(e) and 2.4(a) of the Tax Matters Agreement, be in excess of seven million
five hundred thousand dollars ($7,500,000).

  

  

(c) If, at any time prior to the Effective Time, the Company shall determine
that Merger Sub being a limited liability company instead of a corporation
adversely affects in any material respect or materially delays the parties'
ability to effect the Merger then, at the Company's request, upon no fewer
than five (5) Business Days notice (which notice shall be given no later than
five (5) Business Days before the Closing Date), Parent shall cause Merger Sub
to convert to a corporation as promptly as practicable and the parties shall
amend this Agreement to reflect such conversion.

  

  

[Signature page follows]

  

  

  

 

 

 

  

 

77  

  

 

 

 

  

  

  

IN WITNESS WHEREOF, this Agreement has been duly executed and delivered by the
duly authorized officers of the parties to this Agreement as of the date first
written above.

  

  

  

 

    

CVS CAREMARK CORPORATION

  |   
---|--- 
   |  |   
  

By:

  | /s/ David M. Denton |   
   | Name: David M. Denton  |   
   | Title: Executive Vice President and Chief Financial Officer  
   |  |   
 

 

  

  

  

[Signature Page to Agreement and Plan of Merger]

  

  

  

 

 

 

  

   

  

 

 

 

  

  

 

  

 

 

 

    

 

 

UNIVERSAL AMERICAN CORP.

 

 

  |   
---|--- 
   |  |   
  

By:

  | /s/ Richard A. Barasch |   
   | Name: Richard A. Barasch |   
   | Title: Chief Executive Officer  
   |  |   
 

 

  


 

 

  

 

  

  

[Signature Page to Agreement and Plan of Merger]

  

  

 

 

 

  

 

 

 

  

 

79  

  

 

 

 

  

  

 

  

 

 

    

 

ULYSSES MERGER SUB, L.L.C.

 

  |   
---|--- 
   |  |   
  

By:

  | /s/ Thomas S. Moffatt |   
   | Name: Thomas S. Moffatt |   
   | Title: President  
   |  |   
 

 

  

 

  

  

 

  

[Signature Page to Agreement and Plan of Merger]

  

 

 

  

 

  

 

 

80

 

  

 

 

  

 

 

 

 

    

 

  

 

 

  

  

  

 

 

 

     '

